Document

0001628280-19-005953.txt : 20190507 0001628280-19-005953.hdr.sgml : 20190507 20190506191810 ACCESSION NUMBER: 0001628280-19-005953 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 77 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190507 DATE AS OF CHANGE: 20190506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eHealth, Inc. CENTRAL INDEX KEY: 0001333493 STANDARD INDUSTRIAL CLASSIFICATION: INSURANCE AGENTS BROKERS & SERVICES [6411] IRS NUMBER: 770470789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33071 FILM NUMBER: 19800819 BUSINESS ADDRESS: STREET 1: 2625 AUGUSTINE DRIVE, SECOND FLOOR CITY: SANTA CLARA STATE: CA ZIP: 95054 BUSINESS PHONE: 650-584-2700 MAIL ADDRESS: STREET 1: 2625 AUGUSTINE DRIVE, SECOND FLOOR CITY: SANTA CLARA STATE: CA ZIP: 95054 10-Q 1 ehth3312019form10-q.htm 10-Q Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

001-33071

(Commission File Number)

_____________________________________________

EHEALTH, INC.

(Exact name of registrant as specified in its charter)

_____________________________________________



Delaware (State or other jurisdiction of incorporation or organization)		56-2357876 (I.R.S Employer Identification No)

2625 AUGUSTINE DRIVE, SECOND FLOOR

SANTA CLARA, CALIFORNIA, 95054

(Address of principal executive offices)

(650) 584-2700

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

____________________________________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES x NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer	¨	Accelerated filer	x
Non-accelerated filer	¨	Smaller reporting company	¨
Emerging growth Company	¨

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.001 per share	EHTH	The NASDAQ Stock Market LLC

The number of shares of the registrant’s common stock, par value $0.001 per share, outstanding as of April 30, 2019 was 22,649,067 shares.

Table of Contents

EHEALTH, INC. FORM 10-Q

TABLE OF CONTENTS



	PART I FINANCIAL INFORMATION	PAGE
Item 1.	Financial Statements (unaudited)	4
	Condensed Consolidated Balance Sheets at March 31, 2019 and December 31, 2018	5
	Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2019 and 2018	6
	Condensed Consolidated Statement of Stockholders' Equity for the Three Months Ended March 31, 2019 and 2018	7
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2019 and 2018	8
	Notes to Condensed Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	50
Item 4.	Controls and Procedures	52
	PART II OTHER INFORMATION
Item 1.	Legal Proceedings	53
Item 1A.	Risk Factors	54
Item 6.	Exhibits	79
	Signatures	80
	Exhibit Index	81

Table of Contents

PART I

FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

EHEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, unaudited)



	March 31, 2019			December 31, 2018
Assets
Current assets:
Cash and cash equivalents	$	135,475		$	13,089
Accounts receivable	3,381			3,601
Commissions receivable—current	113,834			134,190
Prepaid expenses and other current assets	6,483			5,288
Total current assets	259,173			156,168
Commissions receivable—non-current	214,377			211,668
Property and equipment, net	7,963			7,684
Operating lease right-of-use assets	25,730			—
Other assets	12,059			11,276
Intangible assets, net	11,702			12,249
Goodwill	40,233			40,233
Total assets	$	571,237		$	439,278
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	4,360		$	5,688
Accrued compensation and benefits	11,373			20,763
Accrued marketing expenses	3,866			11,013
Earnout liability—current	26,500			20,730
Lease liabilities—current	3,430			—
Other current liabilities	5,528			2,425
Total current liabilities	55,057			60,619
Debt	—			5,000
Earnout liability—non-current	—			19,270
Deferred income taxes—non-current	44,358			47,901
Lease liabilities—non-current	24,150			—
Other non-current liabilities	2,022			3,339
Stockholders’ equity:
Common stock	34			31
Additional paid-in capital	445,652			298,024
Treasury stock, at cost	(199,998		)	(199,998		)
Retained earnings	199,806			204,965
Accumulated other comprehensive income	156			127
Total stockholders’ equity	445,650			303,149
Total liabilities and stockholders’ equity	$	571,237		$	439,278

The accompanying notes are an integral part of these condensed consolidated financial statements.

EHEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(in thousands, except per share amounts, unaudited)



	Three Months Ended March 31,
	2019			2018

Revenue
Commission	$	64,227		$	40,707
Other	4,546			2,363
Total revenue	68,773			43,070
Operating costs and expenses:
Cost of revenue	(77		)	152
Marketing and advertising	23,941			15,002
Customer care and enrollment	19,944			13,239
Technology and content	9,017			8,341
General and administrative	11,278			10,691
Acquisition costs	—			58
Change in fair value of earnout liability	13,306			—
Restructuring	—			1,856
Amortization of intangible assets	547			451
Total operating costs and expenses	77,956			49,790
Loss from operations	(9,183		)	(6,720		)
Other income, net	557			184
Loss before benefit from income taxes	(8,626		)	(6,536		)
Benefit from income taxes	(3,467		)	(1,691		)
Net loss	$	(5,159	)	$	(4,845	)
Net loss per share:
Basic and diluted	$	(0.24	)	$	(0.26	)
Weighted-average number of shares used in per share amounts:
Basic and diluted	21,831			18,873
Comprehensive loss
Net loss	$	(5,159	)	$	(4,845	)
Foreign currency translation adjustment, net of taxes	29			65
Comprehensive loss	$	(5,130	)	$	(4,780	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

EHEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, unaudited)



	Common Stock						Treasury Stock
	Shares	Amount		Additional Paid-in Capital			Shares		Amount			Retained Earnings			Accumulated Other Comprehensive Income		Total Stockholders’ Equity
Balance at December 31, 2018	30,863	$	31	$	298,024		(11,426	)	$	(199,998	)	$	204,965		$	127	$	303,149
Issuance of common stock in connection with exercise of common stock options and release of vested restricted stock units, net of cash used to net settle equity awards	172	—		2,367			—		—			—			—		2,367
Common stock traded for employee tax obligation	—	—		(1,280		)	(24	)	—			—			—		(1,280		)
Stock issued in equity offering	2,760	3		126,051			—		—			—			—		126,054
Stock issued for GoMedigap earnout	295	—		17,261			—		—			—			—		17,261
Stock-based compensation expense	—	—		3,229			—		—			—			—		3,229
Foreign currency translation adjustment, net of taxes	—	—		—			—		—			—			29		29
Net loss	—	—		—			—		—			(5,159		)	—		(5,159		)
Balance at March 31, 2019	34,090	$	34	$	445,652		(11,450	)	$	(199,998	)	$	199,806		$	156	$	445,650



	Common Stock						Treasury Stock
	Shares	Amount		Additional Paid-in Capital			Shares		Amount			Retained Earnings			Accumulated Other Comprehensive Income		Total Stockholders’ Equity
Balance at December 31, 2017	29,880	$	30	$	281,706		(11,238	)	$	(199,998	)	$	204,725		$	201	$	286,664
Issuance of common stock in connection with exercise of common stock options and release of vested restricted stock units, net of cash used to net settle equity awards	60	—		109			—		—			—			—		109
Common stock traded for employee tax obligation	—	—		(286		)	(16	)	—			—			—		(286		)
Stock-based compensation expense	—	—		2,801			—		—			—			—		2,801
Stock issued for GoMedigap acquisition	295	—		5,595													5,595
Foreign currency translation adjustment, net of taxes	—	—		—			—		—			—			65		65
Net loss	—	—		—			—		—			(4,845		)	—		(4,845		)
Balance at March 31, 2018	30,235	$	30	$	289,925		(11,254	)	$	(199,998	)	$	199,880		$	266	$	290,103

The accompanying notes are an integral part of these condensed consolidated financial statements.

EHEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, unaudited)



	Three Months Ended March 31,
	2019			2018
Operating activities
Net loss	$	(5,159	)	$	(4,845	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Deferred income taxes	(3,543		)	(1,736		)
Depreciation and amortization	655			619
Amortization of internally developed software	719			477
Amortization of intangible assets	547			451
Stock-based compensation expense	3,229			2,801
Change in fair value of earnout liability	13,306			—
Other non-cash items	(1,194		)	389
Changes in operating assets and liabilities:
Accounts receivable	221			807
Commissions receivable	17,648			22,409
Prepaid expenses and other assets	1,111			(1,793		)
Accounts payable	(768		)	(567		)
Accrued compensation and benefits	(9,390		)	(6,912		)
Accrued marketing expenses	(7,147		)	(1,891		)
Accrued restructuring charges	—			1,053
Deferred revenue	2,897			(289		)
Accrued expense and other liabilities	(383		)	(236		)
Net cash provided by operating activities	12,749			10,737
Investing activities
Capitalized internal-use software and website development costs	(1,487		)	(989		)
Purchases of property and equipment and other assets	(1,509		)	(217		)
Acquisition of business, net of cash acquired	—			(14,929		)
Net cash used in investing activities	(2,996		)	(16,135		)
Financing activities
Proceeds from issuance of common stock, net of issuance costs	126,051			—
Net proceeds from exercise of common stock options	2,367			109
Cash used to net-share settle equity awards	(1,280		)	(286		)
Payment of debt	(5,000		)	—
Acquisition-related contingent payments	(9,542		)	—
Principal payments in connection with finance leases	(25		)	(26		)
Net cash provided by (used in) financing activities	112,571			(203		)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	62			50
Net increase (decrease) in cash, cash equivalents and restricted cash	122,386			(5,551		)
Cash, cash equivalents and restricted cash at beginning of period	13,089			40,293
Cash, cash equivalents and restricted cash at end of period	$	135,475		$	34,742

The accompanying notes are an integral part of these condensed consolidated financial statements.

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 1—Summary of Business and Significant Accounting Policies

Description of Business—eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading private health insurance exchange for individuals, families and small businesses in the United States. Through our website addresses (www.eHealth.com, www.eHealthInsurance.com, www.eHealthMedicare.com, www.Medicare.com, www.PlanPrescriber.com and www.GoMedigap.com), consumers can get quotes from leading health insurance carriers, compare plans side-by-side, and apply for and purchase Medicare-related, individual and family, small business and ancillary health insurance plans. We actively market the availability of Medicare-related insurance plans and offer Medicare plan comparison tools and educational materials for Medicare-related insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans. Our ecommerce technology also enables us to deliver consumers’ health insurance applications electronically to health insurance carriers. We are licensed to market and sell health insurance in all 50 states and the District of Columbia.

Basis of Presentation—The accompanying condensed consolidated balance sheets as of March 31, 2019 and December 31, 2018 and the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2019 and 2018, the condensed consolidated statements of stockholders' equity, and the condensed consolidated statements of cash flows for the three months ended March 31, 2019 and 2018, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2018 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission on March 14, 2019. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K.

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with such rules and regulations. However, the Company believes the disclosures made are adequate to make the information not misleading. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2018 and include all adjustments necessary for the fair presentation of our financial position as of March 31, 2019 and December 31, 2018, our results of operations for the three months ended March 31, 2019 and 2018 and our cash flows for the three months ended March 31, 2019 and 2018. The results for the three months ended March 31, 2019 are not necessarily indicative of the results to be expected for any subsequent period or for the fiscal year ending December 31, 2019 and therefore should not be relied upon as an indicator of future results.

Principles of Consolidation—The condensed consolidated financial statements include the accounts of eHealth, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles.

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

regarding our business operations. The performance measures of our segments include total revenue and profit. Our business structure is comprised of two operating segments:

•Medicare; and

•Individual, Family and Small Business

The Medicare segment consists primarily of commissions earned from our sale of Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans, and to a lesser extent, ancillary products sold to our Medicare-eligible customers, including but not limited to, dental and vision insurance, as well as our advertising program that allows Medicare-related carriers to purchase advertising on a separate website developed, hosted and maintained by us and our delivery and sale to third parties of Medicare-related health insurance leads generated by our ecommerce platforms and our marketing activities.

The Individual, Family and Small Business segment consists primarily of commissions earned from our sale of individual and family and small business health insurance plans and ancillary products sold to our non-Medicare-eligible customers, including but not limited to, dental, vision, and short-term insurance. To a lesser extent, the Individual, Family and Small Business segment consists of amounts earned from our online sponsorship program that allows carriers to purchase advertising space in specific markets in a sponsorship area on our website, our licensing to third parties the use of our health insurance ecommerce technology and our delivery and sale to third parties of individual and family health insurance leads generated by our ecommerce platforms and our marketing activities.

Marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect marketing and advertising, customer care and enrollment and technology and content operating expenses are allocated to each segment based on usage. Other indirect general and administrative operating expenses are managed in a corporate shared services environment and, since they are not the responsibility of segment operating management, are not allocated to the two operating segments and are presented as a reconciling item to our consolidated financial results.

Segment profit is calculated as total revenue for the applicable segment less direct and allocated marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses, excluding stock-based compensation, depreciation and amortization expense and amortization of intangible assets.

Use of Estimates—The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the useful lives of intangible assets, fair value of investments, recoverability of intangible assets, the commissions we expect to collect for each approved member cohort, valuation allowance for deferred income taxes, provision for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates.

Seasonality—A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter.

The majority of our individual and family health insurance plans are sold in the fourth quarter during the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.

Cash Equivalents—We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value.

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Revenue Recognition—We are compensated by the receipt of commission payments from health insurance carriers whose health insurance policies are purchased through our ecommerce platforms or our customer care centers. We may also receive commission bonuses based on our attaining predetermined target sales levels for Medicare, individual and family, small business and ancillary health insurance products, or other objectives, as determined by the health insurance carrier, which we recognize as commission revenue when we achieve the predetermined target sales levels or other objectives. In addition, we also generate revenue from non-commission revenue sources, which include online sponsorship and advertising, technology licensing and lead referrals. Payment is typically received within 60 days of approval.

We account for revenue under ASC 606—Revenue from Contracts with Customers. The core principle of ASC 606 is to recognize revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services. Accordingly, we recognize revenue for our services in accordance with the following five steps outlined in ASC 606:

•

Identification of the contract, or contracts, with a customer. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

•

Identification of the performance obligations in the contract. Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract.


•	Determination of the transaction price. The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.

•

Allocation of the transaction price to the performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price ("SSP") basis.


•	Recognition of revenue when, or as, we satisfy a performance obligation. We satisfy performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.

Commission Revenue—Our commission revenue is primarily comprised of commissions paid to us by health insurance carriers related to insurance plans that have been purchased by a member through our health insurance exchange service. We define a member as an individual currently covered by an insurance plan, which include Medicare-related, individual and family, small business and ancillary plans. We are compensated by the health insurance carrier, which we define as our customer.

We typically enter into contractual agency relationships with health insurance carriers that are non-exclusive and terminable on short notice by either party for any reason. In addition, health insurance carriers often have the ability to terminate or amend our agreements unilaterally on short notice, including provisions in our agreements relating to the commission rates paid to us by the health insurance carriers. The amendment or termination of an agreement we have with a health insurance carrier may adversely impact the commissions we are paid on health insurance plans purchased from the carrier by means of our health insurance exchange services.

For both Medicare Advantage and Medicare Part D prescription drug plans, we receive a fixed, annual commission payment from insurance carriers once the plan is approved by the carrier and either a fixed, monthly or annual commission payment beginning with and subsequent to the second plan year. In the first plan year of a Medicare Advantage and Medicare Part D prescription drug plan, after the health insurance carrier approves the application but during the effective year of the plan, we are paid a fixed commission that is prorated for the number of months remaining in the calendar year. Additionally, if the plan is the first Medicare Advantage or Medicare Part D plan issued to the member, we may receive a higher commission rate that covers a full twelve-month period, regardless of the month the plan was effective. We earn commission revenue for Medicare Advantage and Medicare Part D prescription drug plans for which we are the broker of record, typically until either the policy is cancelled or we otherwise do not remain the agent on the policy.

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

For individual and family, Medicare Supplement, small business and ancillary plans, our commissions generally represent a flat amount per member per month or a percentage of the premium amount collected by the carrier during the period that a member maintains coverage under a plan. Premium-based commissions are reported to us after the premiums are collected by the carrier, generally on a monthly basis. We generally continue to receive the commission payment from the relevant insurance carrier until the health insurance plan is cancelled or we otherwise do not remain the agent on the policy.

We utilize a practical expedient to estimate commission revenue for each insurance product by applying the use of a portfolio approach to group approved members by the effective month of the relevant policy (referred to as a “cohort”). This allows us to estimate the commissions we expect to collect for each approved member cohort by evaluating various factors, including but not limited to, contracted commission rates, carrier mix and expected member churn.

For Medicare-related, individual and family and ancillary health insurance plans, our services are complete once a submitted application is approved by the relevant health insurance carrier. Accordingly, we recognize commission revenue based upon the total estimated lifetime commissions we expect to receive for selling the plan after the carrier approves an application, net of an estimated constraint. We refer to these estimated and constrained lifetime values as the "constrained LTV" for the plan. We provide annual services in selling and renewing small business health insurance plans; therefore, we recognize small business health insurance plan commission revenue at the time the plan is approved by the carrier, and when it renews each year thereafter, equal to the estimated commissions we expect to collect from the plan over the following 12 months. Our estimate of commission revenue for each product line is based on a number of assumptions, which include, but are not limited to, estimating conversion of an approved member to a paying member, forecasting member churn and forecasting the commission amounts likely to be received per member. These assumptions are based on historical trends and incorporate management’s judgment in interpreting those trends and in applying constraints discussed below. To the extent we make changes to the assumptions, we will recognize any material impact of the changes to commission revenue in the reporting period in which the change is made, including revisions of estimated lifetime commissions either below or in excess of previously estimated constrained LTV recognized as revenue.

For Medicare-related, individual and family and ancillary health insurance plans, we apply constraints to determine the amount of commission revenue to recognize per approved member. The constraints are applied to help ensure that the total estimated lifetime commissions expected to be collected for an approved member’s plan are recognized as revenue only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with future commissions receivable from the plan is subsequently resolved. We evaluate the appropriateness of these constraints on at least an annual basis, including assessing factors affecting our estimate of the estimated lifetime value of commissions per approved member based on current trends impacting our business and assessing whether any adjustment to those constraints should be made. We update the assumptions when we observe a sufficient level of evidence that would suggest that the long term expectation of the assumption has changed.

For the three months ended March 31, 2019 and 2018, the constraints applied to the total estimated lifetime commissions we expect to receive for selling the plan after the carrier approves an application in order to derive the constrained lifetime value of commissions per approved member are as follows:

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)



	Three Months Ended
	March 31,
	2019		2018
Medicare
Medicare Advantage	7	%	7	%
Medicare Supplement	5	%	5	%
Medicare Part D	5	%	5	%

Individual and Family
Non-Qualified Health Plans	15	%	15	%
Qualified Health Plans	20	%	20	%

Ancillaries	10	%	10	%

Small Business	—	%	—	%

Other Revenue—Our sponsorship and advertising program allows carriers to purchase advertising space in specific markets in a sponsorship area on our website. In return, we are typically paid a monthly fee, which is recognized over the period that advertising is displayed, and often a performance fee based on metrics such as submitted health insurance applications, which is recognized based on attainment of metrics. We also offer Medicare advertising services, which include website development, hosting and maintenance. In these instances, we are typically paid a fixed, up-front fee, which we recognize as revenue ratably over the service period.

Our commercial technology licensing business allows carriers the use of our ecommerce platform to offer their own health insurance policies on their websites and agents to utilize our technology to power their online quoting, content and application submission processes. Typically, we are paid a one-time implementation fee, which we recognize ratably on a straight-line basis over the estimated term of the customer relationship (generally the initial term of the agreement), commencing once the technology is available for use by the third party, and a performance fee based on metrics such as submitted health insurance applications. The metrics used to calculate performance fees for both sponsorship and advertising and technology licensing are based on performance criteria that are either measured based on data tracked by us, or based on data tracked by the third party. In instances where the performance criteria data is tracked by us, we recognize revenue in the period of performance and when all other revenue recognition criteria have been met. In instances where the performance criteria data is tracked by the third party, we recognize revenue at amounts in which reversal of such amounts is not likely to occur. Typically, this occurs through our receipt of a cash payment from the third party along with a detailed statement containing the data that is tracked by the third party.

Deferred Revenue—Deferred revenue includes deferred technology licensing implementation fees and amounts billed for or collected from sponsorship or technology licensing customers in advance of our performing our service for such customers. It also includes the amount by which both unbilled and billed services provided under our technology licensing arrangements exceed the straight-line revenue recognized to date.

Disaggregation of Revenue—The table below depicts the disaggregation of revenue by product for the three months ended March 31, 2019 and 2018 and is consistent with how we evaluate our financial performance (in thousands):

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)



	Three Months Ended
	March 31, 2019		March 31, 2018
Commission Revenue:
Medicare
Medicare Advantage	$	39,843	$	21,935
Medicare Supplement	8,597		5,592
Medicare Part D	2,336		1,159
Total Medicare	50,776		28,686
Individual and Family ⁽¹⁾
Non-Qualified Health Plans	2,629		1,441
Qualified Health Plans	3,508		2,162
Total Individual and Family	6,137		3,603
Ancillaries
Short-term	1,316		1,250
Dental	790		1,219
Vision	462		340
Other	951		2,771
Total Ancillaries	3,519		5,580
Small Business	2,640		2,359
Commission Bonus	1,155		479
Total Commission Revenue	64,227		40,707
Other Revenue	4,546		2,363
Total Revenue	$	68,773	$	43,070



(1)	We define our Individual and Family Plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both Qualified and Non-Qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase Non-Qualified health plans cannot receive a subsidy in connection with the purchase of Non-Qualified plans.

Incremental Costs to Obtain a Contract

We reviewed our sales compensation plans, which are directed at converting leads into approved members, and concluded that they are fulfillment costs and not costs to obtain a contract with a customer. Additionally, we reviewed compensation plans related to personnel responsible for identifying new health insurance carriers and entering into contracts with new health insurance carriers and concluded that no incremental costs are incurred to obtain such contracts.

Accounting Pronouncement Not Yet Adopted

Financial Instruments—Credit Losses (Topic 326)—In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326), which amends the guidance for accounting for assets which are potentially subject to credit risk. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. ASU 2016-13 is effective for us beginning January 1, 2020 using a modified retrospective transition method. We are still in process of assessing the impact, if any, this ASU will have on our condensed consolidated financial statements.

Recently Adopted Accounting Pronouncement

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Leases (Topic 842)—In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize a right-of-use asset and lease liability for all leases with terms of more than 12 months. Recognition, measurement, and presentation of expenses will depend on classification as a finance or operating lease; for lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct finance leases. The guidance also eliminates existing real estate-specific provisions for all entities. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. We adopted the standard using the modified retrospective method on January 1, 2019. As a result of adopting the ASU, as of January 1, 2019, we recorded an increase to our right-of-use asset and lease liability of $23.3 million and $24.6 million, respectively, which are discussed in Note 11—Leases in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q.

Note 2—Acquisition

On January 22, 2018, we completed our acquisition of all outstanding membership interests of Wealth, Health and Life Advisors, LLC, more commonly known as GoMedigap, a technology-enabled provider of Medicare Supplement enrollment services. This acquisition is expected to enhance our growing presence in the Medicare Supplement market and put us in a stronger position with carriers and strategic partners. The acquisition consideration consisted of cash of $15.0 million, less $0.1 million cash acquired, and 294,637 shares of our common stock. In addition, the members are entitled to receive earnout payments ("Earnout Consideration") consisting of up to $20 million in cash and 589,275 shares of our common stock. The Earnout Consideration becomes payable, subject to the terms and conditions of the purchase agreement relating to the acquisition, upon the final determination of the achievement of certain milestones in 2018 and 2019.

The GoMedigap acquisition was accounted for using the acquisition method of accounting under ASC 805—Business Combinations. The acquisition method of accounting requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The major classes of assets and liabilities to which we have preliminarily allocated the acquisition consideration were as follows (in thousands):



Acquisition Consideration
Cash paid	$	15,000
Fair value of equity awards issued to GoMedigap members ⁽¹⁾	5,595
Estimated fair value of earnout liability	27,700
	$	48,295
Allocation
Cash and cash equivalents	$	71
Commission receivable—current	4,371
Prepaid expenses and other current assets	11
Commission receivable—non-current	11,103
Property and equipment, net	174
Accounts payable	(110		)
Accrued compensation and benefits	(132		)
Other current liabilities	(130		)
Net tangible assets acquired	15,358
Intangible assets	6,800
Goodwill	26,137
Total intangible assets acquired	32,937
Total net assets acquired	$	48,295

(1) The fair value of equity awards issued was determined based on the January 22, 2018 closing price of our common stock of $18.99.

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Goodwill and Intangible Assets—Goodwill represents the excess of the purchase price of the acquired business over the acquisition date fair value of the net assets acquired. Goodwill is primarily attributable to the assembled workforce, new product development capabilities and anticipated synergies and economies of scale expected from the operations of the combined company. The goodwill was assigned to our Medicare segment. Goodwill is tested for impairment on an annual basis in the fourth quarter of each year or whenever events or changes in circumstances indicate that the asset may be impaired. Factors that we consider in deciding when to perform an impairment test include significant negative industry or economic trends or significant changes or planned changes in our use of the intangible assets. Goodwill will be deductible for tax purposes over 15 years.

Earnout liability—The earnout liability represents the fair value of the Earnout Consideration payable and will be adjusted to fair value at each reporting date until settled. Changes in fair value will be recognized in operations while changes in the earnout liability due to the passage of time will be recognized as other expense. The earnout liability will be adjusted to the extent the specified enrollment targets are not achieved. The first earnout liability settlement was made during the three months ended March 31, 2019, which consisted of a $9.5 million cash payment as well as a $17.3 million non-cash issuance of common stock. The second payment is expected to be made in the first quarter of 2020. See Note 4—Fair Value Measurement for additional information regarding change in fair value of the earnout liability for the three months ended March 31, 2019.

Fair Value Measurements—The assets acquired and liabilities assumed of GoMedigap have been recognized at fair value in accordance with ASC 820—Fair Value Measurement. ASC 820 defines fair value as the price that would be received to sell an asset or would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 requires three levels of hierarchy, which prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy level assigned to each asset and liability is based on the assessment of the transparency and reliability of inputs used in the valuation of such items based on the lowest level of input that is significant to fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and lowest priority to unobservable inputs (Level 3 measurements).

Assets acquired and liabilities assumed measured and reported at fair value are classified in one of the following categories based on inputs:



Level 1	Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2	Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability.
Level 3	Unobservable inputs for the asset or liability.

The fair value of prepaid expenses and other current assets, property and equipment, net, accounts payable, accrued compensation and benefits and other current liabilities approximated their carrying value at the date of acquisition. The fair value of commissions receivable was determined using a discount rate of interest, which is a Level 2 input. Intangible assets and the earnout liability were valued using Level 3 inputs.

The fair values of the acquired intangible assets were determined using the profit allocation method, which is based on determining the estimated royalties we are relieved from paying because we own the assets.

The fair value of the earnout liability was measured using probability-weighted analysis and is discounted using a rate that appropriately captures the risk associated with the obligation. Key assumptions included new enrollments and volatility for the years ended December 31, 2018 and ending December 31, 2019 and eHealth’s simulated stock price at the time of payment. The Earnout Consideration payable was part of the acquisition consideration and will be adjusted to fair value at each reporting date until settled. The fair value adjustments to the earnout liability during the three months ended March 31, 2019 totaled $13.3 million. We will continue to update the key assumptions each period and record any fair value adjustments, as necessary.

Following are the details of the acquisition consideration allocated to the intangible assets acquired (in thousands):



Technology	$	2,000
Trade names, trademarks and website addresses	4,800
Total intangible assets	$	6,800

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

We will amortize the existing technology and trade name using a straight-line method over an estimated life of 3 and 10 years, respectively. The estimated useful lives are based on the time periods during which the intangibles are expected to result in incremental cash flows.

We incurred $0.1 million acquisition-related costs during the first quarter of 2018, which were expensed as incurred.

Note 3—Balance Sheet Accounts

Cash and Cash Equivalents—As of March 31, 2019 and December 31, 2018, our cash equivalents consisted of money market accounts that invested in U.S. government-sponsored enterprise bonds and discount notes, U.S. government treasury bills and notes and repurchase agreements collateralized by U.S. government obligations. As of March 31, 2019 and December 31, 2018, our cash equivalents carried no unrealized gains or losses. We had no restricted cash as of March 31, 2019.

As of March 31, 2019 and December 31, 2018, our cash and cash equivalent balances were invested as follows (in thousands):



	March 31, 2019		December 31, 2018
Cash	$	27,501	$	12,766
Money market funds	107,974		323
Total cash and cash equivalents	$	135,475	$	13,089

Total Accounts Receivable—We do not require collateral or other security for our total accounts receivable. We believe the potential for collection issues with any of our customers was minimal as of March 31, 2019. Accordingly, our estimate for uncollectible amounts at March 31, 2019 was immaterial. Total accounts receivable as of March 31, 2019 and December 31, 2018 was comprised of the following (in thousands):



	March 31, 2019		December 31, 2018
Accounts receivable	$	3,381	$	3,601
Commissions receivable—current	113,834		134,190
Commissions receivable—non-current	214,377		211,668
Total accounts receivable	$	331,592	$	349,459

Concentration of Credit Risk—Our financial instruments that are exposed to concentrations of credit risk principally consist of cash, cash equivalents and total accounts receivable (which includes commissions receivable). We invest our cash and cash equivalents with major banks and financial institutions and, at times, such investments are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government.

We do not require collateral or other security for our total accounts receivable. Carriers that represented 10% or more of our total accounts receivable balance of $331.6 million and $349.5 million as of March 31, 2019 and December 31, 2018, respectively, were as follows (in thousands):



	March 31, 2019		December 31, 2018
UnitedHealthcare ⁽¹⁾	20	%	19	%
Humana	18	%	19	%
Aetna⁽²⁾	20	%	19	%

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)


(1)	UnitedHealthcare also includes other carriers owned by UnitedHealthcare.


(2)	Aetna also includes other carriers owned by Aetna.

Prepaid Expenses and Other Current Assets—Prepaid expenses and other current assets consisted of the following (in thousands):



	March 31, 2019		December 31, 2018
Prepaid maintenance contracts	$	2,778	$	1,937
Equity issuance costs	—		294
Prepaid insurance	213		161
Prepaid rent	324		324
Income tax receivable	1,108		1,108
Prepaid advertising	610		62
Other current assets	1,450		1,402
Total prepaid expenses and other current assets	$	6,483	$	5,288

Intangible Assets—The carrying amounts, accumulated amortization, net carrying value and weighted average remaining life of our definite-lived amortizable intangible assets, as well as our indefinite-lived intangible trademarks, are presented in the tables below for (dollars in thousands, weighted-average remaining life in years):



	March 31, 2019								December 31, 2018
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Weighted-Average Remaining Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Technology	$	2,000	$	(778	)	$	1,222	1.8	$	2,000	$	(611	)	$	1,389
Pharmacy and customer relationships	9,500		(8,471		)	1,029		1.1	9,500		(8,234		)	1,266
Trade names, trademarks and website addresses	5,700		(1,363		)	4,337		8.7	5,700		(1,220		)	4,480
Total intangible assets subject to amortization	$	17,200	$	(10,612	)	6,588			$	17,200	$	(10,065	)	7,135
Indefinite-lived trademarks and domain names						5,114		Indefinite						5,114
Total intangible assets						$	11,702							$	12,249

As of March 31, 2019, expected amortization expense in future periods is as follows (in thousands):



Years Ending December 31,	Technology		Pharmacy and Customer Relationships		Trade Names, Trademarks and Website Addresses		Total
Remainder of 2019	$	499	$	712	$	427	$	1,638
2020	667		317		510		1,494
2021	56		—		480		536
2022	—		—		480		480
2023	—		—		480		480
Thereafter	—		—		1,960		1,960
Total	$	1,222	$	1,029	$	4,337	$	6,588

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 4—Fair Value Measurements

We define fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques we use to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We classify the inputs used to measure fair value into the following hierarchy:



Level 1		Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2		Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability.
Level 3		Unobservable inputs for the asset or liability.

The following table is a summary of financial assets measured at fair value on a recurring basis and their classification within the fair value hierarchy (in thousands).



	March 31, 2019								December 31, 2018
	Carrying Value		Level 1		Level 3		Total		Carrying Value		Level 1		Level 3		Total
Assets
Money market funds	$	107,974	$	107,974	$	—	$	107,974	$	323	$	323	$	—	$	323
Total assets measured and recorded at fair value	$	107,974	$	107,974	$	—	$	107,974	$	323	$	323	$	—	$	323

Liabilities
Earnout liability—current	$	26,500	$	—	$	26,500	$	26,500	$	20,730	$	—	$	20,730	$	20,730
Earnout liability—non-current	—		—		—		—		19,270		—		19,270		19,270
Total liabilities measured and recorded at fair value	$	26,500	$	—	$	26,500	$	26,500	$	40,000	$	—	$	40,000	$	40,000

Our cash equivalents were invested in money market funds and were classified as Level 1. We endeavor to utilize the best available information in measuring fair value. We used observable prices in active markets in determining the classification of our money market funds as Level 1.

The earnout liability represents the fair value of the Earnout Consideration payable to acquire GoMedigap and will be adjusted to fair value at each reporting date until settled. Changes in fair value will be recognized in operations while changes in the earnout liability due to the passage of time will be recognized as other expense.

We measure the earnout liability using internally developed assumptions, therefore it is classified as Level 3. The fair value of the earnout liability was measured using probability-weighted analysis and is discounted using a rate that appropriately captures the risk associated with the obligation. Key assumptions included new enrollments and volatility for the year ending December 31, 2019 and our simulated stock price at the time of payment.

Earnout liability activity during the three months ended March 31, 2019 was as follows (in thousands):



Balance at December 31, 2018	$	40,000
Settlement of first earnout liability	(26,800		)
Change in fair value	13,300
Balance at March 31, 2019	$	26,500

The first earnout liability settlement was made during the three months ended March 31, 2019, which consisted of a $9.5 million cash payment as well as a $17.3 million non-cash issuance of common stock.

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 5—Stockholder's Equity

2014 Equity Incentive Plan—The following table summarizes activity under our 2014 Equity Incentive Plan (the “2014 Plan”) for the three months ended March 31, 2019 (in thousands):



	Shares Available for Grant
Shares available for grant December 31, 2018	512
Restricted stock units granted ⁽¹⁾	—
Options granted ⁽²⁾	—
Restricted stock units cancelled ⁽³⁾	37
Options cancelled	8
Shares available for grant March 31, 2019	557


(1)	Includes grants of restricted stock units with service, performance-based or market-based vesting criteria.


(2)	Includes grants of stock options with service, performance-based or market-based vesting criteria.


(3)	Includes cancelled restricted stock units with service, performance-based or market-based vesting criteria.

The following table summarizes stock option activity (in thousands, except weighted-average exercise price and weighted-average remaining contractual life data):



	Number of Stock Options ⁽¹⁾		Weighted Average Exercise Price		Weighted-Average Remaining Contractual Life (years)	Aggregate Intrinsic Value ⁽²⁾
Balance outstanding at December 31, 2018	1,005		$	18.34	5.0	$	20,226
Granted	—		$	—
Exercised	(108	)	$	21.88
Cancelled	(11	)	$	33.30
Balance outstanding at March 31, 2019	886		$	17.72	5.0	$	39,521
Vested and expected to vest at March 31, 2019	845		$	17.50	5.0	$	37,912
Exercisable at March 31, 2019	439		$	14.46	4.4	$	21,006


(1)	Includes certain stock options with service, performance-based or market-based vesting criteria.


(2)	The aggregate intrinsic value is calculated as the difference between the closing price of our common stock as of March 31, 2019 and December 31, 2018 and the exercise price multiplied by number of in-the-money options.

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

The following table summarizes restricted stock unit activity (in thousands, except weighted-average grant date fair value and weighted-average remaining contractual life data):



	Number of Restricted Stock Units ⁽¹⁾		Weighted-Average Grant Date Fair Value		Weighted-Average Remaining Service Period (years)	Aggregate Intrinsic Value ⁽²⁾
Unvested as of December 31, 2018	1,869		$	16.95	4.8	$	71,816
Granted	—		$	—
Vested	(64	)	$	13.56
Cancelled	(37	)	$	16.78
Unvested as of March 31, 2019	1,768		$	17.03	5.3	$	110,230


(1)	Includes certain restricted stock units with service, performance-based or market-based vesting criteria.


(2)	The aggregate intrinsic value is calculated as the product of our closing stock price as of March 31, 2019 and December 31, 2018, and the number of restricted stock units outstanding as of March 31, 2019 and December 31, 2018, respectively.

Stock Repurchase Programs—We had no stock repurchase activity during the three months ended March 31, 2019. In addition to 10,663,888 shares repurchased under our past repurchase programs as of March 31, 2019, we have in treasury 785,615 shares that were previously surrendered by employees to satisfy tax withholdings due in connection with the vesting of certain restricted stock units. As of March 31, 2019 and December 31, 2018, we had a total of 11,449,503 shares and 11,426,292 shares, respectively, held in treasury.

For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method.

Stock-Based Compensation Expense—The following table summarizes stock-based compensation expense recorded during the three months ended March 31, 2019 and 2018 (in thousands):



	Three Months Ended March 31,
	2019		2018
Common stock options	$	602	$	498
Restricted stock units	2,627		2,303
Total stock-based compensation expense	$	3,229	$	2,801

The following table summarizes stock-based compensation expense by operating function for the three months ended March 31, 2019 and 2018 (in thousands):



	Three Months Ended March 31,
	2019		2018
Marketing and advertising	$	629	$	370
Customer care and enrollment	273		165
Technology and content	549		343
General and administrative	1,778		1,672
Restructuring	—		251
Total stock-based compensation expense	$	3,229	$	2,801

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

During the three months ended March 31, 2018, as part of our workforce reduction, we accelerated the vesting dates of certain stock options and restricted stock units granted to a former employee. We recorded a $0.3 million incremental stock-based compensation expense in connection with this modification.

Note 6—Income Taxes

The following table summarizes our benefit from income taxes and our effective tax rates for the three months ended March 31, 2019 and 2018 (in thousands, except effective tax rate):



	Three Months Ended March 31,
	2019			2018
Loss before benefit from income taxes	$	(8,626	)	$	(6,536	)
Benefit from income taxes	(3,467		)	(1,691		)
Effective tax rate	40.2		%	25.9		%

For the three months ended March 31, 2019, we recognized a benefit for income taxes of $3.5 million, representing an effective tax rate of 40.2% which was higher than the statutory federal tax rate due primarily to stock-based compensation adjustments, and lobbying and other non-deductible expenses, partially offset by research and development credits. For the three months ended March 31, 2018, we recognized a benefit from income taxes of $1.7 million, representing an effective tax rate of 25.9%, which was higher than the statutory federal tax rate due primarily to stock based compensation adjustments, non-deductible lobbying expenses, and foreign income inclusions, partially offset by research and development credits.

Assessing the realizability of our deferred tax assets is dependent upon several factors, including the likelihood and amount, if any, of future taxable income in relevant jurisdictions during the periods in which those temporary differences become deductible. We forecast taxable income by considering all available positive and negative evidence, including our history of operating income and losses and our financial plans and estimates that we use to manage the business. These assumptions require significant judgment about future taxable income. As a result, the amount of deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change. We continue to recognize our deferred tax assets as of March 31, 2019, as we believe it is more likely than not that the net deferred tax assets will be realized, with the exception of certain state net operating losses that are expected to expire unutilized which have a valuation allowance.

As a result of our adoption of ASC 606 using the full retrospective method, we recognized a significant deferred tax liability due to the resulting acceleration of revenue recognition while revenue for tax purposes will continue to be recognized as we collect cash. This deferred tax liability is a source of income that can be used to support the realizability of our deferred tax assets. As a result of the significantly increased deferred tax liability, in 2018, we reversed the valuation allowance recorded against our U.S. deferred tax assets as of January 1, 2015, the earliest period to which the retrospective adoption of ASC 606 was applied.

Note 7—Net Loss Per Share

For each of the three months ended March 31, 2019 and 2018, we had securities outstanding that could potentially dilute earnings per share, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net loss per share as their effect would have been anti-dilutive. The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of the following (in thousands):



	Three Months Ended March 31,
	2019	2018
Common stock options	960	1,006
Restricted stock units	1,426	1,426
Total	2,386	2,432

Note 8—Commitments and Contingencies

Operating Leases

Refer to Note 11—Leases for commitments related to our operating leases.

Contingencies

From time to time, we receive inquiries from governmental bodies and also may be subject to various legal proceedings and claims arising in the ordinary course of business. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings or other contingencies could result in material costs, even if we ultimately prevail.

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Legal Proceedings

On April 6, 2018, a former California employee filed a complaint against us in the Superior Court of the State of California for the County of Sacramento. The plaintiff’s complaint was filed pursuant to the California Labor Code Private Attorneys General Act of 2004, purportedly on behalf of all current and former hourly-paid or non-exempt employees who work or have worked for us in California. The complaint alleges that we violated a number of wage and hour laws with respect to these non-exempt employees, including, among other things, the failure to comply with California law as to (i) the payment of overtime wages; (ii) the payment of minimum wages; (iii) providing uninterrupted meal and rest periods, (iv) the payment of wages earned during employment and owed upon the termination of employment; (v) providing complete and accurate wage statements, (vi) keeping of accurate payroll records; and (vii) the proper reimbursement for necessary business-related expenses and costs. The complaint seeks allegedly unpaid wages, civil penalties and costs, expenses and attorneys’ fees. Discovery has only recently commenced, and as a result we cannot estimate the likelihood of liability or the amount of potential damages.

On April 17, 2019, an individual filed a putative class action complaint against us that alleges we violated the Telephone Consumer Protection Act (“TCPA”), 47 U.S.C. §§ 227(b)(1) and (c)(5) and certain provisions of 47 C.F.R. § 64.1200 promulgated thereunder. The complaint alleges, among other things, that we (i) made unsolicited telephone calls to the Plaintiff and putative class members using a prerecorded voice message in violation of 47 U.S.C. § 227(b)(1); and (ii) made more than one unsolicited telephone call to Plaintiff and putative class members within a 12-month period without express consent and without instituting procedures that comply with regulatory minimum standards for implementing Do Not Call in violation of 47 C.F.R. § 64.1200 and 47 U.S.C. § 227(c)(5). The complaint seeks an order certifying two classes: (i) a class of individuals in the United States who we (or agents acting on our behalf) called using a prerecorded voice message for substantially the same reason we allegedly called the Plaintiff; and (ii) a class of individuals in the United States who we (or agents acting on our behalf) called more than one time within any 12-month period for substantially the same reason we allegedly called the Plaintiff. The complaint also seeks (i) an award of actual and/or statutory damages for the benefit of Plaintiff and the classes; (ii) an order declaring that our actions violate the TCPA; (iii) an injunction requiring us to cease all unsolicited calling activity and to otherwise protect the interest of the classes; and (iv) such further other relief as the court deems just and proper.

Service and Licensing Obligations

We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance and software licensing. The terms of these services and licensing agreements are generally up to three years. As the benefits of these agreements are experienced uniformly over the applicable contractual periods, we record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements.

The following table presents a summary of our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2019 (in thousands):



For the Years Ending December 31,	Service and Licensing Obligations
Remainder of 2019	$	3,366
2020	2,462
2021	946
2022	434
2023	444
Thereafter	229
Total	$	7,881

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 9—Operating Segments, Geographic Information and Significant Customers

Operating Segments

We report segment information based on how our chief executive officer, who is CODM, regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. The performance measures of our segments include total revenue and profit (loss). Our business structure is comprised of two operating segments.

•Medicare

•Individual, Family and Small Business

The Individual, Family and Small Business segment consists primarily of commissions earned from our sale of individual and family and small business health insurance plans and ancillary products sold to our non-Medicare-eligible customers, including but not limited to, dental, vision, and short-term health insurance. To a lesser extent, the Individual, Family and Small Business segment consists of amounts earned from our online sponsorship program that allows carriers to purchase advertising space in specific markets in a sponsorship area on our website, our licensing to third parties the use of our health insurance ecommerce technology and our delivery and sale to third parties of individual and family health insurance leads generated by our ecommerce platforms and our marketing activities.

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

The following table presents summary results of our operating segments for the three months ended March 31, 2019 and 2018 (in thousands):



	Three Months Ended March 31,
	2019			2018
Revenue
Medicare	$	54,901		$	30,763
Individual, Family and Small Business	13,872			12,307
Total revenue	$	68,773		$	43,070

Segment profit
Medicare segment profit	$	10,826		$	3,180
Individual, Family and Small Business segment profit	6,024			3,488
Total segment profit	16,850			6,668
Corporate	(8,296		)	(7,854		)
Stock-based compensation expense	(3,229		)	(2,550		)
Depreciation and amortization	(655		)	(619		)
Acquisition costs	—			(58		)
Change in fair value of earnout liability	(13,306		)	—
Restructuring	—			(1,856		)
Amortization of intangible assets	(547		)	(451		)
Other income, net	557			184
Loss before benefit from income taxes	$	(8,626	)	$	(6,536	)

There are no internal revenue transactions between our operating segments. Our CODM does not separately evaluate assets by segment, and therefore assets by segment are not presented.

Geographic Information

Our long-lived assets consisted primarily of property and equipment and internally-developed software. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area as of March 31, 2019 and December 31, 2018 were as follows (in thousands):



	March 31, 2019		December 31, 2018
United States	$	16,697	$	15,614
China	342		378
Total	$	17,039	$	15,992

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Significant Customers

Substantially all revenue for the three months ended March 31, 2019 and 2018 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue for the three months ended March 31, 2019 and 2018 are presented in the table below:



	Three Months Ended March 31,
	2019		2018
Humana	23	%	15	%
UnitedHealthcare ⁽¹⁾	17	%	21	%
Aetna⁽²⁾	17	%	10	%


(1)	UnitedHealthcare also includes other carriers owned by UnitedHealthcare.


(2)	Aetna also includes other carriers owned by Aetna.

As of March 31, 2019, our total outstanding accounts receivable balance was $331.6 million. Our contracts with the above carriers expose us to credit risk that a financial loss could be incurred if the counterparty does not fulfill its financial obligation. While we are exposed to credit losses due to the non-performance of our counterparties, we consider the risk of this remote. We estimate our maximum credit risk in determining the commissions receivable amount recorded on the balance sheet.

Note 10—Restructuring

In February 2018, our Board of Directors approved a plan to close our sales call center in Massachusetts and to terminate the employment of other employees in certain other locations. As part of this plan, we eliminated approximately 110 full-time positions, representing approximately 10% of our workforce, primarily within customer care and enrollment, and to a lesser extent, in our marketing and advertising and general and administrative groups.

Total pre-tax restructuring charges for the year ended December 31, 2018 were $1.9 million, which included approximately $1.6 million for employee termination benefits and $0.3 million in non-cash accelerated stock based compensation. Substantially all of the restructuring charges resulted in cash expenditures. The restructuring activities comprising the plan were completed by December 31, 2018, and there were no restructuring charges during the three months ended March 31, 2019.

Note 11—Leases

Adoption of ASC 842

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

On January 1, 2019, we adopted ASC 842—Leases, using the modified retrospective method. We have operating and finance leases for our corporate offices and certain equipment. Our leases have remaining lease terms of 1 year to 11 years. Our operating lease expense accounted for under ASC 842 for the three months ended March 31, 2019 was $1.3 million, and our cash outflows related to operating leases were $0.9 million for the three months ended March 31, 2019. As a result of adopting the ASU, as of January 1, 2019, we recorded an increase to our right-of-use asset and lease liability of $23.3 million and $24.6 million, respectively. For the three months ended March 31, 2019, we recorded an additional lease liability of $3.5 million related to an amendment entered into on March 26, 2019 for our Salt Lake City office, which is described further below. The adoption of this ASU resulted in a total non-cash increase to our lease liability of $28.1 million for the three months ended March 31, 2019.

Supplemental information related to leases was as follows (in thousands):



	March 31, 2019
Operating lease right-of-use assets	$	25,730
Operating lease liabilities	$	27,580

Weighted-average remaining lease term of operating leases (in years)	7.5
Weighted-average discount rate of operating leases	6.1		%

Maturities of operating lease liabilities are as follows (in thousands):



Year ending December 31,
Remainder of 2019	$	3,641
2020	5,502
2021	4,068
2022	4,189
2023	3,972
Thereafter	13,765
Total lease payments	35,137
Less imputed interest	(7,557		)
Total	$	27,580

Operating Lease Obligations

We lease our operating facilities and certain of our equipment and furniture and fixtures under various operating leases, the latest of which expires in February 2029. Certain of these leases have free or escalating rent payment provisions. We recognize rent expense on our operating leases on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements.

On March 26, 2019, we entered into an amendment to the lease agreement for our Salt Lake City, Utah, office to expand our office space to a total of 41,813 square feet from 28,915 square feet. The lease term for the expanded office space is expected to commence on May 1, 2019. The term of the lease for the original and expanded office space was also extended to terminate on the last day of the month that is 84 months after the commencement date of the expanded space. As of March 31, 2019, future minimum payments are expected to be $7.2 million over the remaining term of the lease plus our proportionate share of certain operating expenses, insurance costs and taxes for each calendar year during the lease.

On April 25, 2018, we entered into a lease agreement to lease approximately 32,492 square feet of office space located in Santa Clara, California. We entered into this lease agreement as a result of the expiration of one of our leases in Mountain View, California on December 31, 2018. The term of the lease is approximately one hundred twenty-three months, commencing on October 1, 2018 and ending on an estimated date of February 28, 2029. As of March 31, 2019, future minimum payments are expected to be $17.1 million over the remaining term of the lease plus our proportionate share of certain operating expenses, insurance costs and taxes for each calendar year during the lease.

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

In connection with the Santa Clara, California lease agreement, we entered into a financial guarantee consisting of a standby letter of credit for $1.5 million, which may be reduced in increments of 20% of the original amount thereof on the second, third, fourth and fifth anniversaries of the commencement date, and may be reduced by an additional 8% of the original amount on the sixth anniversary of the commencement date, subject to our compliance with the applicable conditions to such reductions set forth in the lease.

In March 2018, we entered into an agreement to lease 26,878 square feet of office space in Austin, Texas. The term of this lease agreement is 90 months, commencing in September 2018 and ending in May 2026. As of March 31, 2019, future minimum payments are expected to be $4.4 million over the remaining term of the lease plus our proportionate share of certain operating expenses, insurance costs and taxes for each calendar year during the lease.

In connection with the Austin, Texas office lease agreement, we entered into a financial guarantee consisting of a standby letter of credit for $0.6 million, which may be reduced on the third and subsequent anniversaries of the commencement date, subject to our compliance with the applicable conditions to such reductions set forth in the lease.

In March 2012, we entered into an agreement to lease 18,272 square feet of office space in Mountain View, California. In connection with this lease agreement, we entered into a financial guarantee consisting of a standby letter of credit for $0.6 million, which may be reduced in increments of 25% of the original amount thereof on the first, second and third anniversaries of the commencement date, subject to our compliance with the applicable conditions to such reductions set forth in the lease. On November 2, 2018, we entered into an agreement to sublease this office space to a third party. As of March 31, 2019, future minimum payments are expected to be $3.3 million. The obligation as of March 31, 2019 was immaterial net of sublease income.

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 12—Debt

On September 17, 2018, we entered into a Credit Agreement with Royal Bank of Canada (“RBC”), as administrative agent and collateral agent (the “Credit Agreement”). The Credit Agreement provides for a $40 million secured asset-backed revolving credit facility with a $5 million letter of credit sub-facility. The commitments under the Credit Agreement expire on September 17, 2021, at which time any amounts drawn under facility are contractually due.

The borrowing base under the Credit Agreement is comprised of an amount equal to (a) the lesser of (i) eighty percent (80%) of Eligible Commissions Receivables (as defined in the Credit Agreement) we actually collected by during the immediately preceding period of three months or (ii) eighty percent (80%) of our Eligible Commission Receivables for the immediately succeeding period of three months, plus (b) fifty percent (50%) of our Eligible Commission Receivables for the immediately succeeding period of six months (excluding the immediately succeeding period of three months), in each case subject to reserves established by RBC (the “Borrowing Base”). The proceeds of the loans under the Credit Agreement may be used for working capital and general corporate purposes. The Borrowers have the right to prepay the loans under the Credit Agreement in whole or in part at any time without penalty. Subject to availability under the Borrowing Base, amounts repaid may be reborrowed.

Amounts not borrowed under the Credit Agreement will be subject to a commitment fee of 0.5% per annum on the daily unused portion of the credit facility, to be paid in arrears on the first business day of each calendar quarter. At closing, the Company paid a one-time facility fee of 1.75% of the total commitments under the Credit Agreement. The Company is also obligated to pay other customary administration fees for a credit facility of this size and type.

Availability under the credit facility is up to the lesser of $40 million or the Borrowing Base, which may be reduced from time to time pursuant to the Credit Agreement. In addition, the Credit Agreement contains a financial covenant requiring that we maintain Excess Availability (as defined in the Credit Agreement) at or above $6 million at any time. As of March 31, 2019, we were in compliance with all debt covenants.

We incurred $1.2 million of issuance costs in connection with the Credit Agreement, which were capitalized as part of other assets on the balance sheet. As of March 31, 2019, the balance of these issuance costs was $1.0 million.

As of March 31, 2019, we had no outstanding principal amount under our revolving credit facility.

Note 13—Public Offering of Common Stock

Pursuant to the effective registration statement which was filed on December 17, 2018, and amended on January 22, 2019, we entered into an underwriting agreement to issue a total of 2,760,000 shares of common stock, which included the exercise in full of the underwriters’ option to purchase 360,000 additional shares of common stock, at a price to the public of $48.50 per share in January 2019. Net proceeds from the offering were approximately $126.1 million after deducting underwriting discounts, commissions and expenses of the offering. We intend to use the net proceeds of the offering for general corporate purposes, including working capital.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In addition to historical information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, among other things, statements regarding our expectations relating to submitted and approved applications, membership and lifetime value of commissions; our expectations relating to revenue, sources of revenue, cost of revenue, the collectability of our accounts receivable, operating expenses and profitability; our expectations regarding our strategy and investments including our acquisition of GoMedigap, and impact to our operating results; growth opportunities in our business; our expectations regarding the impact of future and existing healthcare laws and regulations on our business; our ability to enroll and plans relating to the enrollment of individuals and families into qualified health plans through government health insurance exchanges; our belief that the Internet will be a frequently utilized channel for researching and enrolling in health insurance plans; the anticipated trends and market opportunity for Medicare and health insurance plans; our execution during the Medicare annual enrollment period; the scalability of our Medicare business; our expectations regarding commission rates, payment rates, conversion rates, membership retention rates and membership acquisition costs; our estimates regarding membership and the constrained lifetime value of commissions per approved member; our expectations regarding the supply and demand of individual and family health insurance; our expectations relating to the seasonality of our business; our expectations relating to marketing and advertising expense and expected contributions from our marketing partner channel; the timing of our receipt of commission and other payments; our critical accounting policies and related estimates; our estimates relating to fair value of earnout liability; our belief that cash generated from operations and our

current cash and cash equivalents will be sufficient to fund operations for the next twelve months; our use of proceeds from our equity offering; future capital requirements; expected competition from government-run health insurance exchanges and other sources; the timing and source of our Medicare-related revenue; political, legislative, regulatory and legal challenges; the merits or potential impact of any lawsuits filed against us; as well as other statements regarding our future operations, financial condition, prospects and business strategies. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those risks associated with the impact of healthcare reform; our ability to retain existing members and enroll a large number of new members during the annual healthcare reform open enrollment period and Medicare annual enrollment period; the impact of annual enrollment period for the purchase of individual and family health insurance and its timing on our recognition of revenue; our ability to sell qualified health insurance plans to subsidy-eligible individuals and to enroll subsidy eligible individuals through government-run health insurance exchanges; the success of our health insurance benefit packages; our ability to comply with CMS guidance and impact on conversion rates as a result of the federal exchange changes to enrollment; competition, including competition from government-run health insurance exchanges; seasonality of our business and the fluctuation of our operating results; our ability to retain existing members and limit member turnover; changes in consumer behaviors and their selection of individual and family health insurance products, including the selection of products for which we receive lower commissions; product offerings among carriers and the resulting impact on our commission revenue; carriers exiting the market of selling individual and family health insurance and the resulting impact on our supply and commission revenue; our ability to execute on our growth strategy in the Medicare and small business health insurance markets; the impact of increased health insurance costs on demand; our ability to timely receive and accurately predict the amount of commission payments from health insurance carriers; medical loss ratio requirements; delays in our receipt of items required to recognize Medicare revenue; changes in member conversion rates; our ability to accurately estimate membership and lifetime value of commissions; our relationships with health insurance carriers; customer concentration and consolidation of the health insurance industry; our success in marketing and selling health insurance plans and our unit cost of acquisition; our ability to hire, train and retain licensed health insurance agents and other employees; the need for health insurance carrier and regulatory approvals in connection with the marketing of Medicare-related insurance products; costs of acquiring new members; scalability of the Medicare business; lack of membership growth and retention rates; consumer satisfaction of our service; our ability to attract and to convert online visitors into paying members; changes in products offered on our ecommerce platform; changes in commission rates; maintaining and enhancing our brand identity; our ability to derive desired benefits from investments in our business, including membership growth initiatives; dependence on acceptance of the Internet as a marketplace for the purchase and sale of health insurance; reliance on marketing partners; the impact of our direct-to-consumer email, telephone and television marketing efforts; timing of receipt and accuracy of commission reports; payment practices of health insurance carriers; our ability to successfully make and integrate acquisitions; dependence on our operations in China; the restrictions in our debt obligations; compliance with insurance and other laws and regulations; exposure to security risks and our ability to safeguard sensitive data; and the performance, reliability and availability of our ecommerce platform and underlying network infrastructure. Other risks include the risks discussed under the heading “Risk Factors” in Part II, Item 1A. of this report and those discussed in our other Securities and Exchange Commission filings. The following discussion should be read in conjunction with our Annual Report on Form 10-K as filed with the Securities and Exchange Commission in March 2019, and the audited consolidated financial statements and related notes contained therein. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements.

Overview

We are a leading private health insurance exchange for individuals, families and small businesses. Through our website addresses (www.eHealth.com, www.eHealthInsurance.com, www.eHealthMedicare.com, www.Medicare.com, www.PlanPrescriber.com and www.GoMedigap.com), consumers can get quotes from leading health insurance carriers, compare plans side-by-side, and apply for and purchase Medicare-related, individual and family, small business and ancillary health insurance plans. Our ecommerce technology also enables us to deliver consumers’ health insurance applications electronically to health insurance carriers. As a result, we simplify and streamline the complex and traditionally paper-intensive health insurance sales and purchasing process.

On January 22, 2018, we completed our acquisition of Wealth, Health and Life Advisors, LLC, more commonly known as GoMedigap, a technology-enabled provider of Medicare Supplement enrollment services. GoMedigap has built a leading consumer acquisition and engagement platform focused on meeting the Medicare Supplement insurance needs of its individual customers with a technology-enabled, consumer-centric approach that aligns with our mission and operations. For more information on our acquisition of GoMedigap, see Note 2—Acquisition in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q.

We have invested heavily in technology and content related to our ecommerce platforms. We have also invested significant time and resources in obtaining licenses to sell health insurance in all 50 states and the District of Columbia, developing member acquisition programs, obtaining necessary regulatory approvals of our websites and establishing relationships and appointments with leading health insurance carriers, enabling us to offer thousands of health insurance plans online. Our ecommerce platforms can be accessed directly through our websites as well as through our network of marketing partners.

We operate as two distinct reporting segments:

•Medicare

•Individual, Family and Small Business.

For more information regarding our segments, see Note 9—Operating Segments, Geographic Information and Significant Customers in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q.

Adoption of Accounting Standard Update No. 2016-02, Leases (Topic 842)

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize a right-of-use asset and lease liability for all leases with terms of more than 12 months. Recognition, measurement, and presentation of expenses will depend on classification as a finance or operating lease; for lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct finance leases. The guidance also eliminates existing real estate-specific provisions for all entities. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. We adopted the standard using the modified retrospective method on January 1, 2019. As a result of adopting the ASU, as of March 31, 2019, we recorded an increase to our right-of-use asset and lease liability of $25.7 million and $27.6 million, respectively, which are discussed in Note 11—Leases in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q.

Summary of Selected Metrics

In addition to traditional financial metrics, we rely upon certain metrics to estimate and recognize commission revenue, evaluate our business performance and facilitate strategic planning. Our commission revenue is influenced by a number of factors including:


•	the number of individuals on applications for Medicare-related, individual and family, small business and ancillary health insurance plans we submit to and are approved by the relevant health insurance carriers, and


•	the constrained lifetime value of approved members for Medicare-related, individual and family and ancillary health insurance plans we sell as well as the estimated annual value of approved members for small business plans we sell.

Submitted Applications and Approved Members

The following table shows submitted applications and approved members by product for the three months ended March 31, 2019 and 2018 (amounts in thousands):



	Submitted Applications ⁽¹⁾				Approved Members ⁽¹⁾
	Three Months Ended March 31,				Three Months Ended March 31,
	2019	2018	Percent Change		2019	2018	Percent Change
Medicare ⁽²⁾
Medicare Advantage ⁽³⁾	44,491	24,796	79	%	40,741	24,620	65	%
Medicare Supplement ⁽³⁾	10,303	6,388	61	%	8,631	5,416	59	%
Medicare Part D	9,052	3,845	135	%	8,527	4,302	98	%
Total Medicare	63,846	35,029	82	%	57,899	34,338	69	%
Individual and Family ⁽⁴⁾
Non-Qualified Health Plans	2,372	3,886	(39	)%	6,071	9,213	(34	)%
Qualified Health Plans	855	2,684	(68	)%	5,527	14,686	(62	)%
Total Individual and Family	3,227	6,570	(51	)%	11,598	23,899	(51	)%
Ancillaries ⁽⁵⁾
Short-term	15,609	19,495	(20	)%	14,932	20,996	(29	)%
Dental	11,163	12,993	(14	)%	13,056	14,162	(8	)%
Vision	5,531	5,584	(1	)%	6,415	6,595	(3	)%
Other	6,213	13,341	(53	)%	5,212	9,246	(44	)%
Total Ancillaries	38,516	51,413	(25	)%	39,615	50,999	(22	)%
Small Business ⁽⁶⁾	1,969	1,720	14	%	4,252	5,294	(20	)%
Total	107,558	94,732	14	%	113,364	114,530	(1	)%



(1)	The number of approved members is equal to the number of individuals on applications that were approved during the period presented and includes individuals on approved applications that were submitted prior to the period presented. A single application for some products may cover more than one individual. Each of the individuals on a single submitted application are counted as approved members after the application is approved.
(2)	Medicare-related health insurance applications submitted on our website or through our customer care center during the period, including Medicare Advantage, Medicare Part D prescription drug and Medicare Supplement plans.
(3)	The percentage of members who submit applications for Medicare Advantage and Medicare Supplement products online through our platform increased from 7% for the three months ended March 31, 2018 to 12% for the three months ended March 31, 2019.
(4)	Major medical Individual and Family plan ("IFP") health insurance applications submitted on our website during the period. An applicant may submit more than one application. We define our IFP offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans.
(5)	Ancillary Plans consists primarily of short-term, dental and vision insurance plans submitted on our website during the period.
(6)	Applications for small business health insurance applications are counted as submitted when the applicant completes the application, the employees complete their applications, the applicant submits the application to us and we submit the application to the carrier.

Submitted Applications

Applications are counted as submitted when the applicant completes the application and either clicks the submit button on our website or provides verbal authorization to submit the application. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier, such as providing additional information. In addition, an applicant may submit more than one application.

Medicare submitted applications grew 82% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 primarily due to 79% growth in submitted applications for Medicare Advantage plans. Individual and family plan submitted applications declined 51% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 due to market conditions in the individual and family plan market. The decline in the individual and family plan submitted applications also limited our ability to cross-sell ancillary plans, resulting in a decline of 25% in submitted applications for the three months ended March 31, 2019 compared to the three months ended March 31, 2018, which was primarily due to a 20% decrease in submitted applications for short-term plans year-over-year. Small business submitted applications grew 14% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 due to improved focus on key partnerships, technology enhancements and increased conversions.

Approved Members

Approved Members represents the number of individuals on submitted applications that were approved by the relevant insurance carrier for the identified product during the current period. The applications may be submitted in either the current period or prior periods. Approved members may not pay for their plan and become paying members.

Medicare total approved members grew 69% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018. Approved Medicare Advantage members grew 65%, approved Medicare Supplement plan members grew 59% and approved members on Medicare Part D plans increased 98% compared to the first quarter of 2018. Individual and family plan approved members declined 51% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 due to market conditions in the individual and family plan market. Ancillary approved members declined 22% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 primarily due to a decline in our cross-selling of short-term plans as a result of the decline in individual and family plan approved members. Small business approved members declined 20% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 mainly due to timing of submitted application approval and a decrease in the percentage of approved applications.

Constrained Lifetime Value of Commissions Per Approved Member

The following table shows our estimated constrained lifetime value, or LTV, of commissions per approved member by product for the three months ended March 31, 2019 and 2018:



	Three Months Ended March 31,
	2019		2018		Percentage Change
Medicare
Medicare Advantage	$	954	$	880	8	%
Medicare Supplement	$	999	$	1,029	(3	)%
Medicare Part D	$	258	$	270	(4	)%

Individual and Family
Non-Qualified Health Plans	$	178	$	140	27	%
Qualified Health Plans	$	194	$	134	45	%

Ancillaries
Short-term	$	65	$	60	9	%
Dental	$	71	$	74	(4	)%
Vision	$	63	$	51	23	%

Small Business	$	155	$	178	(13	)%

Constrained lifetime value of commissions per approved member represents commissions estimated to be collected over the estimated life of an approved member’s policy after applying constraints in accordance with our revenue recognition policy. The estimate is driven by multiple factors, including but not limited to, contracted commission rates, carrier mix, expected policy churn and applied constraints. These factors may result in varying values from period to period. We evaluate lifetime values on a quarterly basis, and as part of that process, we apply an estimated future churn factor that is based on observed historical results for that relevant product. For additional information on constraints see Note 1—Summary of Business and Significant Accounting Policies in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q.

For small business the constrained lifetime value represents the estimated commissions we expect to collect on each member covered by the policy over the following 12 months. The estimate is driven by multiple factors, including but not limited to, contracted commission rates, carrier mix, expected policy churn and applied constraints. These factors may result in varying values from period to period.

The constrained LTV of commissions per approved member for Medicare Advantage increased 8% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 primarily due to improved member retention and commission rate increases. The constrained LTV of commissions per Medicare Supplement approved member and constrained LTV of commissions per Medicare Part D approved member decreased 3% and 4%, respectively, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 primarily as a result of an increase in member churn. The constrained LTV of commissions per short-term approved member increased 9% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 primarily as a result of selling higher priced plans and an increase in average duration.

Estimated Membership

Estimated membership represents the estimated number of members active as of the date indicated based on the number of members for whom we have received or applied a commission payment during the month of estimation.

The following table shows estimated membership by product as of March 31, 2019 and 2018:



	As of March 31,
	2019	2018	Percent Change
Medicare ⁽¹⁾
Medicare Advantage	280,763	218,685	28	%
Medicare Supplement	76,875	58,507	31	%
Medicare Part D	146,239	104,595	40	%
Total Medicare	503,877	381,787	32	%
Individual and Family ⁽²⁾	130,297	182,655	(29	)%
Ancillaries ⁽³⁾
Short-term	23,626	15,467	53	%
Dental	137,179	162,570	(16	)%
Vision	76,303	79,872	(4	)%
Other	37,985	35,423	7	%
Total Ancillaries	275,093	293,332	(6	)%
Small Business ⁽⁴⁾	42,972	35,545	21	%
Total Estimated Membership	952,239	893,319	7	%



(1)	For Medicare-related health insurance plans, we take the sum of (i) the number of members for whom we have received or applied a commission payment for a month that is up to two months prior to the date of estimation (after reducing that number using historical experience for assumed member cancellations over the period being estimated); and (ii) the number of applicants since that month (after reducing that number using historical experience for an assumed number of members who do not accept their approved application from the same period the previous year and for estimated member cancellations through the date of the estimate). To the extent we determine we have received substantially all of the commission payments related to a given month during the period being estimated, we will take the number of members for whom we have received or applied a commission payment during the month of estimation. Estimated number of members active on Medicare-related health insurance as of the date indicated based on the number of members for whom we have received or applied a commission payment during the month of estimation.
(2)	To estimate the number of members on Individual and Family health insurance plans, we take the sum of (i) the number of IFP members for whom we have received or applied a commission payment for a month that is up to six months prior to the date of estimation after reducing that number using historical experience for assumed member cancellations over the period being estimated; and (ii) the number of approved applications since that month (after reducing that number by the percentage of members who do not accept their approved policy from the same month of the previous year for estimated member cancellations through the date of the estimate). To the extent we determine we have received substantially all of the commission payments related to a given month during the period being estimated, we will take the number of members for whom we have received or applied a commission payment during the month of estimation.
(3)	For ancillary health insurance plans (such as short-term, dental and vision insurance), we take the sum of (i) the number of members for whom we have received or applied a commission payment for a month that is up to three months prior to the date of estimation (after reducing that number using historical experience for assumed member cancellations over the period being estimated); and (ii) the number of approved members over that period (after reducing that number using historical experience for an assumed number of members who do not accept their approved policy from the same month of the previous year and for estimated member cancellations through the date of the estimate). To the extent we determine we have received substantially all of the commission payments related to a given month during the period being estimated, we will take the number of members for whom we have received or applied a commission payment during the month of estimation. The one to three-month period varies by insurance product and is largely dependent upon the timeliness of commission payment and related reporting from the related carriers.
(4)	For small business health insurance plans, we estimate the number of members using the number of initial members at the time the group is approved, and we update this number for changes in membership if such changes are reported to us by the group or carrier in the period it is reported. However, groups generally notify the carrier directly of policy cancellations and increases or decreases in group size without informing us. Health insurance carriers often do not communicate policy cancellation information or group size changes to us. We often are made aware of policy cancellations and group size changes at the time of annual renewal and update our membership statistics accordingly in the period they are reported.

Health insurance carriers bill and collect insurance premiums paid by our members. The carriers do not report to us the number of members that we have as of a given date. The majority of our members who terminate their plans do so by discontinuing their premium payments to the carrier and do not inform us of the cancellation. Also, some of our members pay their premiums less frequently than monthly. Given the number of months required to observe non-payment of commissions in order to confirm cancellations, we estimate the number of members who are active on insurance policies as of a specified date.

After we have estimated membership for a period, we may receive information from health insurance carriers that would have impacted the estimate if we had received the information prior to the date of estimation. We may receive commission payments or other information that indicates that a member who was not included in our estimates for a prior period was in fact an active member at that time, or that a member who was included in our estimates was in fact not an active member of ours. For instance, we reconcile information carriers provide to us and may determine that we were not historically paid commissions owed to us, which would cause us to have underestimated membership. Conversely, carriers may require us to return commission payments paid in a prior period due to policy cancellations for members we previously estimated as being active. We do not update our estimated membership numbers reported in previous periods. Instead, we reflect updated information regarding our historical membership in the membership estimate for the current period. As a result of the delay in our receipt of information from insurance carriers, actual trends in our membership are most discernible over periods longer than from one quarter to the next. As a result of the delay we experience in receiving information about our membership, it is difficult for us to determine with any certainty the impact of current conditions on our membership retention. Various circumstances could cause the assumptions and estimates that we make in connection with estimating our membership to be inaccurate, which would cause our membership estimates to be inaccurate. A member who purchases and is active on multiple standalone insurance plans will be counted as a member more than once. For example, a member who is active on both an individual and family health insurance plan and a standalone dental plan will be counted as two continuing members.

Medicare membership grew 32% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 primarily due to 28% growth in Medicare Advantage membership. Individual and family plan membership declined 29% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 due to market conditions in the individual and family plan market. Ancillary membership declined 6% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 as a result of the decline in individual and family plan membership, partially offset by growth in short-term plan members. Small business estimated membership grew 21% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 due to improved focus on key partnerships, technology enhancements and increased conversions.

Member Acquisition

Marketing initiatives are an important component of our strategy to increase revenue. Our marketing initiatives are focused on three primary member acquisition channels: direct, marketing partners and online advertising and are primarily designed to encourage consumers to complete an application for health insurance. In addition, we incur customer care and enrollment expenses in assisting applicants during the enrollment process.

The following table shows our variable marketing cost per approved member and the customer care and enrollment expense per approved member metrics for the three months ended March 31, 2019 and 2018:



	Three Months Ended March 31,
	2019		2018		Percent Change
Medicare variable cost per approved member
Medicare variable marketing cost per approved Medicare Advantage ("MA")-equivalent member ⁽¹⁾	$	334	$	289	16	%
Medicare customer care and enrollment ("CC&E") cost per approved MA-equivalent member ⁽²⁾	$	344	$	350	(2	)%
Total Medicare variable cost per approved member	$	678	$	639	6	%

Individual and Family Plan ("IFP") variable cost per approved member
IFP variable marketing cost per approved IFP-equivalent member ⁽³⁾	$	24	$	41	(42	)%
IFP CC&E cost per approved IFP-equivalent member ⁽⁴⁾	$	66	$	43	55	%
Total IFP variable cost per approved member	$	90	$	84	7	%

Expense Metrics Per Approved Member



(1)	Variable marketing cost per approved MA-equivalent member represents direct costs incurred in member acquisition for Medicare Advantage, Medicare Supplement and Medicare Part D plans from our direct, marketing partners and online advertising channels divided by MA-equivalent approved members in a given period. MA-equivalent members is a derived metric and is equal to the sum of Medicare Part D approved members divided by 4, the number of Medicare Advantage approved members and the number of Medicare Supplement approved members in the given period.
(2)	Medicare CC&E cost per approved MA-equivalent member is equal to the CC&E expense of our Medicare business included in our operating costs divided by MA-equivalent approved members in a given period. MA-equivalent approved members is a derived metric and is equal to the sum of Medicare Part D approved members divided by 4, the number of Medicare Advantage approved members and the number of Medicare Supplement approved members in the given period.
(3)	Variable marketing cost per approved IFP-equivalent member represents direct costs incurred in member acquisition for IFP plans from our direct, marketing partners and online advertising channels divided by IFP-equivalent approved members in a given period. IFP-equivalent approved members is a derived metric and is equal to the sum of the number of short-term approved members divided by 3 and the IFP approved members in the given period.
(4)	IFP CC&E cost per approved IFP-equivalent member is equal to the CC&E expense of our IFP business included in our operating costs divided by IFP-equivalent approved members in a given period. IFP-equivalent approved members is a derived metric and is equal to the sum of the number of short-term approved members divided by 3 and the IFP approved members in the given period.

Variable marketing cost per approved MA-equivalent member increased 16% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 due to higher investments in our Medicare marketing efforts. Medicare CC&E expense per approved MA-equivalent member decreased 2% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 due to an increase in online enrollments.

Variable marketing cost per approved IFP-equivalent member decreased 42% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 due to lower volumes per sales agent in the IFP market. IFP CC&E expense per approved IFP-equivalent member increased 55% in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 due to an increase in the number of sales agents.

Critical Accounting Policies and Estimates

The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles, or U.S. GAAP, requires us to make judgments, assumptions, and estimates that affect the amounts reported in the consolidated financial statements and the accompanying notes. These estimates and assumptions are based on current facts, historical experience, and various other factors that we believe are reasonable under the circumstances to determine reported amounts of assets, liabilities, revenue and expenses that are not readily apparent from other sources. To the extent there are material differences between our estimates and the actual results, our future consolidated results of operations may be affected.

An accounting policy is considered to be critical if the nature of the estimates or assumptions is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and the effect of the estimates and assumptions on financial condition or operating performance. The accounting policies we believe to reflect our more significant estimates, judgments and assumptions and are most critical to understanding and evaluating our reported financial results are as follows:


•	Revenue Recognition;


•	Stock-Based Compensation;


•	Business Combinations;


•	Realizability of Long-Lived Assets and;


•	Accounting for Income Taxes.

There have been no changes to our significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 14, 2019, that have had a material impact on our condensed consolidated financial statements and related notes. Please refer to Management's Discussion and Analysis of Financial Condition and Results of Operations contained in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2018, for a complete discussion of our other critical accounting policies and estimates.

Results of Operations

The following table sets forth our operating results and related percentage of total revenues for the three months ended March 31, 2019 and 2018 (in thousands):



	For the Three Months Ended March 31,
	2019					2018
Revenue
Commission	$	64,227		93	%	$	40,707		95	%
Other	4,546			7	%	2,363			5	%
Total revenue	68,773			100	%	43,070			100	%
Operating costs and expenses:
Cost of revenue	(77		)	—	%	152			—	%
Marketing and advertising	23,941			35	%	15,002			35	%
Customer care and enrollment	19,944			29	%	13,239			31	%
Technology and content	9,017			13	%	8,341			19	%
General and administrative	11,278			16	%	10,691			25	%
Acquisition costs	—			—	%	58			—	%
Change in fair value of earnout liability	13,306			19	%	—			—	%
Restructuring charges	—			—	%	1,856			4	%
Amortization of intangible assets	547			1	%	451			1	%
Total operating costs and expenses	77,956			113	%	49,790			116	%
Loss from operations	(9,183		)	(13	)%	(6,720		)	(16	)%
Other income, net	557			1	%	184			—	%
Loss before benefit from income taxes	(8,626		)	(13	)%	(6,536		)	(15	)%
Benefit from income taxes	(3,467		)	(5	)%	(1,691		)	(4	)%
Net loss	$	(5,159	)	(8	)%	$	(4,845	)	(11	)%

Operating costs and expenses include the following amounts of stock-based compensation expense (in thousands):



	Three Months Ended March 31,
	2019		2018
Marketing and advertising	$	629	$	370
Customer care and enrollment	273		165
Technology and content	549		343
General and administrative	1,778		1,672
Restructuring	—		251
Total stock-based compensation expense	$	3,229	$	2,801

Three Months Ended March 31, 2019 and 2018

Revenue

The following table presents our commission revenue, other revenue and total revenue for the three months ended March 31, 2019 and 2018 and the dollar and percentage changes from the prior year (dollars in thousands):



	Three Months Ended March 31,						Change
	2019			2018			Amount		Percent
Commission	$	64,227		$	40,707		$	23,520	58	%
Percentage of total revenue	93		%	95		%
Other	4,546			2,363			$	2,183	92	%
Percentage of total revenue	7		%	5		%
Total revenue	$	68,773		$	43,070		$	25,703

Commission revenue increased $23.5 million, or 58%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 due to a $24.1 million, or 78%, increase in commission revenue from the Medicare segment and a $1.6 million, or 13%, increase in commission revenue from the Individual, Family and Small Business segment. The increase in commission revenue from the Medicare segment was primarily attributable to a 69% increase in Medicare approved members in the three months ended March 31, 2019 compared to the three months ended March 31, 2018, as well as an increase in the constrained lifetime value of commissions per Medicare Advantage approved member. The increase in commissions revenue from the Individual, Family and Small Business segment was primarily due to an increase in revenue attributable to a true-up in the lifetime value of previously recognized commission revenue.

Other revenue increased $2.2 million, or 92%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 due to a $2.0 million increase in sponsorship and online advertising revenue and a $0.2 million increase sales of leads.

Cost of Revenue

Included in cost of revenue are payments related to health insurance plans sold to members who were referred to our website by marketing partners with whom we have revenue-sharing arrangements. In order to enter into a revenue-sharing arrangement, marketing partners must be licensed to sell health insurance in the state where the policy is sold. Costs related to revenue-sharing arrangements are expensed as the related revenue is recognized.

The following table presents our cost of revenue for the three months ended March 31, 2019 and 2018 and the dollar and percentage changes from the prior year (dollars in thousands):



	Three Months Ended March 31,						Change
	2019			2018			Amount			Percent
Cost of revenue	$	(77	)	$	152		$	(229	)	(151	)%
Percentage of total revenue	—		%	—		%

Cost of revenue decreased $0.2 million, or 151%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018, mostly due to a decrease in volumes compared to prior year and an adjustment to accrued costs related to partners.

Marketing and Advertising

Marketing and advertising expenses consist primarily of member acquisition expenses associated with our direct, marketing partner and online advertising member acquisition channels, in addition to compensation and other expenses related to marketing, business development, partner management, public relations and carrier relations personnel who support our offerings.

The following table presents our marketing and advertising expenses for the three months ended March 31, 2019 and 2018 and the dollar and percentage changes from the prior year (dollars in thousands):



	Three Months Ended March 31,						Change
	2019			2018			Amount		Percent
Marketing and advertising	$	23,941		$	15,002		$	8,939	60	%
Percentage of total revenue	35		%	35		%

Marketing and advertising expenses increased $8.9 million, or 60%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018, primarily due to increases of $7.8 million in variable marketing costs, $0.6 million in personnel costs, $0.3 million in consulting expenses, $0.3 million in stock-based compensation expense, and $0.1 million of facilities and other operating costs. The increase in variable marketing costs was attributed to an increase of $7.3 million in online advertising costs and partner referral fees for lead aggregators and an increase of $0.5 million in direct marketing costs, driven primarily by our strategy to shift our demand generation in the Medicare market to more cost-effective channels, as well as the higher volume of submitted individual and family applications in the three months ended March 31, 2019 compared to the three months ended March 31, 2018.

Customer Care and Enrollment

Customer care and enrollment expenses primarily consist of compensation and benefits costs for personnel engaged in assistance to applicants who call our customer care center and for enrollment personnel who assist applicants during the enrollment process.

The following table presents our customer care and enrollment expenses for the three months ended March 31, 2019 and 2018 and the dollar and percentage changes from the prior year (dollars in thousands):



	Three Months Ended March 31,						Change
	2019			2018			Amount		Percent
Customer care and enrollment	$	19,944		$	13,239		$	6,705	51	%
Percentage of total revenue	29		%	31		%

Customer care and enrollment expenses increased $6.7 million, or 51%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018, primarily due a $3.7 million increase in personnel costs associated with higher headcount, a $2.5 million increase in consulting expenses, a $0.9 million increase due to license and permit costs, and $0.1 million in stock-based compensation expense, partially offset by a decrease of $0.4 million in facilities and other operating costs.

Technology and Content

Technology and content expenses consist primarily of compensation and benefits costs for personnel associated with developing and enhancing our website technology as well as maintaining our website. A majority of our technology and content group is located at our wholly-owned subsidiary in China, where technology development costs are generally lower than in the United States.

The following table presents our technology and content expenses for the three months ended March 31, 2019 and 2018 and the dollar and percentage changes from the prior year (dollars in thousands):



	Three Months Ended March 31,						Change
	2019			2018			Amount		Percent
Technology and content	$	9,017		$	8,341		$	676	8	%
Percentage of total revenue	13		%	19		%

Technology and content expenses increased $0.7 million, or 8%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 primarily due to a $0.2 million increase in stock-based compensation, $0.2 million in amortization expense, $0.1 million in consulting expenses, and $0.2 million in facilities and other operating costs.

General and Administrative

General and administrative expenses include compensation and benefits costs for staff working in our executive, finance, investor relations, government affairs, legal, human resources, internal audit, facilities and internal information technology departments. These expenses also include fees paid for outside professional services, including audit, tax, legal, government affairs and information technology fees.

The following table presents our general and administrative expenses for the three months ended March 31, 2019 and 2018 and the dollar and percentage changes from the prior year (dollars in thousands):



	Three Months Ended March 31,						Change
	2019			2018			Amount		Percent
General and administrative	$	11,278		$	10,691		$	587	5	%
Percentage of total revenue	16		%	25		%

General and administrative expenses increased $0.6 million, or 5%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018, primarily due to increases of $0.2 million in consulting costs, $0.1 million in personnel and compensation costs, $0.1 million in facilities and other operating costs, $0.1 million in stock-based compensation expense, and $0.3 million of legal costs and other professional fees, partially offset by a decrease of $0.2 million in license and permit costs.

Acquisition Costs

During the first quarter of 2018, we incurred $0.1 million of costs associated with our acquisition of GoMedigap, which was completed on January 22, 2018.

Change in Fair Value of Earnout Liability

During the three months ended March 31, 2019, we recorded $13.3 million of additional earnout consideration expense due to an adjustment in the estimated fair value of the earnout liability related to the acquisition of GoMedigap, which was completed on January 22, 2018. The increase in the fair value of the earnout liability was primarily related to an increase in the value of our common stock. Of the total $13.3 million expense, $6.1 million related to the change in fair value of the first earnout liability upon settlement and $7.2 million related to a revaluation of the second earnout liability.

Restructuring

In February 2018, our Board of Directors approved a plan to close our sales call center in Massachusetts and to terminate the employment of other employees in certain other locations. As part of the plan, we eliminated approximately 110 full-time positions in the United States, representing approximately 10% of our workforce primarily in our customer care and enrollment groups, and to a lesser extent, in our marketing and advertising and general and administrative groups. We incurred

$1.9 million for employee termination benefits and related costs in the three months ended March 31, 2018. Substantially all of the restructuring charges are expected to result in cash expenditures. Restructuring activities comprising the plan were completed during the three months ended June 30, 2018.

The following table presents our restructuring benefit for the three months ended March 31, 2019 and 2018 and the dollar change from the prior year (dollars in thousands):



	Three Months Ended March 31,						Change
	2019			2018			Amount			Percent
Restructuring charges	$	—		$	1,856		$	(1,856	)	(100	)%
Percentage of total revenue	—		%	4		%

Amortization of Intangible Assets

The following table presents our intangible asset amortization expense for the three months ended March 31, 2019 2018 and the dollar change from the prior year (dollars in thousands):



	Three Months Ended March 31,						Change
	2019			2018			Amount		Percent
Amortization of intangible assets	$	547		$	451		$	96	21	%
Percentage of total revenue	1		%	1		%

Amortization expense related to intangible assets purchased through our acquisitions of PlanPrescriber and GoMedigap. Amortization expense in the first quarter of 2019 increased $0.1 million, or 21%, due to a full quarter of amortization of intangible assets from our GoMedigap acquisition, which was completed January 22, 2018.

Other Income, Net

The following table presents our other income, net for the three months ended March 31, 2019 and 2018 and the dollar change from the prior year (dollars in thousands):



	Three Months Ended March 31,						Change
	2019			2018			Amount		Percent
Other income, net	$	557		$	184		$	373	203	%
Percentage of total revenue	1		%	—		%

Other income, net, for the three months ended March 31, 2019 and 2018 primarily consisted of margin earned on commissions received from Medicare plan members transferred to us in 2010 through 2012 by a broker partner, whereby we became the broker of record on the underlying policies. In addition, other income, net included interest income earned on our invested cash, cash equivalents and marketable securities balances, offset by administrative bank fees, investment management fees and interest expense on finance leases and debt.

Other income, net increased $0.4 million, or 203%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018, primarily due to a favorable exchange rate impact.

Benefit from Income Taxes

The following table presents our benefit from income taxes for the three months ended March 31, 2019 and 2018 and the dollar change from the prior year (dollars in thousands):



	Three Months Ended March 31,						Change
	2019			2018			Amount			Percent
Benefit from income taxes	$	(3,467	)	$	(1,691	)	$	(1,776	)	105	%
Effective tax rate	40.2		%	25.9		%

For the three months ended March 31, 2019, we recognized a benefit for income taxes of $3.5 million, representing an effective tax rate of 40.2% which was higher than the statutory federal tax rate due primarily to stock-based compensation adjustments and lobbying and other non-deductible expenses, partially offset by research and development credits. For the three months ended March 31, 2018, we recognized a benefit for income taxes of $1.7 million, representing an effective tax rate of 25.9%, which was higher than the statutory federal tax rate due primarily to stock-based compensation adjustments, non-deductible lobbying expenses, and foreign income inclusions, partially offset by research and development credits.

Segment Information

We report segment information based on how our chief executive officer, who is our chief operating decision maker, or CODM, regularly reviews our operating results, allocates resources, and makes decisions regarding our business operations. The performance measures of our operating segments include revenues and profit and loss. Our business structure is comprised of two operating segments:

•Medicare and

•Individual, Family and Small Business.

Our CODM does not separately evaluate assets by segment, and therefore assets by segment are not presented.

The Individual, Family and Small Business segment consists primarily of commissions earned from our sale of individual and family and small business health insurance plans and ancillary products sold to our non-Medicare-eligible customers, including but not limited to, short term, dental and vision insurance. To a lesser extent, the Individual, Family and Small Business segment consists of amounts earned from our online sponsorship program that allows carriers to purchase advertising space in specific markets in a sponsorship area on our website, our licensing to third parties the use of our health insurance ecommerce technology and our delivery and sale to third parties of individual and family health insurance leads generated by our ecommerce platforms and our marketing activities.

Marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect marketing and advertising, customer care and enrollment, and technology and content operating expenses are allocated to each segment based on usage. Other indirect general and administrative operating expenses are managed in a corporate shared services environment and, since they are not the responsibility of segment operating management, are not allocated to the operating segments and instead reported within Corporate.

Segment loss is calculated as total revenue for the applicable segment less direct and allocated marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses, excluding stock-based compensation, depreciation and amortization expense and amortization of intangible assets.

The following table presents summary results of our operating segments for the three months ended March 31, 2019 and 2018 (in thousands):



	Three Months Ended March 31,						Change
	2019			2018			Amount			Percent
Revenue
Medicare	$	54,901		$	30,763		$	24,138		78	%
Individual, Family and Small Business	13,872			12,307			1,565			13	%
Total revenue	$	68,773		$	43,070		$	25,703		60	%

Segment profit
Medicare segment profit	$	10,826		$	3,180		$	7,646		240	%
Individual, Family and Small Business segment profit	6,024			3,488			2,536			73	%
Total segment profit	16,850			6,668			$	10,182		153	%
Corporate	(8,296		)	(7,854		)	(442		)	6	%
Stock-based compensation expense	(3,229		)	(2,550		)	(679		)	27	%
Depreciation and amortization	(655		)	(619		)	(36		)	6	%
Acquisition costs	—			(58		)	58			(100	)%
Change in fair value of earnout liability	(13,306		)	—			(13,306		)	100	%
Restructuring	—			(1,856		)	1,856			(100	)%
Amortization of intangible assets	(547		)	(451		)	(96		)	21	%
Other income, net	557			184			373			203	%
Loss before benefit from income taxes	$	(8,626	)	$	(6,536	)	$	(2,090	)	32	%

Revenue

Revenue from our Medicare segment increased $24.1 million, or 78%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 due to a $22.1 million increase in Medicare commission revenue and a $2.0 million increase in other Medicare revenue. The increase in commission revenue was primarily attributable to a 69% increase in Medicare approved members in the three months ended March 31, 2019 compared to the three months ended March 31, 2018, as well as an increase in the constrained lifetime value of commissions per Medicare Advantage approved member. The favorable lifetime value of commissions per Medicare Advantage approved member was driven in part by improved churn rates. The increase in other revenue was mostly due to an increase in online sponsorship and advertising revenue.

Revenue from our Individual, Family and Small Business segment increased $1.6 million, or 13%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 primarily attributable to a $1.3 million increase in commission revenue and a $0.3 million increase in other revenue, primarily from sales of IFP leads. The increase in commission revenue was primarily due to the recognition of true-ups of previously recognized lifetime value commission revenue, partially offset by a 51% decrease in individual and family health insurance approved members in the three months ended March 31, 2019 compared to the three months ended March 31, 2018.

Segment Profit

Profit from our Medicare segment was $10.8 million in the three months ended March 31, 2019, a $7.6 million, or 240%, improvement compared to profit of $3.2 million in the three months ended March 31, 2018. The improvement in the Medicare segment in the three months ended March 31, 2019 was primarily due to a $24.1 million increase in revenue, partially offset by a $16.5 million increase in operating expenses, excluding stock-based compensation, change in earnout liability, depreciation and amortization expenses and amortization of intangible assets. The increase in operating expenses was mostly attributable to increased variable marketing costs and customer care and enrollment costs.

Profit from our Individual, Family and Small Business segment was $6.0 million in the three months ended March 31, 2019, a $2.5 million, or 73%, increase compared to profit of $3.5 million from the Individual, Family and Small Business

segment in the three months ended March 31, 2018. The increase in profit from the Individual, Family and Small Business segment in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 was primarily due to a $1.6 million increase in revenue and a $0.9 million decrease in operating expenses, excluding stock-based compensation, change in earnout liability, depreciation and amortization expenses and amortization of intangible assets.

Liquidity and Capital Resources

As of March 31, 2019, our cash and cash equivalents totaled $135.5 million. Cash equivalents, which are comprised of financial instruments with an original maturity of 90 days or less from the date of purchase, primarily consist of money market funds. At December 31, 2018, our cash and cash equivalents totaled $13.1 million. The increase in cash and cash equivalents reflects $112.6 million provided by financing activities, including $126.1 million of net proceeds from our equity offering, $12.7 million provided by operating activities, and $3.0 million used to purchase property and equipment and other assets, including capitalized internal-use software and website development costs. See Note 13—Public Offering of Common Stock.

As of March 31, 2019, we have in treasury shares of our common stock that were previously surrendered by employees to satisfy tax withholdings in connection with the vesting of certain restricted stock units. As of March 31, 2019 and December 31, 2018, we had a total of 11,449,503 shares and 11,426,292 shares, respectively, held in treasury.

The following table presents a summary of our cash flows for the three months ended March 31, 2019 and 2018 (in thousands):



	Three Months Ended March 31,
	2019			2018
Net cash provided by operating activities	$	12,749		$	10,737
Net cash used in investing activities	$	(2,996	)	$	(16,135	)
Net cash provided by (used in) financing activities	$	112,571		$	(203	)

Operating Activities

Cash provided by operating activities primarily consists of net loss, adjusted for certain non-cash items including depreciation and amortization; amortization of intangible assets and internally developed software; stock-based compensation expense and the effect of changes in working capital and other activities.

Collection of commissions receivable depends upon the timing of our receipt of commission payments and associated commission reports from health insurance carriers. If we were to experience a delay in receiving a commission payment from a health insurance carrier within a quarter, our operating cash flows for that quarter could be adversely impacted.

A significant portion of our marketing and advertising expenses is driven by the number of health insurance applications submitted on our ecommerce platform. Since our marketing and advertising costs are expensed and generally paid as incurred and since commission revenue is recognized upon approval of a member but commission payments are paid to us over time, our operating cash flows could be adversely impacted by a substantial increase in the volume of applications submitted during a quarter or positively impacted by a substantial decline in the volume of applications submitted during a quarter. During the Medicare annual enrollment period, we experience an increase in the number of submitted Medicare-related health insurance applications and marketing and advertising expenses compared to outside of Medicare annual enrollment periods. Similarly, during open enrollment periods for individual and family health insurance plans, we experience an increase in the number of submitted individual and family plan health insurance applications and marketing and advertising expenses compared to outside of open enrollment periods. The timing of open enrollment periods for individual and family health insurance and the Medicare annual enrollment period for Medicare-related health insurance affect the positive or negative impacts of our cash flows during each quarter.

Three Months Ended March 31, 2019—Cash provided by operating activities was $12.7 million in the three months ended March 31, 2019, primarily consisting of cash provided by changes in net operating assets and liabilities of $4.2 million and adjustments for non-cash items of $13.7 million, partially offset by a net loss of $5.2 million. Adjustments for non-cash items primarily consisted of $3.2 million of stock-based compensation expense, $1.3 million of amortization of intangible assets and internally-developed software, $13.3 million of expense related to the fair value adjustment of our earnout liability, and $0.7 million of depreciation and amortization, partially offset by a $1.2 million decrease in other non-cash items and a $3.5

million decrease in deferred income taxes. Cash provided by changes in net operating assets and liabilities during the three months ended March 31, 2019 primarily consisted of a decrease of $17.6 million in commissions receivable, an increase of $2.9 million in deferred revenue, a decrease of $0.4 million in accrued expenses and other liabilities, a decrease of $0.2 million in accounts receivable, a decrease of $1.1 million in prepaid expenses and other current assets, a decrease of $9.4 million in accrued compensation and benefits, a decrease of $7.1 million in accrued marketing expenses, and a decrease of $0.8 million in accounts payable.

Three Months Ended March 31, 2018—Cash provided by operating activities was $10.7 million in the three months ended March 31, 2018, primarily consisting of cash provided by changes in net operating assets and liabilities of $12.5 million and adjustments for non-cash items of $3.0 million, partially offset by a net loss of $4.8 million. Adjustments for non-cash items primarily consisted of $2.8 million of stock-based compensation expense, $0.9 million of amortization of intangible assets and internally-developed software, $0.6 million of depreciation and amortization and $0.4 million of other non-cash items, partially offset by a $1.7 million decrease in deferred income taxes. Cash provided by changes in net operating assets and liabilities during the three months ended March 31, 2018 primarily consisted of decreases of $22.4 million in commissions receivable and $0.8 million in accounts receivable and an increase of $1.1 million in accrued restructuring charges, partially offset by decreases of $6.9 million in accrued compensation and benefits, $1.9 million in accrued marketing expenses, $0.6 million in accounts payable and $0.2 million in accrued expenses and other liabilities and an increase of $1.8 million in prepaid expenses and other assets.

Investing Activities

Our investing activities primarily consist of purchases of computer hardware and software to enhance our website and customer care operations, leasehold improvements related to facilities expansion, capitalized internal-use software and website development costs and cash used to acquire a business.

Three Months Ended March 31, 2019—Net cash used in investing activities of $3.0 million in the three months ended March 31, 2019 was due to $1.5 million in capitalized internal-use software and website development costs and $1.5 million used to purchase property and equipment and other assets.

Three Months Ended March 31, 2018—Net cash used in investing activities of $16.1 million in the three months ended March 31, 2018 was due to $14.9 million of cash used to acquire GoMedigap, net of cash acquired, $1.0 million in capitalized internal-use software and website development costs and $0.2 million used to purchase property and equipment and other assets.

Financing Activities

Three Months Ended March 31, 2019—Net cash provided by financing activities of $112.6 million for the three months ended March 31, 2019 was primarily due to $126.1 million net proceeds from the issuance of common stock in a public equity offering and $2.4 million of proceeds from the exercise of common stock options, partially offset by $9.5 million of acquisition-related contingent payments, a $5.0 million debt repayment, and $1.3 million used to net-share settle equity awards.

Three Months Ended March 31, 2018—Net cash used in financing activities of $0.2 million for the three months ended March 31, 2018 was primarily due to $0.3 million used to net-share settle equity awards, partially offset by $0.1 million of proceeds from the exercise of common stock options.

Non-cash Activities

During the three months ended March 31, 2019, we acquired $28.1 million of right-of-use assets due to the adoption of ASC 842 and issued $17.3 million of common stock to settle our first earnout liability with GoMedigap.

Future Needs

As discussed in Note 2—Acquisition of Notes to the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q, on January 22, 2018, we completed our acquisition of Wealth, Health and Life Advisors, LLC, more commonly known as GoMedigap, a technology-enabled provider of Medicare Supplement enrollment services. This strategic acquisition significantly enhances our growing presence in the Medicare Supplement market, puts us in a stronger position with carriers and strategic partners and allows us to accelerate our projected Medicare plan enrollment growth in 2018 and beyond. The acquisition price paid at closing of the transaction consisted of cash of $15.0 million, less $0.1 million cash acquired, and approximately 294,637 shares of our common stock. In addition, we are obligated

to pay up to an additional $20 million in cash and 589,275 shares of our common stock, subject to the terms of the acquisition agreement and upon final determination of the achievement of certain milestones in 2018 and 2019.

As discussed in Note 12—Debt of Notes to the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q, on September 17, 2018, we entered into a Credit Agreement with Royal Bank of Canada, or RBC, as administrative agent and collateral agent, or the Credit Agreement. The Credit Agreement provides for a $40 million secured asset-backed revolving credit facility with a $5 million letter of credit sub-facility. The commitments under the Credit Agreement expire on September 17, 2021.

The borrowing base under the Credit Agreement is comprised of an amount equal to (a) the lesser of (i) eighty percent (80%) of Eligible Commissions Receivables (as defined in the Credit Agreement) we actually collected by during the immediately preceding period of three months or (ii) eighty percent (80%) of our Eligible Commission Receivables for the immediately succeeding period of three months, plus (b) fifty percent (50%) of our Eligible Commission Receivables for the immediately succeeding period of six months (excluding the immediately succeeding period of three months), in each case subject to reserves established by RBC, or “Borrowing Base.” The proceeds of the loans under the Credit Agreement may be used for working capital and general corporate purposes. The Borrowers have the right to prepay the loans under the Credit Agreement in whole or in part at any time without penalty. Subject to availability under the Borrowing Base, amounts repaid may be reborrowed.

Amounts not borrowed under the Credit Agreement are subject to a commitment fee of 0.5% per annum on the daily unused portion of the credit facility, to be paid in arrears on the first business day of each calendar quarter. At closing, we paid a one-time facility fee of 1.75% of the total commitments under the Credit Agreement. We are also obligated to pay other customary administration fees for a credit facility of this size and type.

As of March 31, 2019, we had no outstanding principal amount under our revolving credit facility.

We believe that cash generated from operations and our current cash and cash equivalents will be sufficient to fund our operations, including the additional amounts we are obligated to pay subject to the terms of the acquisition agreement with GoMedigap, for at least twelve months after the filing date of this Quarterly Report on Form 10-Q. Our future capital requirements will depend on many factors, including our expected membership and retention rates, our level of investment in technology, marketing and advertising and our customer care initiatives. In addition, our cash position could be impacted by further acquisitions and investments we make to pursue our growth strategy. We did not have any bank debt outstanding as of March 31, 2019. To the extent that available funds are insufficient to fund our future activities or we otherwise desire to raise additional funds, we may raise additional capital through bank debt, line of credit facilities or public or private equity or debt financing to the extent such funding sources are available.

Contractual Obligations and Commitments

The following table presents a summary of our future minimum payments under non-cancellable operating lease agreements and contractual service and licensing obligations as of March 31, 2019 (in thousands):



For the Years Ending December 31,	Operating Lease Obligations		Service and Licensing Obligations		Total Obligations
Remainder of 2019	$	3,641	$	3,366	$	7,007
2020	5,502		2,462		7,964
2021	4,068		946		5,014
2022	4,189		434		4,623
2023	3,972		444		4,416
Thereafter	13,765		229		13,994
Total	$	35,137	$	7,881	$	43,018

Operating Lease Obligations

We lease our operating facilities and certain of our equipment and furniture and fixtures under various operating leases, the latest of which expires in January 2026. Certain of these leases have free or escalating rent payment provisions. We recognize rent expense on our operating leases on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements.

In connection with our Mountain View, California lease agreement in March 2012, we entered into a financial guarantee consisting of a standby letter of credit for $0.6 million, which may be reduced in increments of 25% of the original amount thereof on the first, second and third anniversaries of the commencement date, subject to our compliance with the applicable conditions to such reductions set forth in the lease. The remaining balance on the financial guarantee is $0.1 million as of March 31, 2019.

Service and Licensing Obligations

We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance and software licensing. The terms of these services and licensing agreements are generally up to three years. We record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, investments in special purpose entities, undisclosed borrowings or debt. Additionally, we are not a party to any derivative contracts or synthetic leases.

Recent Accounting Pronouncements

See Note 1—Summary of Business and Significant Accounting Policies in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q for recently issued accounting standards that could have an effect on us.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our financial instruments that are exposed to concentrations of credit risk principally consist of cash and cash equivalents, accounts receivable and commissions receivable. As of March 31, 2019 and December 31, 2018, our cash and cash equivalents were invested as follows (in thousands):



	March 31, 2019		December 31, 2018
Cash ⁽¹⁾	$	27,501	$	12,766
Money market funds ⁽²⁾	107,974		323
Total cash and cash equivalents	$	135,475	$	13,089


(1)	We deposit our cash and cash equivalents in accounts with major banks and financial institutions and such deposits are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government.


(2)	At March 31, 2019 and December 31, 2018 money market funds consisted of investments in U.S. government-sponsored enterprise bonds and discount notes, U.S. government treasury bills and notes and repurchase agreements collateralized by U.S. government obligations.

As of March 31, 2019, our total outstanding commissions receivable balance was $331.6 million. Our contracts with the above carriers expose us to credit risk that a financial loss could be incurred if the counterparty does not fulfill its financial obligation. While we are exposed to credit losses due to the non-performance of its counterparties, we consider the risk of this remote. We estimate our maximum credit risk in determining the commissions receivable amount recorded on the balance sheet. Total accounts receivable as of March 31, 2019 and December 31, 2018 was comprised of the following (in thousands):



	March 31, 2019		December 31, 2018
Accounts receivable	$	3,381	$	3,601
Commissions receivable—current	113,834		134,190
Commissions receivable—non-current	214,377		211,668
Total accounts receivable	$	331,592	$	349,459

Foreign Currency Exchange Risk

To date, substantially all of our revenue has been derived from transactions denominated in United States Dollars. We have exposure to adverse changes in exchange rates associated with operating expenses of our foreign operations, which are denominated in Chinese Yuan Renminbi. Foreign currency fluctuations have not had a material impact historically on our

results of operations; however, there can be no assurance that future fluctuations will not have material adverse effects on our results of operations. We have not engaged in any foreign currency hedging or other derivative transactions to date.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Our Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rules 13a-15(b) and 15d-15(b) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on management’s evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our chief executive officer and chief financial officer, believes that our disclosure controls and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Table of Contents

PART II

ITEM 1. LEGAL PROCEEDINGS

On April 17, 2019, an individual filed a putative class action complaint against us that alleges we violated the Telephone Consumer Protection Act, “TCPA,” 47 U.S.C. §§ 227(b)(1) and (c)(5) and certain provisions of 47 C.F.R. § 64.1200 promulgated thereunder. The complaint alleges, among other things, that we (i) made unsolicited telephone calls to the Plaintiff and putative class members using a prerecorded voice message in violation of 47 U.S.C. § 227(b)(1); and (ii) made more than one unsolicited telephone call to Plaintiff and putative class members within a 12-month period without express consent and without instituting procedures that comply with regulatory minimum standards for implementing Do Not Call in violation of 47 C.F.R. § 64.1200 and 47 U.S.C. § 227(c)(5). The complaint seeks an order certifying two classes: (i) a class of individuals in the United States who we (or agents acting on our behalf) called using a prerecorded voice message for substantially the same reason we allegedly called the Plaintiff; and (ii) a class of individuals in the United States who we (or agents acting on our behalf) called more than one time within any 12-month period for substantially the same reason we allegedly called the Plaintiff. The complaint also seeks (i) an award of actual and/or statutory damages for the benefit of Plaintiff and the classes; (ii) an order declaring that our actions violate the TCPA; (iii) an injunction requiring us to cease all unsolicited calling activity and to otherwise protect the interest of the classes; and (iv) such further other relief as the court deems just and proper.

ITEM 1A. RISK FACTORS

In addition to other information in this Quarterly Report on Form 10-Q and in other filings we make with the Securities and Exchange Commission, the following risk factors should be carefully considered in evaluating our business as they may have a significant impact on our business, operating results and financial condition. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects could be materially and adversely affected. Because of the following factors, as well as other variables affecting our operating results, past financial performance should not be considered as a reliable indicator of future performance and investors should not use historical trends to anticipate results or trends in future periods.

Risks Related to Our Business

The marketing and sale of Medicare plans are subject to numerous, complex and frequently changing laws and regulations, and non-compliance or changes in laws and regulations could harm our business, operating results and financial condition.

The marketing and sale of Medicare plans are subject to numerous laws, regulations and guidelines at the federal and state level. The marketing and sale of Medicare Advantage and Medicare Part D prescription drug plans are principally regulated by the Centers for Medicare and Medicaid Services, or CMS. The marketing and sale of Medicare Supplement plans are principally regulated on a state-by-state basis by state departments of insurance. The laws and regulations applicable to the marketing and sale of Medicare plans are numerous, ambiguous and complex, and, particularly with respect to regulations and guidance issued by CMS for Medicare Advantage and Medicare Part D prescription drug plans, change frequently. The telephone calls on which we enroll individuals into Medicare Advantage and Medicare Part D prescription drug plans are required to be recorded. Health insurance carriers audit these recordings for compliance and listen to them in connection with their investigation of complaints. In addition, Medicare eligible individuals may receive a special election period and the ability to change Medicare Advantage and Part D prescription drug plans outside the Medicare annual enrollment period in the event the sale of the plan was not in accordance with CMS rules and guidelines. Given CMS’s scrutiny of Medicare product health insurance carriers and the responsibility of the health insurance carriers for actions that we take, health insurance carriers may terminate our relationship with them or take other corrective action if our Medicare product sales, marketing and operations are not in compliance or give rise to too many complaints. The termination of our relationship with health insurance carriers for this reason would reduce the products we are able to offer, could result in the loss of commissions for past and future sales and would otherwise harm our business, operating results and financial condition.

As a result of the laws, regulations and guidelines relating to the sale of Medicare plans, we have altered, and likely will have to continue to alter, our websites and sales process to comply with several requirements that are not applicable to our sale of non-Medicare-related health insurance plans. For instance, many aspects of our online platforms and our marketing material and processes, as well as changes to these platforms, materials and processes, including call center scripts, must be filed on a regular basis with CMS and reviewed and approved by health insurance carriers in light of CMS requirements. In addition, certain aspects of our Medicare plan marketing partner relationships have been in the past, and will be in the future, subjected to CMS and health insurance carrier review. Changes to the laws, regulations and guidelines relating to Medicare plans, their interpretation or the manner in which they are enforced could be incompatible with these relationships, our platforms or our sale of Medicare plans, which could harm our business, operating results and financial condition.

Due to changes in CMS guidance or enforcement or interpretation of existing guidance applicable to our marketing and sale of Medicare products, or as a result of new laws, regulations and guidelines, CMS, state departments of insurance or health insurance carriers may determine to object to or not to approve aspects of our online platforms or marketing material and processes and may determine that certain existing aspects of our Medicare-related business are not in compliance. As a result, the progress of our Medicare operations could be slowed or we could be prevented from operating aspects of our Medicare revenue generating activities altogether, which would harm our business, operating results and financial condition, particularly if it occurred during the Medicare annual enrollment period.

If our ability to enroll individuals during enrollment periods is impeded, our business will be harmed.

It is difficult for the health insurance agents we employ and our systems and processes to handle the increased volume of health insurance transactions that occur in a short period of time during the health care reform annual open enrollment period under the Patient Protection and Affordable Care Act, or Affordable Care Act, and the Medicare annual enrollment period. We contract with outsourced call centers and hire additional employees on a temporary or seasonal basis in a limited period of time to address the expected increase in the volume of health insurance transactions during the Medicare annual enrollment period. We

must ensure that our employee health insurance agents and the health insurance agent employees of outsourced call centers are timely licensed, trained and certified and have the appropriate authority to sell health insurance in a number of states and for a number of different health insurance carriers. We depend upon our own employees, state departments of insurance, government exchanges and health insurance carriers for licensing, certification and appointment. If our ability to market and sell Medicare-related health insurance and individual and family health insurance is constrained during an enrollment period for any reason, such as technology failures, reduced allocation of resources, any inability to timely employ, license, train, certify and retain our employees and our contractors and their health insurance agents to sell health insurance, interruptions in the operation of our website or systems, or issues with government-run health insurance exchanges, we could acquire fewer members, suffer a reduction in our membership and our business, operating results and financial condition could be harmed.

If investments we make in enrollment periods do not result in a significant number of approved and paying members, our business, operating results and financial condition would be harmed.

In an attempt to attract and enroll a large number of individuals during the Medicare annual enrollment period and the health care reform open enrollment period, we may invest in areas of our business, including technology and content, customer care and enrollment, and marketing and advertising. We have in the past made investments in areas of our business in advance of enrollment periods that have not yielded the results we expected when making those investments. Any investment we make in either the Medicare annual enrollment period or the health care reform open enrollment period may not result in a significant number of approved and paying members. If it does not, our business, operating results and financial condition would be harmed.

If we do not successfully compete with government-run health insurance exchanges, our business may be harmed.

We compete with government-run health insurance exchanges, among others, with respect to our sale of Medicare-related and individual and family health insurance. The federal government operates a website where Medicare beneficiaries can shop for and purchase Medicare Advantage and Medicare Part D Prescription Drug plans. CMS has begun making improvements to the consumer experience on this website and proposals exist for it to continue to do so. Medicare beneficiaries can also obtain plan selection assistance from the federal government in connection with their purchase of a Medicare Advantage and Medicare Part D Prescription Drug plan. The exchanges in the individual and family health insurance market created by the Affordable Care Act may elect whether or not we are able to enroll subsidy-eligible individuals in qualified health plans through them, and determine the manner in which we may do so. The Affordable Care Act exchanges have websites where individuals and small businesses can shop for and purchase health insurance, and they also have offline customer support and enrollment capabilities. Individuals who are eligible for government subsidies in the form of premium tax credits and cost sharing reductions must apply for their subsidy and purchase qualified health plans through a government exchange to receive their subsidy. In the aggregate, government exchanges have greater resources and greater public outreach capability than we do and they or the government agencies that run them may in the future impact the process we use to enroll individuals and families in a manner that results in a reduction in our membership. In addition, individuals who utilize our platform and services to apply for subsidies and health insurance through Affordable Care Act exchanges receive marketing and communications from the exchanges after they do so. In the event our existing members purchase health insurance directly through health insurance exchanges without using us as their health insurance agent, as a result of their being eligible for a subsidy or otherwise, we will no longer receive commission payments as a result of our sale of health insurance to them. Competitive pressure from government-run health insurance exchanges has resulted, and may in the future result, in our experiencing increased marketing costs, decreased traffic to our website, a reduction in our membership and revenue and may otherwise harm our business, operating results and financial condition.

Our operating results will be impacted by factors that impact our estimate of the constrained lifetime value of commissions per approved member.

Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (ASC 606) using the full retrospective method, which required us to revise our historical financial information to be consistent with the new standard. The adoption had a material impact on our consolidated financial statements. The most significant impact of the standard was on our commission revenue. We now recognize revenue for Medicare-related, individual and family and ancillary health insurance plan approved members based upon the total expected commissions we expect to receive over the life of the underlying polices, net of a constraint. We now recognize small business health insurance plan commission revenue at the time the application for the plan is approved by the carrier and when it renews each year thereafter, equal to the estimated commissions we expect to collect over the following 12-months. The constrained lifetime value for each product line is an estimate and is based on a number of assumptions, which include, but are not limited to, estimates of the conversion rates of approved members into paying members, forecasted member churn and forecasted commission amounts we expect to receive per approved member. These assumptions are based on historical trends and incorporate management’s judgment. Changes in our historical trends will result in changes to our constrained lifetime value estimates in future periods and therefore could adversely affect our revenue and financial results in those future periods. As a result, negative changes in the factors upon which we estimate constrained

lifetime values, such as reduced conversion of approved members to paying members, increased member churn or a reduction in the lifetime commission amounts we expect to receive for selling the plan to a member or other changes outside our control, would harm our business, operating results and financial condition. In addition, if we ultimately receive commission payments that are less than the amount we estimated when we recognized commission revenue, we would need to write-off of the remaining commission receivable balance, which would harm our business, operating results, cash flows and financial condition.

The rate at which approved members become paying members is a significant factor in our estimation of constrained lifetime values. For example, during the first open enrollment period under the Affordable Care Act, we experienced a decline in the rate at which members approved for individual and family health insurance turned into paying members, which harmed our operating results. To the extent we experience a similar decline in the rate at which approved members turn into our paying members, our business, operating results, cash flows and financial condition would be harmed.

We receive commissions from health insurance carriers for health insurance plans sold through us. When one of these plans is canceled, or if we otherwise do not remain the agent on the policy, we no longer receive the related commission payment. Our estimate of constrained lifetime value is net of an estimated annual health insurance plan cancellation rate based on our historical experience by plan type. As a result, an increase in our annual health insurance plan cancellation rate would harm our business, operating results, cash flows and financial condition.

Commission rates are a significant factor in our estimation of constrained lifetime values. The commission rates we receive are impacted by a variety of factors, including the particular health insurance plans chosen by our members, the carriers offering those plans, our members’ states of residence, the laws and regulations in those jurisdictions, the average premiums of plans purchased through us and health care reform. Our commission revenue per member has in the past decreased, and could in the future decrease, as a result of reductions in contractual commission rates, a change in the mix of carriers whose products we sell during a given period, and increased member churn, all of which are beyond our control and may occur on short notice. To the extent these and other factors cause our commission revenue per member to decline, our revenue may decline and our business, operating results cash flows and financial condition would be harmed. Given that Medicare-related and individual and family health insurance purchasing is concentrated during enrollment periods, we may experience a shift in the mix of Medicare-related and individual and family health insurance products selected by our members over a short period of time. Any reduction in our average commission revenue per member during the open enrollment period caused by such a shift or otherwise would harm our business, operating results, cash flows and financial condition.

Our business may be harmed if we lose our relationship with health insurance carriers or our relationship with health insurance carriers is modified.

We typically enter into contractual relationships with health insurance carriers that are non-exclusive and terminable on short notice by either party for any reason. In many cases, health insurance carriers also may amend the terms of our agreements unilaterally on short notice. Carriers may be unwilling to allow us to sell their existing or new health insurance plans, or desire to amend our agreements with them for a variety of reasons, including for competitive or regulatory reasons, dissatisfaction with the economics of the members that we place with them or because they do not want to be associated with our brand. We may also terminate our relationship with health insurance carriers. In the event we are not successful in gaining or maintaining the ability to sell Medicare, individual and family and qualified health insurance plans, if health insurance carriers pay us no commissions or reduced commissions in connection with the sale of these plans or if health insurance carriers change our relationship with them in other ways, we could lose a substantial number of existing and potential members and commissions, which would materially harm our business, operating results and financial condition. The termination of our relationship with a health insurance carrier by us or the health insurance carrier or the amendment of or change in our relationship with a carrier could reduce the variety of health insurance plans we offer, cause a loss of commission payments, cause a reduction in constrained lifetime values and adversely impact our ability to recognize revenue or have other adverse impacts, which could harm our business, operating results and financial condition. It also could adversely impact, or cause the termination of, commissions for past and future sales, which would materially harm our business, operating results and financial condition. Our business could also be harmed if in the future we fail to develop new carrier relationships and are unable to offer consumers a variety of health insurance plans in each jurisdiction.

Health insurance carriers can unilaterally amend the commission rates that they pay to us. Given the significant losses that carriers have sustained in connection with their sale of individual and family health insurance as a result of health care reform, many health insurance carriers with which we have a relationship, including large national health insurance carriers, reduced or eliminated our commissions for selling individual and family health insurance, and in a limited number of cases, our renewal commissions. As a result, we experienced a meaningful reduction in our average commission rates for our aggregate individual and family health insurance plan membership. In addition, the reduction in contractual commission rates and these carriers’ desire to not sell individual and family health insurance reduced the number of plans that we are able to offer on our websites, which resulted in less consumer demand for the individual and family health insurance that we sell and a reduction in our membership.

In the future and as a result of health care reform or for other reasons, an increasing number of health insurance carriers may decide to reduce our commissions, rely on their own internal distribution channels to sell their own plans, determine not to sell their plans or otherwise limit or prohibit us from selling their plans on our ecommerce platforms. In addition to reducing commission rates, health insurance carriers may determine to exit certain states or increase premiums to a significant degree, which could cause our members’ health insurance to be terminated or our members to purchase new health insurance or determine not to pay for health insurance at all. If we lose these members, our business, operating results and financial condition could be harmed.

Changes in our management and key employees could affect our business and financial results.

Our success is dependent upon our ability to attract and retain qualified personnel for all areas of our organization. We may not be successful in attracting and retaining personnel on a timely basis, on competitive terms or at all. If we are unable to attract and retain the necessary personnel, our business would be harmed. Our executive officers and employees can terminate their employment at any time. We have recently experienced significant changes in our senior management. David Francis, our former chief financial officer appointed in July 2016, most recently became our chief operating officer in January 2018. In June 2018, Derek Yung became our chief financial officer, allowing Mr. Francis to focus on his responsibilities as chief operating officer. In addition to these changes, other senior executive officers have left us, and we have hired additional senior executives, including Tim Hannan, chief marketing officer, Ian Kalin, chief technology officer, and David Nicklaus, senior vice president, sales and operations. The change in leadership we have experienced has been significant and has occurred over a short period of time. The transition and the departure of members of our senior management could result in further attrition in our senior management and key personnel and the significant change in leadership over a short period of time could harm our business, operating results and financial condition.

The loss of the services of any of our executive officers or key employees could harm our business. For example, we appoint a single designated writing agent with each insurance carrier. A small number of our employees act as writing agent and each employee that acts as writing agent does so for a number of carriers. Robert Hurley, our president, carrier and business development, is the writing agent in a large number of our carrier relationships. If we lose the service of our appointed writing agent, the duties of writing agent will need to be transitioned to other company personnel. Due to our national reach and the large number of carrier partners whose policies are purchased by our members, this transition may be difficult and requires a significant period of time to complete, particularly in the case of Mr. Hurley. If the transition is not successful or takes too long to complete, our agency relationship with particular insurance carriers may be terminated, our commission payments could be discontinued or delayed and, as a result, our business, operating results and financial condition would be harmed.

Our business may be harmed if we are not successful in executing on our strategic investments and initiatives.

In 2016 we conducted a strategic review of our business operations and examined potential areas of investment and strategic emphasis. As part of our strategy, we have determined to invest in initiatives to accelerate growth in our Medicare product sales, including Medicare Advantage and Medicare Supplement plans. We also plan to invest resources in efforts to grow our small business group insurance business and pursue cross-selling and adjacent revenue opportunities in our Medicare and small business group businesses. Further, we intend to invest in the sale of short-term health insurance. Pursuing and investing in these initiatives will require significant investments in marketing and advertising, technology and product offerings, and customer care and enrollment, among others, and involves risks and uncertainties described elsewhere in this Risk Factors section, including the initiatives resulting in insufficient revenue to offset any expenses associated with these new investments, inadequate return of capital on our investments, legal and regulatory compliance risks, potential changes in laws and regulations and other issues that could cause us to fail to realize the anticipated benefits of our investments and incur unanticipated liabilities. Our pursuit of these strategic initiatives may not be successful. Our cash flow from operations was negative in each of the years ended December 31, 2018 and 2017. As a result, our investment in these initiatives could result in our needing to raise addition capital. If we are not successful in executing on our business strategy, our future profitability and cash flow would be negatively impacted and our business, operating results and financial condition would be harmed.

Significant consolidation in the health insurance industry could alter our relationships with carriers and harm our business and financial results.

The health insurance industry in the United States has experienced a substantial amount of consolidation, resulting in a decrease in the number of health insurance carriers. Consolidation in the health insurance industry could cause a loss of or changes in our relationship with carriers and reduction in our commission or other revenue, which could harm our business, operating results and financial condition. In the future, we may be forced to offer health insurance from a reduced number of insurance carriers or to derive a greater portion of our revenue from a more concentrated number of carriers as our business and the health insurance industry evolve. Revenue derived from Humana represented approximately 23% and 15% of our total revenue for the three months ended March 31, 2019 and 2018, respectively. Revenue derived from carriers owned by UnitedHealthcare

represented approximately 17% and 21% of our total revenue for the three months ended March 31, 2019 and 2018, respectively. Revenue derived from Aetna represented approximately 17% and 10% of our total revenue for the three months ended March 31, 2019 and 2018, respectively. We have several agreements that govern our sale of health insurance plans with these health insurance carriers. They may be unilaterally amended or terminated by the carrier on short notice and the amendment or termination could adversely impact or cause the termination of the commission payments that we receive from these health insurance carriers, including commissions on plans that we have already sold, which could materially harm our business, operating results and financial condition. Our revenue could be adversely impacted if we are unable to maintain currently-existing levels of business with any of our significant health insurance carriers if we are unable to offset any loss of business with alternative health insurance carriers. We expect that a small number of health insurance carriers will account for a significant portion of our revenue for the foreseeable future and any impairment of our relationship with, or the material financial impairment of, these health insurance carriers could adversely affect our business.

Seasonality may cause fluctuations in our financial results.

The Medicare annual enrollment period occurs from October 15 to December 7 each year, and we experience an increase in the number of submitted Medicare-related applications during the fourth quarter and an increase in Medicare plan related expense during the third and fourth quarters. Beginning the fourth quarter of 2017, the individual and family health insurance open enrollment period was changed to run from November 1 through December 15 of each year, which changed the seasonality of our individual and family business. We expect the number of approved members for individual and family health insurance to be higher in the fourth quarter compared to other quarters of the year as a result. A significant portion of our marketing and advertising expenses is driven by the number of health insurance applications submitted through us. Since our marketing and advertising costs are expensed and generally paid as incurred and commissions from approved members are paid to us over time, our operating cash flows could be adversely impacted by a substantial increase in marketing expense as a result of a higher volume of applications submitted during a quarter or positively impacted by a substantial decline in marketing expense as a result of lower volume of applications submitted during a quarter.

The seasonality of our business could change in the future due to other factors, including as a result of changes in timing of the Medicare or individual and family health plan annual open enrollment periods and changes in the laws and regulations that govern the sale of health insurance. We may not be able to timely adjust to changes in the seasonality of our business. If the timing of the open enrollment periods for Medicare-related health insurance or individual and family health insurance changes, we may not be able to timely adapt to changes in customer demand. If we are not successful in responding to changes in the seasonality of our business, our business, operating results and financial condition could be harmed.

Our financial results will be adversely impacted if our membership does not grow or if we are unable to retain our existing members.

We receive commissions from health insurance carriers for health insurance plans sold through us. When one of these plans is canceled, or if we otherwise do not remain the agent on the plan, we no longer receive the related commission payment. Our members may choose to discontinue their health insurance plans for a variety of reasons. Consumers may also purchase individual and family and Medicare-related health insurance plans directly from other sources, such as government-run health insurance exchanges, and we would not remain the agent on the policy and receive the related commission. Beginning January 1, 2019, Medicare Advantage plan enrollees may enroll in another Medicare Advantage plan or disenroll from their Medicare Advantage plan and return to original Medicare during the new Medicare Advantage open enrollment period that is scheduled to occur between January 1^st and March 31^stof each year. If the new members that we enroll during this Medicare Advantage open enrollment period do not offset any loss of existing Medicare Advantage members or if investments we make during this new Medicare Advantage open enrollment period do not result in a significant number of approved and paying Medicare Advantage members, our business, operating results and financial condition would be harmed. In addition, health insurance carriers have in the past and may in the future terminate health insurance plans purchased and held by our members. Any decrease in the amount of time we retain our members could adversely impact the lifetime value we use for purposes of recognizing revenue, which could harm our business, operating results and financial condition. Moreover, if we are not able to successfully retain existing members and limit member turnover, our cash flows from operations will be adversely impacted and our business, operating results and financial condition would be harmed. In addition, the Medicare-related commission rates that we receive may be higher in the first calendar year of a plan if the plan is the first Medicare-related plan issued to the member. The individual and family commission rates that we receive are typically higher in the first twelve months of a policy. After the first twelve months, they generally decline significantly. As a result, if we do not add a sufficient number of members to new plans, our cash flows will also be negatively impacted. If we experience higher member turnover than we estimated when we recognized commission revenue, we may not collect all of the related commission receivable, resulting in a write-off of the remaining commission receivable balance, which would harm our business, operating results, cash flows and financial condition.

Our business may be harmed if we lose our relationship with health insurance carriers whose Medicare-related health insurance products we sell or if our relationship with those carriers changes.

Our Medicare plan-related revenue is concentrated in a small number of health insurance carriers. The success of our Medicare-related health insurance business depends upon our ability to enter into new and maintain existing relationships with health insurance carriers on favorable economic terms. The concentration of our Medicare plan sales in a limited number of health insurance carriers makes us vulnerable to changes in carrier commission rates and changes in the competitiveness of our carriers’ Medicare products. If our Medicare carriers reduce our commission rates, reduce the amount they pay us for advertising services, or the competitiveness of their products declines compared to original Medicare or the products of Medicare carriers with which we do not have a relationship, our business, operating results and financial condition would be harmed.

We also may temporarily or permanently lose the ability to market and sell Medicare plans for our Medicare plan carriers. The regulations for selling health insurance is complex and frequently changes. We or the health insurance agents we employ have in the past, and may in the future, violate one or more of the many requirements imposed by CMS or state laws and regulations. A carrier may terminate our relationship for that or other reasons, or CMS may penalize health insurance carriers for certain regulatory violations by suspending or terminating the carrier's ability to market and sell Medicare plans for significant periods of time. CMS also may require the carrier to terminate its membership and allow its members to move to other plans. Given the concentration of our Medicare plan sales in a small number of carriers, if we lose a relationship with a health insurance carrier to market their Medicare plans temporarily or permanently or if the health insurance carrier loses its Medicare product membership, our business, operating results and financial condition would be harmed. The agreements that we have with health insurance carriers to sell Medicare plans may be unilaterally amended or terminated by the carrier on short notice and the amendment or termination could adversely impact, or cause the termination of, the commission payments that we receive for selling their Medicare plans, including commissions on plans that we have already sold, which could materially harm our business operating results and financial condition.

Our business may be harmed if we do not market Medicare plans effectively or if our websites and marketing materials are not timely approved or do not comply with legal requirements.

Health insurance carriers whose Medicare plans we sell approve our websites, much of our marketing material and our call center scripts. We must receive these approvals in order for us to be able to generate Medicare plan demand and sell Medicare plans to Medicare-eligible individuals as a health insurance agent. Many of these materials also must be filed with CMS. In the event that CMS or a health insurance carrier requires change to, disapproves, or delays approval of our websites, our marketing material or call center scripts, we could lose a significant source of Medicare plan demand and our ability to sell Medicare plans would be adversely impacted, which would harm our business, operating results and financial condition. The rules and regulations relating to the approval and submission of marketing material are ambiguous and complex and state department of insurance or CMS may determine that certain aspects of our marketing material and processes are not in compliance with legal requirements. The CMS rules and regulations also apply to marketing material of our marketing partners. If we are not successful in timely submitting these marketing materials to health insurance carriers for approval, in gaining that approval and in filing all required marketing material with CMS, we could be prevented from implementing our Medicare marketing initiatives and our Medicare plan marketing could become less effective, which would harm our business, operating results and financial condition, particularly if the delay or non-compliance occurred during the Medicare annual enrollment period. If a marketing partner of ours does not consent to having its website or other marketing material filed with CMS, does not make changes required by carriers or CMS or does not comply with the CMS marketing guidelines or other Medicare program related laws, rules and regulations, we may lose the ability to receive referrals of individuals interested in purchasing Medicare plans from that marketing partner or our ability to receive referrals could be delayed and our business, operating results and financial condition would be harmed.

If we or our marketing partners substantively change our websites or call center scripts after they are filed with CMS, we may need to resubmit them to health insurance carriers and have them re-filed with CMS. We are not permitted to make CMS filings ourselves. Given the review cycles our scripts, websites and other marketing material undergo, it is very difficult and time consuming to make changes to them, and our inability to timely make changes to these marketing materials, whether to comply with new rules and regulations or otherwise, could adversely impact our ability to sell Medicare plans, which could adversely impact our business, operating results and financial condition. In addition, if a change to scripts, our websites or other marketing material is required by CMS, a state department of insurance or health insurance carriers, we may be prevented from using the marketing material until the change is made and approved, which would harm our business, operating results, and financial condition, particularly if it occurred during the annual enrollment period.

Our ability to sell Medicare-related health insurance plans as a health insurance agent depends upon our ability to timely hire, train and retain licensed health insurance agents for our customer care center.

In addition to our websites, we rely upon our customer care centers and, during the Medicare annual enrollment period, outsourced call centers to sell Medicare plans. The success of our customer care center operations is largely dependent on licensed health insurance agents and other employees. In order to sell Medicare-related health insurance plans, our health insurance agent employees and employees of third-party call centers must be licensed by the states in which they are selling plans and certified and appointed with the health insurance carrier that offers the plans in each applicable state. Because a significant number of Medicare plans are sold in the fourth quarter each year during the Medicare annual enrollment period, we retain and train a significant number of additional employees and employees of third-party call centers on a temporary or seasonal basis in a limited period of time. We must also ensure that our health insurance agents are timely licensed in a significant number of states and certified and appointed with the health insurance carriers whose products we sell. We depend upon our employees, state departments of insurance and health insurance carriers for the licensing, certification and appointment of our health insurance agents. We may not be successful in timely hiring a sufficient number of additional licensed agents or other employees for the Medicare annual enrollment period. We also may not be successful in engaging outsourced call centers, and the outsourced call centers may not be successful in engaging a sufficient number of licensed health insurance agents. Even if we and our outsourced call centers are successful, these health insurance agents may experience delays in obtaining health insurance licenses and certifications and health insurance carrier appointments. Temporary or seasonal health insurance agents also may also not perform to the standard we expect of them, which could result in lower than expected conversion rates and revenue and higher costs of acquisition per member. If we and our outsourced call centers are not successful in these regards, our ability to sell Medicare-related health insurance plans will be impaired during the annual enrollment period, which would harm our business, operating results and financial condition.

Our ability to sell Medicare-related health insurance plans as a health insurance agent depends upon maintenance of functioning information technology systems.

The success of our Medicare plan customer care center operations is dependent upon information technology systems. Many of our Medicare plan members utilize our customer care center in connection with their purchase of a Medicare plan. CMS rules require that our health insurance agent employees utilize CMS-approved scripts in connection with the sale of Medicare plans and that we record and maintain the recording of telephonic interactions relating to the sale of Medicare plans. We rely on telephone, call recording, customer relationship management and other systems and technology in our Medicare customer care center operations, and we are dependent upon third parties for some of them, including our telephone and call recording systems. These systems have failed temporarily in the past. The effectiveness and stability of our Medicare customer care center systems and technology are critical to our ability to sell Medicare plans, particularly during the Medicare annual enrollment period, and the failure or interruption of any of these systems and technology or any inability to handle increased volume during the annual enrollment period would harm our business, operating results and financial condition.

Our success in selling Medicare-related health insurance will depend upon a number of factors some of which are outside of our control.

Our success in selling Medicare-related health insurance is dependent in part on the actions of federal and state governments. The adoption of laws, regulations or policies by federal and state governments has in the past and could in the future adversely impact our Medicare business. For example, CMS has in the past determined to reduce the payments it makes to health insurance carriers in connection with the sale of Medicare Advantage plans. Any similar reduction in the future could cause the cost of Medicare Advantage plans to increase or the benefits under Medicare Advantage plans to decrease, either of which would impair our ability to sell Medicare Advantage plans. CMS also has in the past adopted rules relating to the timing and nature of the compensation of agents in connection with the sale of Medicare Advantage and Medicare Part D prescription drug plans. The effect of these rules was to reduce our compensation as a health insurance agent in connection with the sale of these plans or had other adverse consequences. In addition, under the Affordable Care Act, health insurance carriers are required to pay a fee or tax on net premium revenue for certain types of health insurance. The health insurance tax applies to Medicare Advantage, Part D prescription drug, individual and family, and small group health insurance plans. This health insurance tax was suspended by the federal government in 2017 and 2019 and is scheduled to go back into effect in 2020. As a result of the health insurance tax, consumers could experience higher premiums, higher out of pocket costs and/or reduced benefits as health insurance carriers may pass the cost of the health insurance tax to the consumers. Further, the Trump administration has proposed regulations that would narrow the type of prescription drug rebates that are allowed to be paid by manufacturers to pharmacy benefit managers and prescription drug plans and instead require rebates to be passed on directly to consumers. If the proposed regulations are adopted, health insurance companies may raise insurance premiums or reduce Part D prescription drug plan benefits. In the event the actions of the federal government, state governments or other circumstances decrease the demand for the Medicare related health insurance that we sell, or result in a reduction in the amount paid to us or have other adverse impacts, our business, operating results and financial condition could be harmed.

Our success in the Medicare plan market as a health insurance agent will also depend upon a number of additional factors, including:


•	our ability to continue to adapt our ecommerce platforms to market Medicare plans, including our development or acquisition of marketing tools and features important in the sale of Medicare plans online and the effective modification of our user experience;


•	our success in marketing to Medicare-eligible individuals, including television advertising and direct mail marketing, and in entering into marketing partner relationships to drive Medicare-eligible individuals to our ecommerce platforms on a cost-effective basis;


•	our effectiveness in entering into and maintaining relationships with marketing partners that refer Medicare-eligible individuals to us;


•	our ability to hire and retain additional employees with experience in Medicare, including our ability to timely implement Medicare sales expertise into our customer care centers;


•	our ability to implement and maintain an effective information technology infrastructure for the sale of Medicare plans, including the infrastructure and systems that support our websites, call centers and call recording;


•	our ability to leverage technology in order to sell, and otherwise become more efficient at selling, Medicare-related plans over the telephone;


•	our ability to comply with the numerous, complex and changing laws and regulations and CMS guidelines relating to the marketing and sale of Medicare plans, including continuing to conform our online and offline sales processes to those laws and regulations; and


•	the effectiveness with which our competitors market the availability of Medicare plans from sources other than our ecommerce platforms.

As a result of these factors, we may prove unsuccessful in marketing Medicare plans and acting as a health insurance agent in connection with their sale, which would harm our business, operating results and financial condition. In addition, if our efforts to market Medicare plans during any annual enrollment period were impeded due to lack of health insurance carrier or CMS approval, or for other reasons, the impact on our business, operating results and financial condition would be significantly greater given the seasonality of our Medicare-related revenues, membership acquisition and expenses and the fact that much of the sales of Medicare plans occur during this period.

We may be unsuccessful in competing effectively against current and future competitors.

The market for selling health insurance plans is highly competitive. We compete with entities and individuals that offer and sell health insurance plans utilizing traditional distribution channels as well as the Internet. Our competitors include local insurance agents across the United States who sell health insurance plans in their communities. There also are a number of companies that operate websites, provide an online shopping experience for consumers interested in purchasing health insurance and act as a health insurance agent in connection with that purchase. Some local agents also use Internet advertising and “lead aggregator” services that use the Internet to find consumers interested in purchasing health insurance and are compensated for referring those consumers to health insurance agents or carriers. Many health insurance carriers also directly market and sell their plans to consumers through call centers, Internet advertising and their own websites. Although we offer health insurance plans for many of these carriers, they also compete with us by offering their plans directly to consumers. In connection with our marketing of Medicare plans, we compete with the original Medicare program. CMS also offers plan information, comparison tools, call centers and online enrollment for Medicare Advantage and Medicare Part D prescription drug plans. We compete with the Federally Facilitated Marketplace, or FFM, and state health insurance exchanges implemented as a result of health care reform in marketing individual and family health insurance products. Health care reform also has resulted in health insurance plan cost and benefit data being more readily accessible, which has facilitated additional competition.

To remain competitive against our current and future competitors, we will need to market our services effectively and continue to improve the online shopping experience and functionalities of our website and other platforms that our current and future customers may access to purchase health insurance products from us. If we cannot predict, develop and deliver the right shopping experience and functionality in a timely and cost-effective manner, or if we are not effective in cost-effectively driving a substantial number of consumers interested in purchasing health insurance to our website and customer care centers, we may not be able to compete successfully against our current or future competitors and our business, operating results and financial condition may be adversely affected.

Some of our current and potential competitors have longer operating histories, larger customer bases, greater brand recognition and significantly greater financial, technical, marketing and other resources than we do. As compared to us, our current and future competitors may be able to:


•	undertake more extensive marketing campaigns for their brands and services;


•	devote more resources to website and systems development and other aspects of their operations to comply with applicable laws, regulations and rules;


•	negotiate more favorable commission rates and commission override payments; and


•	make more attractive offers to potential employees, marketing partners and third-party service providers.

In addition, CMS has the ability to regulate our marketing and sale of Medicare Advantage and Medicare Part D prescription drug plans, and government-run health insurance exchanges, including CMS with respect to the FFM, have the ability to regulate our marketing and sale of qualified health plans under health care reform. CMS and the exchanges could impact the commissions we receive in connection with the sale of these plans and impose other restrictions and limitations that make it difficult for us to sell them. Competitive pressures may result in our experiencing increased marketing costs, decreased traffic to our website and loss of market share, or may otherwise harm our business, operating results and financial condition.

Changes and developments in the health insurance industry or in the health insurance system in the United States as a result of health care reform could harm our business.

Our business depends upon the private sector of the United States health insurance system, its relative role in financing health care delivery and health insurance carriers’ use of, and payment of commissions to, agents and brokers to market health insurance plans. In March 2010, the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act were signed into law. These health care reform laws contain provisions that have and will continue to change the industry in which we operate in substantial ways. Among several other provisions, health care reform includes a mandate that individuals have qualifying health insurance or face a tax penalty, although the tax penalty is set at zero beginning in 2019; a mandate that certain employers offer their employees group health insurance coverage or face tax penalties; requirements relating to employer contribution to employee health coverage; prohibitions against insurance companies using pre-existing health conditions as a reason to deny an application for health insurance; prohibitions on rescission of health insurance; prohibitions on lifetime coverage limits; requirements for guaranteed renewability of health insurance plans; health insurance premium setting guidelines; limitations on deductibles and cost-sharing; medical loss ratio requirements that require each health insurance carrier to spend a certain percentage of their premium revenue on reimbursement for clinical services and activities that improve health care quality and, if they do not, to provide rebates to policyholders; minimum benefit levels for health insurance plans, including actuarial value standards and limitations on annual coverage limits; taxes and assessments on health insurance carriers; establishment of state and/or federal health insurance exchanges to facilitate access to, and the purchase of, health insurance; open enrollment periods for the purchase of individual and family health insurance; and subsidies and cost-sharing credits to make health insurance more affordable for those below certain income levels. The implementation of health care reform has increased, and could further increase, our competition in the individual and family health insurance market and reduce or eliminate the need for health insurance agents or demand for the health insurance for individuals and families that we sell; further decrease the number of health insurance plans that we sell as well as the number of health insurance carriers offering them; cause a further reduction in our membership and revenue; cause us to incur increased expense across our business and cause health insurance carriers to further reduce our commissions and other amounts they pay for our services or change our relationship with them in other ways, any of which could materially harm our business, operating results and financial condition. These and other impacts of health care reform caused a significant decline in our individual and family plan membership and other changes in the future could have similar impact on our Medicare related health insurance business. In addition, various aspects of health care reform have caused and could continue to cause health insurance carriers to limit the type of health insurance plans we sell and the geographies in which we sell them, to reduce or eliminate the commissions we receive from them as a result of our sale of health insurance plans, to exit the business of selling individual and family and small business health insurance plans in particular jurisdictions or altogether, to eliminate certain categories of products or attempt to move members into new plans for which we receive lower or no commissions, any of which could materially harm our business, operating results and financial condition.

Under the Affordable Care Act, health insurance carriers offering coverage in the individual or small business health insurance market must ensure that such coverage meets certain actuarial value standards, includes certain minimum health benefits and is not subject to lifetime or, for most health insurance benefits, annual dollar amount coverage limits. Moreover, health insurance carriers cannot deny individuals health insurance for health reasons. For these and other reasons, the cost of individual and family health insurance has generally increased and many health insurance carriers suffered financial losses in their individual and family health insurance businesses. As a result, many health insurance carriers exited the individual and family health insurance business in part or altogether. The number of individual and family health insurance plans offered on our website has been reduced, including states and many zip codes where we have no individual and family health insurance plans to offer. If these conditions persist, we anticipate that they will continue to decrease demand for the individual and family health insurance that we sell and harm our business, operating results and financial condition. In addition, if carriers determine to exit the individual and family health insurance market in a jurisdiction, our members on the plans offered by that carrier will lose their health insurance plans and will need to shop for and purchase individual and family health insurance from another health insurance carrier if they desire to maintain individual and family health insurance. These circumstances have resulted and could in the future result in decreased retention

rates in our membership, a reduction in our commission revenue and otherwise harm our business, operating results and financial condition. Many health insurance carriers have increased premiums on the individual and family health insurance that they sell as a result of health care reform. As a result of premium inflation, we have experienced and could in the future experience decreased retention of our members and a reduction in demand for the individual and family health insurance that we sell, which could cause us to suffer a substantial reduction in our membership, and materially harm our business, operating results and financial condition. Moreover, compared to the increased cost of individual and family health insurance plans, government subsidies to purchase health insurance may not be sufficient enough to encourage individuals and families to purchase individual and family health insurance or incentivize our existing members to maintain their individual and family health insurance plans, which could contribute to a decline in our membership and materially harm our business, operating results and financial condition.

The Trump administration and Republican leadership in Congress have attempted on several occasions to repeal or amend the Affordable Care Act, but their efforts at doing so have largely failed. The Affordable Care Act contains a mandate requiring individuals to maintain health insurance plans that comply with the Affordable Care Act or face a tax penalty. As a part of the tax reform law that came into effect in December 2017, the tax penalty for violating the mandate was set at zero effective in 2019, essentially repealing it. The essential repeal of the individual mandate could cause individuals to determine not to purchase or maintain individual and family health insurance and could cause carriers to increase premiums, reduce commissions or exit the business of selling individual and family health insurance, any of which would adversely impact our business, operating results and financial condition.

In addition to eliminating the penalty for violating the individual mandate, the Trump administration issued an executive order in October 2017 that directed the executive branch of the government to consider proposing regulations and revising guidance to expand access to association health plans, expand the availability of short-term health insurance and increase the usability of health reimbursement arrangements. As a result of the executive order, new regulations were adopted in July and August 2018, respectively, that would facilitate association-based health insurance plans and promote the sale of more short-term health insurance. The regulations relating to short-term health insurance plans extend the initial duration of short-term health insurance from three months to less than one year and allow for short-term health insurance plans to be renewed as long as the total duration of the plan does not exceed thirty-six months. However, states have authority to impose their own laws and regulations over short-term health insurance plans sold in their markets and certain states have adopted or are contemplating laws and regulations that would ban the sale of short-term health insurance, limit their duration and renewability, apply certain aspects of the Affordable Care Act to short-term health insurance or impose stronger disclosure requirements than the federal regulation. The expansion of the availability of short-term health insurance in many states may cause individuals and families to purchase short-term health insurance instead of individual and family health insurance, which could adversely impact our business, operating results and financial condition if any reduction in our sales of individual and family health insurance is not offset by increased revenue from sales of short-term health insurance. The regulations relating to association health plans allow small businesses, including sole proprietors and other self-employed individuals, to join industry or geographically-based associations and collectively purchase large group health insurance plans. Large group health insurance is not subject to many of the provisions of the Affordable Care Act, including the requirement that health insurance plans cover all of the essential health benefits defined under the Affordable Care Act. The goal of the new regulation is to create a new health insurance option for small businesses, sole proprietors and other self-employed individuals and to reduce the cost of insurance for these purchasers if they are association members. While the regulation could present new business opportunities for us, it also may reduce the size of the individual, family and small business health insurance markets that we are able to address, which would harm our business, operating results and financial condition. In light of the current state of the individual and family health insurance market, it appears likely that the Trump administration will continue to attempt to make changes to the Affordable Care Act and its implementing regulations. If the changes do not stabilize the individual and family health insurance market and encourage health insurance carriers to sell affordable individual and family health insurance, our individual and family health insurance business will continue to be adversely impacted.

In December 2018, a federal district court in Texas in Texas v. United States of America et al., determined that the individual mandate in the Affordable Care Act is unconstitutional, because it was not within Congress’s tax power or interstate commerce power. It also determined that the remaining provisions of the Affordable Care Act were inseverable and therefore invalid. The court, however, did not rule that the operation of the Affordable Care Act be enjoined, so the law continues to operate until determined otherwise by the court or an appellate court. If the Affordable Care Act were finally determined to be unconstitutional and no longer operated, it is unclear what impact it or its replacement would have on our business. However, it or its replacement could adversely impact our business, operating results and financial condition.

Our business may be harmed if we do not enroll subsidy-eligible individuals through government-run health insurance exchanges efficiently.

In order to offer the qualified health plans that individuals and families must purchase to receive Affordable Care Act subsidies, agents and brokers must meet certain conditions, such as receiving permission to do so from the applicable government

health insurance exchange, entering into an agreement with the health insurance exchange, ensuring that the enrollment and subsidy application is completed through the health insurance exchange and complying with privacy, security and other standards, some of which contain requirements that are new to us. In the event Internet-based agents and brokers such as us use the Internet for completion of qualified health plan selection purposes, their websites are required to meet certain additional requirements. To the extent we enroll individuals and families into qualified health plans, we do so through the Federally Facilitated Marketplace, or FFM, which runs all or part of the health insurance exchange in 36 states. We may experience difficulty in satisfying the conditions and requirements to offer qualified health plans to our existing members and new potential members, and in getting them enrolled through the FFM. If we are not able to satisfy these conditions and requirements, or if we are not able to successfully adopt and maintain solutions that allow us to enroll large numbers of individuals and families in qualified plans over the Internet both during and outside of open enrollment periods, we will lose existing members and new members, and may incur additional expense, which would harm our business, operating results and financial condition. In addition, if we are not able to adopt or contract with and maintain solutions to integrate with government-run health insurance exchanges or if the health insurance exchange websites and other processes are unstable or not consumer friendly, efficient and compatible with the process we have adopted for enrolling individuals and families into qualified health plans through the exchanges, we would not be successful in retaining and acquiring members, and our business, operating results and financial condition would be harmed. The FFM may at any time cease allowing us to enroll individuals in qualified health plans or change the requirements for doing so. If it does so or if the FFM platform does not function properly, our ability to retain existing members and add new members could be negatively impacted, which would harm our business, operating results and financial condition.

CMS has broad authority over the requirements that must be met in order to enroll individuals into qualified health plans through the FFM. CMS directed us to alter our method of enrolling subsidy-eligible individuals into qualified health insurance plans beginning in February 2016. The change required us to cease using the online process we developed for enrolling individuals into qualified health plans through the FFM and use a prescribed FFM “double redirect” process that required that our customers visit the FFM website in the middle of purchasing health insurance to receive a subsidy eligibility determination. The FFM process resulted in a reduction in the rate at which individuals and families starting the application process for qualified health plans and subsidies became members and a reduction in our membership. If we are forced to continue to use this process, we could continue to experience loss of existing members and new potential members and a reduction in our individual and family health insurance plan membership and commission revenue, which would harm our business, operating results and financial condition.

We have entered into agreements with CMS relating to our ability to enroll individuals in qualified health plans through the FFM. The agreements contain comprehensive privacy and security and other requirements. In order to be able to enroll individuals into qualified health plans, we also must satisfy several other regulatory requirements and comply with additional laws and regulations. In order to enroll individuals into qualified health plans online through the FFM, we must among other things, maintain our agreements with the FFM which need to be renewed every year; satisfy the requirements contained in the relevant agreements as well as applicable laws and regulations; maintain a compliant Internet platform incorporating those requirements; maintain qualified health plan information from health insurance carriers and CMS and incorporate it into our web platform; maintain a privacy and security program to conform to the privacy and security requirements of our agreement with CMS as well as applicable laws and regulations; and adopt and maintain solutions that integrate with the FFM (or contract with others that do so) so that information may be passed to and from us relating to enrollment in qualified health plans and subsidy eligibility. If we do not comply with applicable laws, regulations and requirements, our ability to enroll individuals into qualified health plans through the FFM could be terminated, and we may be required to pay significant monetary penalties, either of which would harm our business operating results and financial condition.

CMS issued guidance in May 2017 that made it possible for us to implement a process for subsidy-eligible individuals to enroll into qualified health insurance plans and apply for advanced payment of premium tax credits through the FFM without leaving our website. CMS abandoned the improved process for the qualified health plan open enrollment period that occurred in 2018 for 2019 coverage in favor of another process that allows qualified entities to access the database of information relating to health plans and subsidy eligibility through an application programming interface. CMS indicated that entities must satisfy numerous additional privacy and security requirements to be able to use the new process. We entered into an agreement to outsource certain aspects of the qualified health plan online enrollment process to a third party in light of the expense and burden associated with the additional requirements, and the entity was not successful in passing the required audit to use this new process. As a result, we were required to use the “double redirect” process to enroll individuals and families into qualified health plans during the recently completed open enrollment period. If we do not satisfy the requirements to use the improved qualified health plan enrollment process in the future, or we are unsuccessful in entering into a relationship with a third party who is approved to use the process, we could be required to continue to use the "double redirect" process for qualified health plan enrollment, which would result in our experiencing reduced individual and family health insurance plan membership and revenue and harm our business, operating results and financial condition. In addition, if any third party we contract with to perform certain aspects of the qualified health plan selection and enrollment process has a poor consumer experience or otherwise experiences technical or other difficulties, we

could experience a reduction in our individual and family health insurance plan membership and revenue and our business, operating results and financial condition could be harmed.

The medical loss ratio requirements that are a part of health care reform may harm our business.

The Affordable Care Act contains provisions requiring health insurance carriers to maintain specified medical loss ratios. The medical loss ratio requirements for both individual and family and small business health insurance require health insurance companies to spend 80% of their premium revenue in each of their individual and small group health insurance businesses on reimbursement for clinical services and activities that improve health care quality. The medical loss ratio requirement for Medicare Advantage plans is 85%. If a health insurance carrier fails to meet medical loss ratio requirements, the health insurance carrier is required to rebate a portion of its premium revenue to its members to make up for the difference. Health insurance carriers may determine to reduce our Medicare Advantage plan, individual and family, or small group commissions as a result of the medical loss ratio requirements, which would harm our business, operating results and financial condition.

If we are not successful in cost-effectively converting visitors to our website and customer call centers into members for which we receive commissions, our business and operating results would be harmed.

Our growth depends in large part upon growth in approved members in a given period. The rate at which consumers visiting our ecommerce platform and customer care centers seeking to purchase health insurance are converted into approved members directly impacts our revenue. In addition, the rate at which consumers who are approved become paying members impacts the lifetime value of our approved members, which impacts the revenue that we are able to recognize. A number of factors have influenced, and could in the future influence, these conversion rates for any given period, some of which are outside of our control. These factors include:


•	changes in consumer shopping behavior due to circumstances outside of our control, such as economic conditions, consumers’ ability or willingness to pay for health insurance, availability of unemployment benefits or proposed or enacted legislative or regulatory changes impacting our business, including health care reform;


•	the quality of and changes to the consumer experience on our ecommerce platform or with our customer care center;


•	regulatory requirements, including those that make the experience on our online platforms cumbersome or difficult to navigate;


•	the variety, competitiveness and affordability of the health insurance plans that we offer;


•	system failures or interruptions in the operation of our ecommerce platform or call center operations;


•	changes in the mix of consumers who are referred to us through our direct, marketing partner and online advertising member acquisition channels;


•	health insurance carriers offering the health insurance plans for which consumers have expressed interest, and the degree to which our technology is integrated with those carriers;


•	health insurance carrier guidelines applicable to applications submitted by consumers, the amount of time a carrier takes to make a decision on that application and the percentage of submitted applications approved by health insurance carriers; and


•	our ability to enroll subsidy-eligible individuals in qualified health plans through government-run health insurance exchanges and the efficacy of the process we are required to use to do so.

Our conversion rates can be impacted by changes in the mix of consumers referred to us through our member acquisition channels. We may make changes to our ecommerce platforms in response to regulatory requirements or undertake other initiatives in an attempt to improve consumer experience or for other reasons. These changes have in the past, and may in the future have the unintended consequence of adversely impacting our conversion rates. A decline in the percentage of consumers who submit health insurance applications on our ecommerce platforms or telephonically via our customer care centers and are converted into approved and paying members could cause an increase in our cost of acquiring members on a per member basis and impact our revenue in any given period. To the extent the rate at which we convert consumers visiting our ecommerce platforms or telephonically via our customer care centers into members suffers, our membership may decline, which would harm our business, operating results and financial condition.

Changes in the health insurance market or in the variety, quality and affordability of the health insurance plans that carriers offer on our ecommerce platforms could harm our business and operating results.

The market for private health insurance in the United States is evolving and our future financial performance will depend in part on growth in this market. Changes and developments in the health insurance system in the United States could reduce demand for our products and harm our business. For example, there has been an ongoing national debate relating to the health care reimbursement system in the United States. Some members of Congress have introduced proposals to expand the Medicare program, ranging from proposals that would create a new single payor national health insurance program for all United States

residents, replacing virtually all other sources of public and private insurance, to more incremental approaches such as lowering the age of eligibility for the Medicare program or creating a new public health insurance plan option as a supplement to private sources of coverage. In the event that laws, regulations or rules that eliminate or reduce private sources of health insurance are adopted, the demand for our products could be adversely impacted and our business, operating results and financial condition would be harmed.

The demand for health insurance marketed through our ecommerce platforms is impacted by, among other things, the variety, quality and price of the health insurance plans we offer. If our ability to sell a variety of high-quality, affordable health insurance plans in the Medicare, individual and family, small business and ancillary product markets is impaired, or our health insurance plan offerings are limited or terminated as a result of consolidation in the health insurance industry, health care reform or otherwise, our sales or average commission rate per member may decrease and our business, operating results and financial condition could be harmed. In addition, the cost of health insurance has increased substantially in many states as a result of health care reform implementation, which has reduced demand for individual and family health insurance. To the extent these conditions persist or worsen or the cost of other types of plans we sell increases, our business, operating results and financial condition would be harmed.

If we are not able to maintain and enhance our brand, our business and operating results will be harmed.

We believe that maintaining and enhancing our brand identity is critical to our relationships with existing members, marketing partners and health insurance carriers and to our ability to attract new members, marketing partners and health insurance carriers. The promotion of our brand in these and other ways may require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these branding initiatives may become increasingly difficult and expensive. Our brand promotion activities may not be successful or yield increased revenue, and to the extent that these activities yield increased revenue, the increased revenue may not offset the expenses we incur and our operating results could be harmed. If we do not successfully maintain and enhance our brand, our business may not grow and we could lose our relationships with health insurance carriers, marketing partners and/or members, which would harm our business, operating results and financial condition.

In addition, we have historically received media attention in connection with our public relations efforts. While we cannot be certain of the impact of media coverage on our business, if it were to be reduced or if we were to receive negative publicity, the number of consumers visiting our platforms or customer call centers could decrease, and our cost of acquiring members could increase as a result of a reduction in the number of members coming from our direct member acquisition channel, both of which could harm our business, operating results and financial condition.

Our future operating results are likely to fluctuate and could fall short of expectations.

Our operating results are likely to fluctuate as a result of a variety of factors, including the factors described elsewhere in this Risk Factors section, many of which are outside of our control. Among these factors, the assumptions underlying our estimates of commission revenue as required by Accounting Standards Update 2014-09, Revenue from Contracts with Customers (ASC 606), may vary over time. As a result, comparing our operating results on a period-to-period basis may not be meaningful and you should not rely on our past results as an indication of our future performance, particularly in light of the fact that our business and industry are undergoing substantial change as a result of health care reform and initiatives we determined to pursue. If our revenue or operating results differ from our guidance or fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. In the past, when our revenue and operating results differed from our guidance and the expectations of investors or securities analysts, the price of our common stock was impacted.

System failures or capacity constraints could harm our business and operating results.

The performance, reliability and availability of our ecommerce platforms and underlying network infrastructures are critical to our financial results, our brand and our relationship with members, marketing partners and health insurance carriers. Although we regularly attempt to enhance our ecommerce platform and system infrastructure, system failures and interruptions may occur if we are unsuccessful in these efforts, if we are unable to accurately project the rate or timing of increases in our website traffic or for other reasons, some of which are completely outside our control. Although we have experienced only minor system failures and interruptions to date, we could experience significant failures and interruptions in the future, which would harm our business, operating results and financial condition. If these failures or interruptions occurred during the Medicare annual enrollment period or during the open enrollment period under health care reform, the negative impact on us would be particularly pronounced.

We rely in part upon third-party vendors, including data center and bandwidth providers, to operate our ecommerce platforms. We cannot predict whether additional network capacity will be available from these vendors as we need it, and our network or our suppliers’ networks might be unable to achieve or maintain a sufficiently high capacity of data transmission to

allow us to process health insurance applications in a timely manner or effectively download data, especially if our website traffic increases. Any system failure that causes an interruption in or decreases the responsiveness of our services would impair our revenue-generating capabilities and harm our business and operating results and damage our reputation. In addition, any loss of data could result in loss of customers and subject us to potential liability. Our database and systems are vulnerable to damage or interruption from human error, fire, floods, power loss, telecommunications failures, physical or electronic break-ins, computer viruses, acts of terrorism, other attempts to harm our systems and similar events. In addition, our operations are vulnerable to earthquakes in the San Francisco Bay Area and elsewhere in Northern California.

Consumers may access our customer care centers for assistance in connection with submitting health insurance applications. We depend upon third parties, including telephone service providers and third party software providers, to operate our customer care centers. Any failure of the systems that we rely upon in the operation of our customer care centers could negatively impact sales as well as our relationship with consumers and members, which could harm our business, operating results and financial condition.

We depend upon Internet search engines to attract a significant portion of the consumers who visit our website, and if we are unable to effectively advertise on search engines on a cost-effective basis, our business and operating results would be harmed.

We derive a significant portion of our website traffic from consumers who search for health insurance through Internet search engines, such as Google, Bing and Yahoo!. A critical factor in attracting consumers to our website is whether we are prominently displayed in response to an Internet search relating to health insurance. Search engines typically provide two types of search results, algorithmic listings and paid advertisements. We rely on both to attract consumers to our websites.

Algorithmic search result listings are determined and displayed in accordance with a set of formulas or algorithms developed by the particular Internet search engine. The algorithms determine the order of the listing of results in response to the consumer’s Internet search. From time to time, search engines revise these algorithms. In some instances, these modifications have caused our website to be listed less prominently in algorithmic search results, which has resulted in decreased traffic to our website. We may also be listed less prominently as a result of new websites or changes to existing websites that result in these websites receiving higher algorithmic rankings with the search engine. For example, government health insurance exchange websites appear prominently in algorithmic search results. Our website may become listed less prominently in algorithmic search results for other reasons, such as search engine technical difficulties, search engine technical changes and changes we make to our website. In addition, search engines have deemed the practices of some companies to be inconsistent with search engine guidelines and decided not to list their website in search result listings at all. If we are listed less prominently in, or removed altogether from, search result listings for any reason, the traffic to our websites would decline and we may not be able to replace this traffic, which would harm our business, operating results and financial condition. If we decide to attempt to replace this traffic, we may be required to increase our marketing expenditures, which would also increase our cost of member acquisition and harm our business, operating results and financial condition.

We purchase paid advertisements on search engines in order to attract consumers to our website. We typically pay a search engine for prominent placement of our website when particular health insurance-related terms are searched for on the search engine, regardless of the algorithmic search result listings. The prominence of the placement of our advertisement is determined by a combination of factors, including the amount we are willing to pay and algorithms designed to determine the relevance of our paid advertisement to a particular search term. As with algorithmic search result listings, search engines may revise the algorithms relevant to paid advertisements and websites other than our ecommerce platform may become more optimized for the algorithms. These changes may result in our having to pay increased amounts to maintain our paid advertisement placement in response to a particular search term. We could also have to pay increased amounts should the market share of major search engines continue to become more concentrated with a single search engine. Additionally, we bid against our competitors and others for the display of these paid search engine advertisements. Many of our competitors, including many health insurance carriers and government-run health insurance exchanges, have greater resources with which to bid and better brand recognition than we do. We have experienced increased competition from health insurance carriers, government health insurance exchanges and some of our marketing partners for both algorithmic search result listings and for paid advertisements. The competition has increased the cost of paid internet search advertising and has increased our marketing and advertising expenses. The competition increases substantially during the enrollment periods for Medicare related health insurance and for individual and family health insurance. If paid search advertising costs increase or become cost prohibitive, whether as a results of competition, algorithm changes or otherwise our advertising expenses could rise significantly or we could reduce or discontinue our paid search advertisements, either of which would harm our business, operating results and financial condition.

We rely significantly on marketing partners and our business and operating results would be harmed if we are unable to maintain effective relationships with our existing marketing partners or if we do not establish successful relationships with new marketing partners.

In addition to marketing through Internet search engines, we frequently enter into contractual marketing relationships with other online and offline businesses that promote us. These marketing partners include financial and online service companies, affiliate programs and online advertisers and content providers. We also have relationships with marketing partners, including hospitals and pharmacy chains that promote our Medicare platforms to their customers. We compensate many of our marketing partners for their referrals on a submitted health insurance application basis and, if they are licensed to sell health insurance, may share a percentage of the commission we earn from the health insurance carrier for each member referred by the marketing partner.

Many factors influence the success of our relationship with our marketing partners, including:


•	the continued positive market presence, reputation and growth of the marketing partner;


•	the effectiveness of the marketing partner in marketing our website and services, including whether the marketing partner is successful in maintaining the prominence of its website in algorithmic search result listings and paid Internet advertisements;


•	the compliance of our marketing partners, and of the manner marketing partners refer consumers to our platforms, with applicable laws, regulations and guidelines;


•	the interest of the marketing partner’s customers in the health insurance plans that we offer on our ecommerce platform;


•	the contractual terms we negotiate with the marketing partner, including the marketing fees we agree to pay a marketing partner;


•	the percentage of the marketing partner’s customers that submit applications or purchase health insurance policies through our ecommerce platform;


•	the ability of a marketing partner to maintain efficient and uninterrupted operation of its website; and


•	our ability to work with the marketing partner to implement website changes, launch marketing campaigns and pursue other initiatives necessary to maintain positive consumer experiences and acceptable traffic volumes.

For instance, we partner with Internet lead aggregators who refer a significant number of consumers to our online platforms. Major search engines have in the past and may in the future determine not to list lead aggregator websites prominently in search result listings for various reasons, which would cause a significant reduction in the number of consumers referred to us through our marketing partner channel. While we have relationships with a large number of marketing partners, we depend upon referrals from a limited number of marketing partners for a significant portion of the submitted applications we receive from our marketing partner customer acquisition channel.

Given our reliance on our marketing partners, our business operating results and financial condition would be harmed if any of the following were to occur:


•	if we are unable to maintain successful relationships with our existing marketing partners, particularly marketing partners responsible for a significant number of our submitted applications;


•	if we fail to establish successful relationships with new marketing partners;


•	if we experience competition in our receipt of referrals from our high volume marketing partners; and


•	if we are required to pay increased amounts to our marketing partners.

Competition for referrals from our marketing partners has increased particularly during the open enrollment periods for Medicare-related health insurance and individual and family health insurance. We may lose marketing partner referrals if our competitors pay marketing partners more than we do or be forced to pay increased fees to our marketing partners, which could harm our business, operating results and financial condition. If we lose marketing partner referrals during the Medicare or individual and family health insurance annual open enrollment periods, the adverse impact on our business would be particularly pronounced. In addition, the promulgation of laws, regulations or guidelines, or the interpretation of existing laws, regulations and guidelines, by state departments of insurance or by CMS, could cause our relationships with our marketing partners to be in non-compliance with those laws, regulations and guidelines. We also have relationships with hospital systems and pharmacy chains that utilize aspects of our platform and tools. Our relationships with these hospital systems and pharmacy chains result in the referral of a significant number of individuals to us who are interested in purchasing Medicare-related health insurance plans. If CMS or state departments of insurance were to change existing laws, regulations or guidelines, or interpret existing laws, regulations or guidelines, to prohibit these arrangements, or if hospital systems or pharmacy partners otherwise decided to no longer utilize aspects of our platform and tools, we could experience a significant decline in the number of Medicare-eligible individuals who are referred to our platforms and customer care centers, which would harm our business, operating results and financial condition.

If commission reports we receive from carriers are inaccurate or not sent to us in a timely manner, our business and operating results could be harmed and we may not recognize trends in our membership.

We rely on health insurance carriers to timely and accurately report the amount of commissions earned by us, and we calculate our commission rates per member, prepare our financial reports, projections and budgets and direct our marketing and other operating efforts based on the reports we receive from health insurance carriers. There have been instances where we have determined that policy cancellation data reported to us by a health insurance carrier has not been accurate. The extent to which health insurance carriers are inaccurate in their reporting of policy cancellations could cause us to change our cancellation estimates, which could adversely impact our revenues. We apply judgment and make estimates based on historical data and current trends to independently determine whether or not carriers are accurately reporting commissions due to us. Our revenue recognition policy changed in the first quarter of 2018 as a result of our adoption of Accounting Standards Update 2014-09, Revenue from Contracts with Customers (ASC 606), as discussed in Note 1-Summary of Business and Significant Accounting Policies in the Notes to Condensed Consolidated Financial Statements of this report. Prospectively, to the extent that health insurance carriers understate or fail to accurately report the amount of commissions due to us in a timely manner or at all, our estimates of constrained lifetime value may be adversely impacted, which would harm our business, operating results and financial condition. In addition, any inaccuracies in the reports would adversely impact our commission revenue for future periods which is based on historical trends of factors including the trends in contracted commission rates and expected member churn.

We depend on health insurance carriers and others for data related to our membership. For instance, with respect to health insurance plans other than small business health insurance, health insurance carriers do not directly report member cancellations to us, resulting in the need for us to determine cancellations using payment data that carriers provide. We infer cancellations from this payment data by analyzing whether payments from members have ceased for a period of time, and we may not learn of a cancellation for several months. With respect to our small business membership, many groups notify the carrier directly with respect to increases or decreases in group size and policy cancellations. Our insurance carrier partners often do not communicate this information to us, and it often takes a significant amount of time for us to learn about small business group cancellations and changes in our membership within the group itself. We often are not made aware of policy cancellations until the time of the group’s annual renewal.

After we have estimated membership for a period, we may receive information from health insurance carriers that would have impacted the estimate if we had received the information prior to the date of estimation. We may receive commission payments or other information that indicates that a member who was not included in our estimates for a prior period was in fact an active member at that time, or that a member who was included in our estimates was in fact not an active member of ours. We also reconcile information health insurance carriers provide to us and may determine that we were not historically paid commissions owed to us, which would cause us to have underestimated our membership. As a result of open enrollment periods, we may not receive information from our carriers on as timely a basis due to the significant increase in health insurance transaction volume, which could impair the accuracy of our membership estimates. Additionally, health insurance carriers may require us to return commission payments paid in a prior period due to policy cancellations for members we previously estimated as being active. For these and other reasons, including if current trends in membership cancellation are inconsistent with past cancellation trends that we use to estimate our membership or if carriers subsequently report changes to the commission payments that they previously reported to us, our actual membership could be different from our estimates, perhaps materially. If our actual membership is different from our estimates, the lifetime value component of our revenue recognition could also be inaccurate, including as a result of an inaccurate estimate of the average amount of time our members maintain their health insurance plans.

Our business is subject to security risks and, if we are subject to cyber-attacks, security breaches or otherwise unable to safeguard the security and privacy of confidential data, including personal health information, our business will be harmed.

Our services involve the collection and storage of confidential and personally identifiable information of consumers and the transmission of this information to their chosen health insurance carriers and to government. For example, we collect names, addresses, Social Security and credit card numbers and protected health information such as information regarding the medical history of consumers. As a result, we are subject to various laws and regulations and contractual requirements regarding the collection, maintenance, protection, use, transmission, disclosure and disposal of sensitive personal information. We also hold a significant amount of information relating to our current and former employees. We cannot guarantee that our facilities and systems, and those of our third party service providers, will be free of security breaches, cyber-attacks, acts of vandalism, computer viruses, malware, misplaced or lost data, programming and/or human errors or other similar events. Compliance with privacy and security laws, requirements and regulations may result in cost increases due to new constraints on our business, the development of new processes, the effects of potential non-compliance by us or third party service providers, and enforcement actions. We may be required to expend significant amounts and other resources to protect against security breaches or to alleviate problems caused by security breaches. Despite our implementation of security measures, techniques used to obtain unauthorized access or to sabotage

systems change frequently. As a result, we may be unable to anticipate these techniques or to implement adequate preventative measures. Additionally, our third party service providers may cause security breaches for which we are responsible.

Any compromise or perceived compromise of our security by us or by one of our vendors could damage our reputation, cause the termination of relationships with government-run health insurance exchanges and our members, marketing partners and health insurance carriers, reduce demand for our services and subject us to significant liability and expense as well as regulatory action and lawsuits, which would harm our business, operating results and financial condition. In addition, in the event that additional data security laws are implemented, or our health insurance carrier or other partners determine to impose requirements on us relating to data security, we may not be able to timely comply with such requirements or such requirements may not be compatible with our current processes. Changing our processes could be time consuming and expensive, and failure to timely implement required changes could result in our inability to sell health insurance plans in a particular jurisdiction or for a particular health insurance carrier or subject us to liability for non-compliance, any of which would damage our business, operating results and financial condition. For instance, health insurance carriers may require us to be compliant with Payment Card Industry, or PCI, security standards in order to accept credit card information from consumers or require us to comply with privacy and security standards to do business with us at all. PCI compliance and compliance with other privacy and security standards are regularly assessed, and we may not always be compliant with the standards. If we are not in compliance, we may not be able to accept credit card information from consumers or conduct health insurance business, and our relationship with health insurance carriers could be adversely impacted or terminated, which would harm our business, operating results and financial condition.

There are many risks associated with our operations in China.

A portion of our operations is conducted by our subsidiary in China. Among other things, we use employees in China to maintain and update our ecommerce platform and perform certain tasks within our finance and customer care and enrollment functions. We rely on the Internet to communicate with our subsidiary in China. Our business would be harmed if our ability to communicate over the Internet with these employees failed, and we were prevented from promptly updating our software or implementing other changes to our database and systems, among other things. From time-to-time we receive inquiries from health insurance carriers relating to our operations in China and the security measures we have implemented to protect data that our employees in China may be able to access. As a part of these inquiries, we have implemented additional security measures relating to our operations in China. We may be required to implement further security measures to continue aspects of our operations in China or health insurance carriers may require us to bring aspects of our operations in China back to the United States, which could be time consuming and expensive and harm our operating results and financial condition. Health insurance carriers may also terminate our relationship due to concerns surrounding protection of data, which would harm our business, operating results and financial condition.

Our operations in China also expose us to different and unfamiliar laws, rules and regulations, including different intellectual property laws, which are not as protective of our intellectual property as the laws in the United States. United States and Chinese trade laws may also impose restrictions on the importation of programming or technology to or from the United States. We are also subject to anti-bribery and anti-corruption laws, labor laws, tax laws, foreign exchange controls and cash repatriation restrictions in China. Although we have implemented policies and procedures to comply with these laws and regulations, violations of them could adversely affect our brand and could result in the imposition of civil or criminal penalties and fines. In addition, our business may be adversely impacted by changes in China’s economic or political condition. We have recently experienced greater competition for qualified personnel in China, which has raised market salaries and increased our compensation costs related to employees in China. If competition for personnel increases further, our compensation expenses could rise considerably or, if we determine to not increase compensation levels, our ability to attract and retain qualified personnel in China may be impaired, which could harm our business, operating results and financial condition. These risks could cause us to incur increased expenses and could harm our ability to effectively and successfully manage our operations in China. Moreover, any significant or prolonged deterioration in the relationship between United States and China could adversely affect our operations in China. Certain risks and uncertainties of doing business in China are solely within the control of the Chinese government, and Chinese law regulates the scope of our foreign investments and business conducted within China. The escalation of trade tensions initiated by the current administration has increased the risk associated with our operations in China. Either the United States or the Chinese government may sever our ability to communicate with our China operations or may take actions that force us to close our operations in China. We employ a large number of our technology and content employees in China, and we have other employees in China that support our business. Any sudden disruption of our operations in China would adversely impact our business. If we are required to move aspects of our operations from China to our offices in the United States as a result of political instability, changes in laws, inquiries from health insurance carriers or for other reasons, we could incur increased expenses, and our business, operating results and financial condition could be harmed.

Our sponsorship and advertising business may not be successful.

We sell advertising space to health insurance carriers on our website through our sponsorship and advertising program. Our sponsorship and advertising program allows carriers to purchase advertising space in specific markets in a sponsorship area on our website. Health insurance carriers have generally determined not to spend on individual and family health insurance advertising through our sponsorship and advertising program as a result of the impact of health care reform on the profitability of their individual and family health insurance businesses. To the extent that economic conditions, health care reform or other factors impact the amount health insurance carriers are willing to pay for advertising on our ecommerce platform, our sponsorship and advertising program will be adversely impacted. Since much of our sponsorship revenue depends upon the number of applications we submit to health insurance carriers, a reduction in demand for the carrier’s product (such as outside open enrollment periods) would reduce our sponsorship revenue and our business, operating results and financial condition could be harmed. The success of our sponsorship and advertising program depends on a number of other factors, including the effectiveness of the sponsorship and advertising program as a cost-effective method for carriers to obtain additional members, consumer and health insurance carrier adoption of the Internet and our ecommerce platform as a medium for the purchase and sale of health insurance, our ability to attract consumers visiting our ecommerce platform and convert those consumers into members, the existence of a relationship between us and a diverse group of carriers that offer a number of health insurance plans in the markets in which we attempt to sell advertising, the cost, benefit and brand recognition of the health insurance plan that is the subject of the advertising, the impact the advertising has on the sale of the health insurance plan that is the subject of the advertising and the effectiveness of the carrier’s other means of advertising. In addition, while our practice of selling advertising is described on our ecommerce platform, it could cause consumers to perceive us as not objective, which could harm our brand and result in a decline in our health insurance sales. It also could adversely impact our relationship with health insurance carriers that do not purchase our advertising or otherwise result in accusations that we are favoring certain plans over others. As a result, our business, operating results and financial condition could be harmed.

We also develop, host and maintain carrier dedicated Medicare plan websites through our advertising program. Our success in doing so is dependent upon the same factors that could impact our sponsorship program. In addition, since we maintain relationships with a limited number of health insurance carriers to sell their Medicare plans, our Medicare plan-related advertising revenue is concentrated in a small number of health insurance carriers and our ability to generate Medicare plan-related advertising revenue would be harmed by the termination or non-renewal of any of these relationships as well as by a reduction in the amount a health insurance carrier is willing to pay for these services. Moreover, in light of the regulations applicable to the marketing and sale of Medicare plans, and given that these regulations are often unclear, change frequently and are subject to changing interpretations, we may in the future not be permitted to sell Medicare plan-related advertising. If we are not successful in generating Medicare plan-related advertising revenue, our business operating results and financial condition could be harmed.

We may not be able to adequately protect our intellectual property, which could harm our business and operating results.

We believe that our intellectual property is an essential asset of our business and that our technology currently gives us a competitive advantage in the distribution of Medicare-related, individual and family and small business health insurance. We rely on a combination of copyright, trademark and trade secret laws as well as confidentiality procedures and contractual provisions to establish and protect our intellectual property rights in the United States. The efforts we have taken to protect our intellectual property may not be sufficient or effective, and our trademarks may be held invalid or unenforceable. Moreover, the law relating to intellectual property is not as developed in China, and our intellectual property rights may not be as respected in China as they are in the United States. We may not be effective in policing unauthorized use of our intellectual property, trade secrets and other confidential information, and even if we do detect violations, litigation may be necessary to enforce our intellectual property rights. Any enforcement efforts we undertake, including litigation, could be time-consuming and expensive, could divert our management’s attention and may result in a court determining that our intellectual property or other rights are unenforceable. If we are not successful in cost-effectively protecting our intellectual property rights, trade secrets and confidential information, our business, operating results and financial condition could be harmed.

We may in the future be subject to intellectual property rights claims, which are extremely costly to defend, could require us to pay significant damages and could limit our ability to use certain technologies in the future.

There are a large number of patents, copyrights, trademarks and trade secrets applicable to the internet and technology industries and entities frequently enter into litigation based on allegations of infringement or other violations of intellectual property rights. We have received, and may in the future receive, notices that claim we have misappropriated, infringed or misused other parties’ intellectual property rights, and, to the extent we gain greater visibility, we face a higher risk of being the subject of intellectual property infringement claims. There may be third-party intellectual property rights, including issued or pending patents that cover significant aspects of our technologies or business methods or that cover third-party technology that we use as a part of our websites. Any intellectual property claim against us, with or without merit, could be time consuming, expensive to settle or litigate and could divert our management’s attention and other resources. These claims also could subject us to significant liability for damages and could result in our having to stop using technology found to be in violation of a third party’s rights. We might be

required to seek a license for third-party intellectual property, which may not be available on reasonable terms or at all. Even if a license is available, we could be required to pay significant royalties, which would increase our operating expenses. We may also be required to develop alternative non-infringing technology, which could require significant effort and expense. If we cannot license or develop technology for any infringing aspect of our business, we would be forced to limit our services and may be unable to compete effectively. Any of these results would harm our business, operating results and financial condition.

Any legal liability, regulatory penalties, or negative publicity for the information on our website or that we otherwise provide could harm our business and operating results.

We provide information on our website, through our customer care centers, in our marketing materials and in other ways regarding health insurance in general and the health insurance plans we market and sell, including information relating to insurance premiums, coverage, benefits, provider networks, exclusions, limitations, availability, plan comparisons and insurance company ratings. A significant amount of both automated and manual effort is required to maintain the considerable amount of insurance plan information on our website. Separately, from time to time, we use the information provided on our website and otherwise collected by us to publish reports designed to educate consumers, facilitate public debate, and facilitate reform at the state and federal level. If the information we provide on our website, through our customer care centers, in our marketing materials or otherwise is not accurate or is construed as misleading, or if we do not properly assist individuals and businesses in purchasing health insurance, members, health insurance carriers and others could attempt to hold us liable for damages, our relationships with health insurance carriers could be terminated or impaired and regulators could attempt to subject us to penalties, revoke our licenses to transact health insurance business in a particular jurisdiction, and/or compromise the status of our licenses to transact health insurance business in other jurisdictions, which could result in our loss of our commission revenue. In the ordinary course of operating our business, we have received complaints that the information we provided was not accurate or was misleading. Although in the past we have resolved these complaints without significant financial cost or impact to our brand or reputation, we cannot guarantee that we will be able to do so in the future. Our recent focus in selling short-term health insurance that does not have the same benefits as major medical health insurance may increase our risks of receiving complaints regarding our marketing and business practice due to the potential for consumer confusion between short-term health insurance and major medical health insurance. In addition, these types of claims could be time-consuming and expensive to defend, could divert our management’s attention and other resources, and could cause a loss of confidence in our services. As a result, whether or not we are able to successfully resolve these claims, they could harm our business, operating results and financial condition.

In the ordinary course of our business, we have received and may continue to receive inquiries from state regulators relating to various matters. We also have become, and may in the future become, involved in litigation or claims in the ordinary course of our business, including with respect to employment-related claims such as workplace discrimination or harassment. We have, and may in the future, face claims of violations of other local, state, and federal labor or employment laws, laws and regulations relating to marketing and laws and regulations relating to the sale of insurance. If we are found to have violated laws or regulations, we could lose our relationship with health insurance carriers and be subject to various fines and penalties, including revocation of our licenses to sell insurance which would cause us to lose our commission revenue, and our business, operating results and financial condition would be materially harmed. In addition, if regulators believe our websites or marketing material are not compliant with applicable laws or regulations, we could be forced to stop using our websites, marketing material or certain aspects of them, which would harm our business, operating results and financial condition.

Acquisitions could disrupt our business and harm our financial condition and operating results.

We recently acquired Wealth, Health and Life Advisors, LLC, more commonly known as GoMedigap, in January 2018 and in the future may decide to acquire other businesses, products and technologies. Our ability as an organization to successfully make and integrate acquisitions is unproven. Acquisitions could require significant capital infusions and could involve many risks, including the following:

•

an acquisition may negatively impact our results of operations because it will require us to incur transaction expenses, and after the transaction, may require us to incur charges and substantial debt or liabilities, may require the amortization, write down or impairment of amounts related to deferred compensation, goodwill and other intangible assets, or may cause adverse tax consequences, substantial depreciation or deferred compensation charges;


•	an acquisition undertaken for strategic business purposes may negatively impact our results of operations;


•	we may encounter difficulties in assimilating and integrating the business, technologies, products, personnel or operations of companies that we acquire, particularly if key personnel of the acquired company decide not to work for us;


•	an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our management;


•	we may be required to implement or improve internal controls, procedures and policies appropriate for a public company at a business that prior to the acquisition lacked these controls, procedures and policies;


•	the acquired businesses, products or technologies may not generate sufficient revenue to offset acquisition costs or to maintain our financial results;


•	we may have to issue equity securities to complete an acquisition, which would dilute our stockholders’ ownership and could adversely affect the market price of our common stock; and


•	acquisitions may involve the entry into geographic or business markets in which we have little or no prior experience.

We cannot assure you that we will be able to identify or consummate any future acquisition on favorable terms, or at all. If we do pursue an acquisition, it is possible that we may not realize the anticipated benefits from the acquisition or that the financial markets or investors will negatively view the acquisition. Even if we successfully complete an acquisition, it could harm our business, operating results and financial condition.

As part of our initiative to expand our presence in the Medicare supplement market, we acquired GoMedigap in January 2018. We may not be able to realize anticipated synergies and opportunities as a result of the acquisition, and the business may not perform as planned as a result of many of the risks and uncertainties that apply to the rest of our business. We may also encounter difficulties in integrating GoMedigap into our existing business. If anticipated synergies and opportunities are not realized, our business, operating results and financial condition would be harmed.

Our debt obligations contain restrictions that impact our business and expose us to risks that could materially adversely affect our liquidity and financial condition.

In September 2018, we entered into a credit agreement with Royal Bank of Canada, as administrative agent and collateral agent. This credit agreement imposes certain covenants and restrictions on our business and our ability to obtain additional financing. As of March 31, 2019, we had no outstanding principal amount under our revolving credit facility.

Among other things, the credit agreement requires the lender’s consent, under certain circumstances, to:


•	merge or consolidate;


•	sell or transfer assets outside the ordinary course of business;


•	make certain types of investments and restricted payments;


•	incur additional indebtedness or guarantee indebtedness of others;


•	pay dividends on our capital stock;


•	enter into transactions with affiliates; and


•	grant liens on our assets, subject to certain exceptions.

Our credit agreement also contains customary affirmative covenants, including covenants regarding the payment of taxes and other obligations, maintenance of insurance, reporting requirements and compliance with applicable laws and regulations. Further, the credit agreement contains a financial covenant requiring the Company to maintain a minimum level of excess availability at any time. The facility contains events of default, including, among others, non-payment defaults, inaccuracy of representations and warranties, covenant defaults, cross-defaults to other indebtedness, judgment defaults, collateral defaults, bankruptcy and insolvency defaults and a change of control default.

If we experience a decline in cash flow due to any of the factors described in this “Risk Factors” section or otherwise, we could have difficulty paying interest and principal amounts due on our indebtedness and meeting the financial covenants set forth in our loan facility. If we are unable to generate sufficient cash flow or otherwise obtain the funds necessary to make required payments under the credit facility, or if we fail to comply with the requirements of our indebtedness, we could default under our credit facility. Any default that is not cured or waived could result in the acceleration of the obligations under the credit facility, an increase in the applicable interest rate under the credit facility, and would permit our lender to exercise rights and remedies with respect to all of the collateral that is securing the credit facility, which includes substantially all of our assets. Any such default could materially adversely affect our liquidity and financial condition.

Even if we comply with all of the applicable covenants, the restrictions on the conduct of our business could materially adversely affect our business by, among other things, limiting our ability to take advantage of financings, mergers, acquisitions and other corporate opportunities that may be beneficial to the business. Even if the credit facility were terminated, additional debt we could incur in the future may subject us to similar or additional covenants, which could place restrictions on the operation of our business.

If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements could be impaired, which could adversely affect our operating results, our ability to operate our business and our stock price.

We have a complex business organization. Ensuring that we have adequate internal financial and accounting controls and procedures in place to help ensure that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently and is complicated by the expansion of our business operations and changing accounting requirements. Our management, including our chief executive officer and chief financial officer, does not expect that our internal control over financial reporting will prevent all errors or all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Over time, controls may become inadequate because changes in conditions or deterioration in the degree of compliance with policies or procedures may occur. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. We cannot assure that significant deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in significant deficiencies or material weaknesses, cause us to fail to timely meet our periodic reporting obligations, or result in material misstatements in our financial statements. Any such failure could also adversely affect the results of periodic management evaluations and annual auditor attestation reports regarding disclosure controls and the effectiveness of our internal control over financial reporting required under Section 404 of the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder. The existence of a material weakness could result in errors in our financial statements that could result in a restatement of financial statements, cause us to fail to timely meet our reporting obligations and cause investors to lose confidence in our reported financial information, leading to a decline in our stock price and potential lawsuits against us.

Changes in our provision for income taxes or adverse outcomes resulting from examination of our income or other tax returns or changes in tax legislation could adversely affect our results.

Our provision for income taxes is subject to volatility and could be adversely affected by earnings differing materially from our projections, changes in the valuation of our deferred tax assets and liabilities, tax effects of share-based compensation, outcomes as a result of tax examinations or by changes in tax laws, regulations, accounting principles, including accounting for uncertain tax positions, or interpretations thereof.

To the extent that our provision for income taxes is subject to volatility or adverse outcomes as a result of tax examinations, our operating results could be harmed. Significant judgment is required to determine the recognition and measurement attribute prescribed in U.S. generally accepted accounting principles (“U.S. GAAP”) relating to accounting for income taxes. In addition, we are subject to examinations of our income tax returns by the Internal Revenue Service, or IRS, and other tax authorities. We assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our provision for income taxes. There may be exposure that the outcomes from these examinations will have an adverse effect on our operating results and financial condition.

Regulation of the sale of health insurance is subject to change, and future regulations could harm our business and operating results.

The laws and regulations governing the offer, sale and purchase of health insurance are subject to change, and future changes may be adverse to our business. For example, a long standing provision in each state’s law that we believe is advantageous to our business is that once health insurance premiums are set by the carrier and approved by state regulators, they are fixed and not generally subject to negotiation or discounting by insurance companies or agents. Additionally, state regulations generally prohibit carriers, agents and brokers from providing financial incentives, such as rebates, to their members in connection with the sale of health insurance. As a result, we do not currently compete with carriers or other agents and brokers on the price of the health insurance plans offered on our website. If these regulations change, we could be forced to reduce prices or provide rebates or other incentives for the health insurance plans sold through our ecommerce platform, which would harm our business, operating results and financial condition.

States have adopted and will continue to adopt new laws and regulations in response to health care reform legislation. It is difficult to predict how these new laws and regulations will impact our business, but in some cases such laws and regulations could amplify the adverse impacts of health care reform to our business, or states may adopt new requirements that adversely impact our business, operating results and financial condition. For example, certain states have adopted or are contemplating rules and regulations that would either ban the sale of short-term health insurance, limit its duration and renewability, or apply certain aspects of the Affordable Care Act to short-term health insurance, such as the essential health benefits or requiring that short-term health insurance cover pre-existing conditions. Rules and regulations such as these could adversely impact our sale of short-term health insurance for several reasons, including because carriers may exit the market of selling short-term health insurance due to

regulatory concerns, determine it is not profitable to sell the plans or increase plan premiums to a degree that reduces consumer demand for them. States may also require stronger disclosure and marketing rules governing the sale of short-term health insurance which may impact our conversion rates on the sale of short-term health insurance. Moreover, our sales outside of the health care reform open enrollment period could decline, because many individuals and families choose to purchase short-term health insurance outside of the open enrollment period given the unavailability of major medical individual and family health insurance to them. Additionally, states and the federal government may adopt laws and regulations that further impact the types of health insurance coverage available to consumers, the product features and benefits, and the role and compensation of agents and brokers in the sale of health insurance.

We are also subject to additional insurance regulatory risks because we use the Internet as a distribution platform. In many cases, it is not clear how existing insurance laws and regulations apply to Internet-related health insurance advertisements and transactions. To the extent that new laws or regulations are adopted that conflict with the way we conduct our business, or to the extent that existing laws and regulations are interpreted adversely to us, our business, operating results and financial condition would be harmed.

If we fail to comply with the numerous state laws and regulations that are applicable to the sale of health insurance, our business and operating results could be harmed.

The sale of health insurance is heavily regulated by each state in the United States. For instance, in addition to the impact and changes in regulations resulting from health care reform, state regulators require us to maintain a valid license in each state in which we transact health insurance business and further require that we adhere to sales, documentation and administration practices specific to that state. We must maintain our health insurance licenses to continue selling plans and to continue to receive commissions from health insurance carriers. In addition, each employee who transacts health insurance business on our behalf must maintain a valid license in one or more states. Because we do business in all 50 states and the District of Columbia, compliance with health insurance-related laws, rules and regulations is difficult and imposes significant costs on our business. Each jurisdiction’s insurance department typically has the power, among other things, to:


•	grant and revoke licenses to transact insurance business;


•	conduct inquiries into the insurance-related activities and conduct of agents and agencies;


•	require and regulate disclosure in connection with the sale and solicitation of health insurance;


•	authorize how, by which personnel and under what circumstances insurance premiums can be quoted and published and an insurance policy sold;


•	approve which entities can be paid commissions from carriers and the circumstances under which they may be paid;


•	regulate the content of insurance-related advertisements, including web pages, and other marketing practices;


•	approve policy forms, require specific benefits and benefit levels and regulate premium rates;


•	impose fines and other penalties; and


•	impose continuing education requirements.

Due to the complexity, periodic modification and differing interpretations of insurance laws and regulations, we may not have always been, and we may not always be, in compliance with them. New insurance laws, regulations and guidelines also may not be compatible with the sale of health insurance over the Internet or with various aspects of our platform or manner of marketing or selling health insurance plans. Failure to comply with insurance laws, regulations and guidelines or other laws and regulations applicable to our business could result in significant liability, additional department of insurance licensing requirements, required modification of our advertising and business practices, the revocation of our licenses in a particular jurisdiction, termination of our relationship with health insurance carriers, loss of commissions and/or our inability to sell health insurance plans, which could significantly increase our operating expenses, result in the loss of carrier relationships and our commission revenue and otherwise harm our business, operating results and financial condition. Moreover, an adverse regulatory action in one jurisdiction could result in penalties and adversely affect our license status, business or reputation in other jurisdictions due to the requirement that adverse regulatory actions in one jurisdiction be reported to other jurisdictions. Even if the allegations in any regulatory or other action against us are proven false, any surrounding negative publicity could harm consumer, marketing partner or health insurance carrier confidence in us, which could significantly damage our brand. Changes in insurance laws, regulations and guidelines may also be incompatible with various aspects of our business and require that we make significant modifications to our existing technology or practices, which may be costly and time-consuming to implement and could also harm our business, operating results and financial condition.

We have received, and may in the future receive, inquiries from regulators regarding our marketing and business practices and compliance with laws and regulations. We typically respond to these inquiries by explaining how we believe we are in compliance with relevant regulations, or may modify our practices in connection with the inquiry. CMS and certain state regulators notified us in advance of and during the most recently completed Medicare annual enrollment period that certain marketing material that we were using relating to one of our websites was misleading and did not follow certain legal and regulatory requirements.

We are in the process of working through the matter with the relevant regulators and have entered into a consent order with a department of insurance. We also recently received a letter from the Committee on Energy and Commerce of the United States House of Representatives in March 2019 requesting information relating to our sale of short-term health insurance. The letter indicates that the committee is conducting oversight of short term health insurance and companies that assist consumers enroll in short term health insurance plans in light of committee concerns, including its concern relating to the understanding of consumers who purchase short term health insurance coverage. Inquiries and proceedings initiated by the government could adversely impact our health insurance licenses, require us to pay fines, require us to modify marketing and business practices, result in litigation and otherwise harm our business, operating results or financial condition.

Government regulation of the Internet could adversely affect our business.

The laws governing general commerce on the Internet remain unsettled and it may take years to fully determine whether and how existing laws such as those governing intellectual property, privacy and taxation apply to the Internet. In addition, the growth and development of the market for electronic commerce may prompt calls for more stringent consumer protection laws that may impose additional burdens on companies conducting business over the Internet. Any new laws or regulations or new interpretations of existing laws or regulations relating to the Internet could harm our business and we could be forced to incur substantial costs in order to comply with them, which would harm our business, operating results and financial condition.

Our business could be harmed if we are unable to contact our consumers or market the availability of our products through specific channels.

We use email and telephone, among other channels, to market our services to potential members and as the primary means of communicating with our existing members. The laws and regulations governing the use of emails and telephone calls for marketing purposes continue to evolve, and changes in technology, the marketplace or consumer preferences may lead to the adoption of additional laws or regulations or changes in interpretation of existing laws or regulations. If new laws or regulations are adopted, or existing laws and regulations are interpreted or enforced, to impose additional restrictions on our ability to send email or telephone messages to our members or potential members, we may not be able to communicate with them in a cost-effective manner. In addition to legal restrictions on the use of email, Internet service providers, e-mail service providers and others attempt to block the transmission of unsolicited email, commonly known as “spam.” Many Internet and e-mail service providers have relationships with organizations whose purpose it is to detect and notify the Internet and e-mail service providers of entities that the organization believes is sending unsolicited e-mail. If an Internet or e-mail service provider identifies email from us as “spam” as a result of reports from these organizations or otherwise, we can be placed on a restricted list that will block our email to members or potential members.

We use telephones to communicate with customers and prospective customers and some of these communications may be subject to the Telephone Consumer Protection Act, or TCPA, and other telemarketing laws. The TCPA and other laws, including state laws, relating to telemarketing restrict our ability to market using the telephone in certain respects. For instance, the TCPA prohibits us from using an automatic telephone dialing system to make certain telephone calls to consumers without prior express consent. We have policies in place to comply with the TCPA and other telemarketing laws. However, despite our legal compliance, we have in the past and may in the future become subject to claims that we have violated the TCPA. The TCPA provides for statutory damages of $500 for each violation and $1,500 for each willful violation. For instance, we have been experiencing complaints from consumers that we are violating the TCPA as a result of third parties, who are falsely indicating to consumers that they are associated with us to gain credibility in connection with their attempts to sell insurance. In the event that we are found to have violated the TCPA, our business, operating results and financial condition could be harmed. In addition, telephone carriers may block or put consumer warnings on calls originating from call centers. Consumers increasingly screen their incoming emails and telephone calls, including by using screening tools and warnings, and therefore our members or potential members may not reliably receive our emails or telephone messages. If we are unable to communicate effectively by email or telephone with our members and potential members as a result of legislation, blockage, screening technologies or otherwise, our business, operating results and financial condition would be harmed.

Consumers depend upon third-party service providers to access our website, and our business and operating results could be harmed as a result of technical difficulties experienced by these service providers.

Consumers using our website depend upon Internet, online and other service providers for access to our website. Many of these service providers have experienced significant outages, delays and other difficulties in the past and could experience them in the future. Any significant interruption in access to our website or increase in our website’s response time as a result of these difficulties could damage our relationship with insurance carriers, marketing partners and existing and potential members and could harm our business, operating results and financial condition.

Risks Related to Ownership of Our Common Stock

Our actual operating results may differ significantly from our guidance.

From time to time, we have released, and may continue to release guidance in earnings conference calls, earnings releases, or otherwise, regarding our future performance that represents our management's estimates as of the date of release. This guidance, which includes forward-looking statements, has been and will be based on projections prepared by our management. These projections are not prepared with a view toward compliance with published guidelines of the American Institute of Certified Public Accountants, and neither our registered public accountants nor any other independent expert or outside party compiles or examines the projections. Accordingly, no such person expresses any opinion or any other form of assurance with respect to the projections.

Projections are based upon a number of assumptions and estimates that, while presented with numerical specificity, are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. Among these factors, the assumptions underlying our estimates of commission revenue as required by Accounting Standards Update 2014-09, Revenue from Contracts with Customers (ASC 606), may vary over time. We may state possible outcomes as high and low ranges. Any range we provide is not intended to imply that actual results could not fall outside of the suggested ranges. The principal reason that we release guidance is to provide a basis for our management to discuss our business outlook with analysts and investors and we may decide to suspend guidance at any time. We do not accept any responsibility for any projections or reports published by any such third parties.

Guidance is necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the guidance furnished by us will not materialize or will vary significantly from actual results. Accordingly, our guidance is only an estimate of what management believes is realizable as of the date of release. Our actual results have, and may in the future, vary from our guidance and the variations may be material. In light of the foregoing, investors are urged not to rely upon our guidance in making an investment decision regarding our common stock.

Any failure to successfully implement our operating strategy or the occurrence of any of the events or circumstances set forth in this “Risk Factors” section could result in the actual operating results being different from our guidance, and the differences may be adverse and material.

The price of our common stock has been and may continue to be volatile, and the value of your investment could decline.

The trading price of our common stock has been volatile and is likely to continue to fluctuate substantially. For the quarter ended March 31, 2019, the trading price of our common stock fluctuated from a low of $36.00 per share to a high of $67.44 per share. The trading price of our common stock depends on a number of factors, including those described in this “Risk Factors” section, many of which are beyond our control and may not be related to our operating performance. These fluctuations could cause you to lose all or part of your investment in our common stock since you might be unable to sell your shares at or above the price you paid. Factors that could cause fluctuations in the trading price of our common stock include the following:


•	price and volume fluctuations in the overall stock market from time to time;


•	volatility in the market prices and trading volumes of our competitors' shares, including high technology stocks, which have historically experienced high levels of volatility;


•	new laws or regulations or new interpretations of existing laws or regulations applicable to our business, including developments relating to the health care industry, particularly health care reform legislation and the implementation of health care reform;


•	actual or anticipated changes in our operating results or fluctuations in our operating results;


•	changes in operating performance and stock market valuations of other technology companies generally, and of our competitors;


•	failure of securities analysts to maintain coverage of us, changes in financial estimates by any securities analysts who follow our company, or our failure to meet these estimates or the expectations of investors;


•	sales of shares of our common stock by us or our stockholders;


•	announcements by us or our competitors of new products or services;


•	the public’s reaction to our press releases, other public announcements, and filings with the SEC;


•	rumors and market speculation involving us or other companies in our industry;


•	actual or anticipated developments in our business, our competitors' businesses, or the competitive landscape generally;


•	our ability to control costs, including our operating expenses;


•	litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;


•	developments or disputes concerning our intellectual property or other proprietary rights;


•	announced or completed acquisitions of businesses or technologies by us or our competitors;


•	changes in accounting standards, policies, guidelines, interpretations, or principles;


•	any significant change in our management; and


•	general economic conditions and slow or negative growth of our markets.

The effect of such factors on the trading market for our stock may be enhanced by the lack of a large and established trading market for our stock. In addition, the stock market in general, and the market for technology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Additionally, as a public company, we face the risk of shareholder lawsuits, particularly if we experience declines in the price of our common stock. In the past, following periods of volatility in the overall market and the market prices of a particular company's securities, securities class action lawsuits have often been instituted against affected companies. We have been, and may in the future be, subject to such legal actions.

Anti-takeover provisions contained in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.

Our certificate of incorporation, bylaws, and Delaware law contain provisions which could have the effect of rendering more difficult, delaying, or preventing an acquisition deemed undesirable by our board of directors. Our corporate governance documents include provisions:


•	creating a classified board of directors whose members serve staggered three-year terms;


•	authorizing undesignated preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend, and other rights superior to our common stock;


•	limiting the liability of, and providing indemnification to, our directors and officers;


•	limiting the ability of our stockholders to call and bring business before special meetings;


•	requiring advance notice of stockholder proposals for business to be conducted at meetings of our stockholders and for nominations of candidates for election to our board of directors;


•	controlling the procedures for the conduct and scheduling of board of directors and stockholder meetings; and


•	providing our board of directors with the express power to postpone previously scheduled annual meetings and to cancel previously scheduled special meetings.

These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.

As a Delaware corporation, we are also subject to provisions of Delaware law, including Section 203 of the Delaware General Corporation law, which prevents some stockholders holding more than 15% of our outstanding common stock from engaging in certain business combinations without approval of the holders of substantially all of our outstanding common stock.

Any provision of our certificate of incorporation, bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.

We do not expect to declare any dividends in the foreseeable future.

We have never declared or paid any cash dividends on our common stock. We currently intend to retain any future earnings to fund our growth, and we do not anticipate declaring or paying any cash dividends in the foreseeable future. Additionally, the terms of our current debt instruments restrict our ability to pay cash dividends on our common stock. Any future determination to declare cash dividends will be made at the discretion of our board of directors, subject to applicable laws and provisions of our debt instruments and organizational documents, after taking into account our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors may deem relevant.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended March 31, 2019, we issued 294,637 shares of our common stock as earnout consideration for our acquisition of GoMedigap in January 2019 as described in Item 8—Financial Statements and Note 2—Acquisition of this Quarterly Report on Form 10-Q. The shares were issued in reliance on Section 4(a)(2) of the Securities Act of 1933 as a transaction not involving any public offering.

Table of Contents


ITEM 6.	EXHIBITS

(a) Exhibits

Except as so indicated in Exhibits 32.1 and 32.2, the following exhibits are filed as part of, or incorporated by reference into, this quarterly report on Form 10-Q.



			Incorporation by Reference Herein
Exhibit Number		Description of Exhibit	Form	Date
10.1	†	Amendment No. 3 to Lease, dated March 20, 2019, between SLC Lake Pointe SPE LLC and eHealthInsurance Services, Inc.	Current Report on Form 8-K (File No. 001-33071)	March 26, 2019
31.1	†	Certification of Scott N. Flanders, Chief Executive Officer of eHealth, Inc., pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	†	Certification of Derek N. Yung, Chief Financial Officer of eHealth, Inc., pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	‡	Certification of Scott N. Flanders, Chief Executive Officer of eHealth, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	‡	Certification of Derek N. Yung, Chief Financial Officer of eHealth, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

† Filed herewith.

‡ Furnished herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

May 6, 2019

eHealth, Inc.



/s/ SCOTT N. FLANDERS		/s/ DEREK N. YUNG
Scott N. Flanders Chief Executive Officer		Derek N. Yung Chief Financial Officer

EXHIBIT INDEX



			Incorporation by Reference Herein
Exhibit Number		Description of Exhibit	Form	Date
10.1	†	Amendment No. 3 to Lease, dated March 20, 2019, between SLC Lake Pointe SPE LLC and eHealthInsurance Services, Inc.	Current Report on Form 8-K (File No. 001-33071)	March 26, 2019
31.1	†	Certification of Scott N. Flanders, Chief Executive Officer of eHealth, Inc., pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	†	Certification of Derek N. Yung, Chief Financial Officer of eHealth, Inc., pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	‡	Certification of Scott N. Flanders, Chief Executive Officer of eHealth, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	‡	Certification of Derek N. Yung, Chief Financial Officer of eHealth, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

† Filed herewith.

‡ Furnished herewith.

EX-31.1 2 ehth3312019ex311.htm EXHIBIT 31.1 Exhibit

Exhibit 31.1

CERTIFICATION

I, Scott N. Flanders, certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of eHealth, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):


a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 6, 2019




	/s/ SCOTT N. FLANDERS
	Scott N. Flanders
	Chief Executive Officer

EX-31.2 3 ehth3312019ex312.htm EXHIBIT 31.2 Exhibit

Exhibit 31.2

CERTIFICATION

I, Derek N. Yung, certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of eHealth, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):


a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 6, 2019






	/s/ DEREK N. YUNG
	Derek N. Yung
	Chief Financial Officer

EX-32.1 4 ehth3312019ex321.htm EXHIBIT 32.1 Exhibit

Exhibit 32.1

Certification of Chief Executive Officer, Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of eHealth, Inc. on Form 10-Q (the “Form 10-Q”) for the quarter ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott N. Flanders, Chief Executive Officer of eHealth, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:


(1)	The Form 10-Q, to which this certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of eHealth, Inc.

/s/ SCOTT N. FLANDERS

Scott N. Flanders

Chief Executive Officer

May 6, 2019

A signed original of this written statement required by Section 906 has been provided to eHealth, Inc. and will be retained by eHealth, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 ehth3312019ex322.htm EXHIBIT 32.2 Exhibit

Exhibit 32.2

Certification of Chief Financial Officer, Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of eHealth, Inc. on Form 10-Q (the “Form 10-Q”) for the quarter ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Derek N. Yung, Chief Financial Officer of eHealth, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:


(1)	The Form 10-Q, to which this certification is attached as Exhibit 32.2, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of eHealth, Inc.

/s/ DEREK N. YUNG

Derek N. Yung

Chief Financial Officer

May 6, 2019

EX-101.INS 6 ehth-20190331.xml XBRL INSTANCE DOCUMENT 0001333493 2019-01-01 2019-03-31 0001333493 2019-04-30 0001333493 2019-03-31 0001333493 2018-12-31 0001333493 2018-01-01 2018-03-31 0001333493 ehth:CommissionMember 2019-01-01 2019-03-31 0001333493 ehth:CommissionMember 2018-01-01 2018-03-31 0001333493 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-03-31 0001333493 us-gaap:ProductAndServiceOtherMember 2018-01-01 2018-03-31 0001333493 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001333493 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001333493 us-gaap:RetainedEarningsMember 2019-03-31 0001333493 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001333493 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001333493 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001333493 us-gaap:CommonStockMember 2019-03-31 0001333493 us-gaap:TreasuryStockMember 2018-12-31 0001333493 us-gaap:TreasuryStockMember 2019-03-31 0001333493 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001333493 us-gaap:RetainedEarningsMember 2018-12-31 0001333493 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001333493 us-gaap:CommonStockMember 2018-12-31 0001333493 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001333493 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001333493 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001333493 2018-03-31 0001333493 us-gaap:CommonStockMember 2017-12-31 0001333493 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001333493 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0001333493 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001333493 2017-12-31 0001333493 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001333493 us-gaap:CommonStockMember 2018-03-31 0001333493 us-gaap:TreasuryStockMember 2017-12-31 0001333493 us-gaap:RetainedEarningsMember 2017-12-31 0001333493 us-gaap:RetainedEarningsMember 2018-03-31 0001333493 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001333493 us-gaap:TreasuryStockMember 2018-03-31 0001333493 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001333493 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001333493 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001333493 ehth:OtherMember ehth:AncillariesMember 2018-01-01 2018-03-31 0001333493 ehth:SmallBusinessMember 2019-01-01 2019-03-31 0001333493 ehth:SmallBusinessMember 2018-01-01 2018-03-31 0001333493 ehth:CommissionBonusMember 2019-01-01 2019-03-31 0001333493 ehth:MedicareAdvantageMember ehth:MedicareMember 2019-01-01 2019-03-31 0001333493 ehth:CommissionBonusMember 2018-01-01 2018-03-31 0001333493 ehth:DentalMember ehth:AncillariesMember 2018-01-01 2018-03-31 0001333493 ehth:ShorttermMember ehth:AncillariesMember 2018-01-01 2018-03-31 0001333493 ehth:MedicareMember 2018-01-01 2018-03-31 0001333493 ehth:VisionMember ehth:AncillariesMember 2018-01-01 2018-03-31 0001333493 ehth:AncillariesMember 2019-01-01 2019-03-31 0001333493 ehth:MedicarePartDMember ehth:MedicareMember 2018-01-01 2018-03-31 0001333493 ehth:MedicareSupplementMember ehth:MedicareMember 2019-01-01 2019-03-31 0001333493 ehth:QualifiedHealthPlansMember ehth:IndividualandFamilyMember 2019-01-01 2019-03-31 0001333493 ehth:AncillariesMember 2018-01-01 2018-03-31 0001333493 ehth:MedicareSupplementMember ehth:MedicareMember 2018-01-01 2018-03-31 0001333493 ehth:IndividualandFamilyMember 2018-01-01 2018-03-31 0001333493 ehth:NonQualifiedHealthPlansMember ehth:IndividualandFamilyMember 2018-01-01 2018-03-31 0001333493 ehth:VisionMember ehth:AncillariesMember 2019-01-01 2019-03-31 0001333493 ehth:MedicareMember 2019-01-01 2019-03-31 0001333493 ehth:MedicareAdvantageMember ehth:MedicareMember 2018-01-01 2018-03-31 0001333493 ehth:OtherMember ehth:AncillariesMember 2019-01-01 2019-03-31 0001333493 ehth:DentalMember ehth:AncillariesMember 2019-01-01 2019-03-31 0001333493 ehth:IndividualandFamilyMember 2019-01-01 2019-03-31 0001333493 ehth:NonQualifiedHealthPlansMember ehth:IndividualandFamilyMember 2019-01-01 2019-03-31 0001333493 ehth:MedicarePartDMember ehth:MedicareMember 2019-01-01 2019-03-31 0001333493 ehth:QualifiedHealthPlansMember ehth:IndividualandFamilyMember 2018-01-01 2018-03-31 0001333493 ehth:ShorttermMember ehth:AncillariesMember 2019-01-01 2019-03-31 0001333493 ehth:MedicareAdvantageMember ehth:MedicareMember 2019-03-31 0001333493 ehth:QualifiedHealthPlansMember ehth:IndividualandFamilyMember 2018-03-31 0001333493 ehth:NonQualifiedHealthPlansMember ehth:IndividualandFamilyMember 2019-03-31 0001333493 ehth:NonQualifiedHealthPlansMember ehth:IndividualandFamilyMember 2018-03-31 0001333493 ehth:QualifiedHealthPlansMember ehth:IndividualandFamilyMember 2019-03-31 0001333493 ehth:AncillariesMember 2018-03-31 0001333493 ehth:SmallBusinessMember 2019-03-31 0001333493 ehth:AncillariesMember 2019-03-31 0001333493 ehth:MedicarePartDMember ehth:MedicareMember 2019-03-31 0001333493 ehth:MedicareSupplementMember ehth:MedicareMember 2018-03-31 0001333493 ehth:MedicareSupplementMember ehth:MedicareMember 2019-03-31 0001333493 ehth:MedicarePartDMember ehth:MedicareMember 2018-03-31 0001333493 ehth:SmallBusinessMember 2018-03-31 0001333493 ehth:MedicareAdvantageMember ehth:MedicareMember 2018-03-31 0001333493 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001333493 ehth:GoMedigapMember us-gaap:TrademarksAndTradeNamesMember 2018-01-22 0001333493 ehth:GoMedigapMember 2018-01-22 0001333493 ehth:GoMedigapMember us-gaap:TechnologyBasedIntangibleAssetsMember 2018-01-22 0001333493 ehth:GoMedigapMember 2018-01-22 2018-01-22 0001333493 ehth:GoMedigapMember 2019-01-01 2019-03-31 0001333493 srt:MaximumMember ehth:GoMedigapMember us-gaap:TrademarksAndTradeNamesMember 2019-01-01 2019-03-31 0001333493 2018-01-22 0001333493 srt:MinimumMember ehth:GoMedigapMember us-gaap:TrademarksAndTradeNamesMember 2019-01-01 2019-03-31 0001333493 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-12-31 0001333493 us-gaap:TrademarksAndTradeNamesMember 2019-01-01 2019-03-31 0001333493 us-gaap:CustomerRelationshipsMember 2018-12-31 0001333493 us-gaap:TrademarksAndTradeNamesMember 2018-12-31 0001333493 us-gaap:TrademarksAndTradeNamesMember 2019-03-31 0001333493 us-gaap:CustomerRelationshipsMember 2019-03-31 0001333493 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-03-31 0001333493 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-03-31 0001333493 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-03-31 0001333493 ehth:AetnaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31 0001333493 ehth:AetnaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001333493 ehth:UnitedhealthcareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31 0001333493 ehth:UnitedhealthcareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001333493 ehth:HumanaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31 0001333493 ehth:HumanaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001333493 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001333493 ehth:ContingentConsiderationCurrentMember 2019-03-31 0001333493 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0001333493 us-gaap:FairValueInputsLevel3Member ehth:ContingentConsiderationCurrentMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0001333493 us-gaap:MoneyMarketFundsMember 2018-12-31 0001333493 us-gaap:FairValueInputsLevel3Member ehth:ContingentConsiderationCurrentMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001333493 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001333493 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001333493 ehth:ContingentConsiderationNonCurrentMember 2019-03-31 0001333493 ehth:ContingentConsiderationCurrentMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0001333493 us-gaap:FairValueInputsLevel1Member ehth:ContingentConsiderationNonCurrentMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0001333493 us-gaap:MoneyMarketFundsMember 2019-03-31 0001333493 us-gaap:FairValueInputsLevel3Member ehth:ContingentConsiderationNonCurrentMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0001333493 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0001333493 us-gaap:FairValueInputsLevel1Member ehth:ContingentConsiderationCurrentMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0001333493 us-gaap:FairValueInputsLevel1Member ehth:ContingentConsiderationCurrentMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001333493 ehth:ContingentConsiderationCurrentMember 2018-12-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001333493 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0001333493 ehth:ContingentConsiderationNonCurrentMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0001333493 ehth:ContingentConsiderationNonCurrentMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0001333493 ehth:ContingentConsiderationCurrentMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001333493 ehth:ContingentConsiderationNonCurrentMember 2018-12-31 0001333493 us-gaap:FairValueInputsLevel1Member ehth:ContingentConsiderationNonCurrentMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001333493 us-gaap:FairValueInputsLevel3Member ehth:ContingentConsiderationNonCurrentMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001333493 ehth:ContingentConsiderationMember 2019-01-01 2019-03-31 0001333493 ehth:ContingentConsiderationMember 2019-03-31 0001333493 ehth:ContingentConsiderationMember 2018-12-31 0001333493 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001333493 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0001333493 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001333493 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001333493 2014-04-01 2019-03-31 0001333493 ehth:CustomerCareAndEnrollmentExpenseMember 2018-01-01 2018-03-31 0001333493 ehth:TechnologyAndContentExpenseMember 2018-01-01 2018-03-31 0001333493 ehth:TechnologyAndContentExpenseMember 2019-01-01 2019-03-31 0001333493 us-gaap:RestructuringChargesMember 2019-01-01 2019-03-31 0001333493 us-gaap:RestructuringChargesMember 2018-01-01 2018-03-31 0001333493 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-03-31 0001333493 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0001333493 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-03-31 0001333493 ehth:CustomerCareAndEnrollmentExpenseMember 2019-01-01 2019-03-31 0001333493 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001333493 us-gaap:EmployeeStockOptionMember 2019-03-31 0001333493 us-gaap:EmployeeStockOptionMember 2018-12-31 0001333493 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001333493 ehth:A2014EquityIncentivePlanMember 2019-01-01 2019-03-31 0001333493 ehth:A2014EquityIncentivePlanMember 2018-12-31 0001333493 ehth:A2014EquityIncentivePlanMember 2019-03-31 0001333493 us-gaap:RestrictedStockUnitsRSUMember 2019-03-31 0001333493 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001333493 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001333493 us-gaap:RestrictedStockMember 2018-01-01 2018-03-31 0001333493 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0001333493 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001333493 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001333493 ehth:ServiceAndLicensingObligationsMember 2019-01-01 2019-03-31 0001333493 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001333493 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0001333493 us-gaap:OperatingSegmentsMember ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2018-01-01 2018-03-31 0001333493 us-gaap:OperatingSegmentsMember 2018-01-01 2018-03-31 0001333493 us-gaap:OperatingSegmentsMember ehth:MedicareSegmentMember 2019-01-01 2019-03-31 0001333493 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-03-31 0001333493 us-gaap:OperatingSegmentsMember ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2019-01-01 2019-03-31 0001333493 us-gaap:OperatingSegmentsMember ehth:MedicareSegmentMember 2018-01-01 2018-03-31 0001333493 country:US 2018-12-31 0001333493 country:US 2019-03-31 0001333493 country:CN 2018-12-31 0001333493 country:CN 2019-03-31 0001333493 ehth:UnitedhealthcareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31 0001333493 ehth:AetnaMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31 0001333493 ehth:HumanaMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31 0001333493 ehth:HumanaMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001333493 ehth:AetnaMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001333493 ehth:UnitedhealthcareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001333493 us-gaap:OneTimeTerminationBenefitsMember 2018-01-01 2018-12-31 0001333493 2018-01-01 2018-12-31 0001333493 2018-02-01 2018-02-28 0001333493 us-gaap:SpecialTerminationBenefitsMember 2018-01-01 2018-12-31 0001333493 ehth:AustinTexasMember 2019-03-31 0001333493 ehth:MountainViewCaliforniaMember us-gaap:StandbyLettersOfCreditMember ehth:A6MillionStandbyLetterofCreditMember 2012-01-01 2012-03-31 0001333493 ehth:MountainViewCaliforniaMember 2012-03-31 0001333493 ehth:SantaClaraCaliforniaMember us-gaap:StandbyLettersOfCreditMember 2018-04-25 0001333493 ehth:SantaClaraCaliforniaMember us-gaap:StandbyLettersOfCreditMember ehth:A1.5MillionStandbyLetterofCreditMember 2018-04-25 2018-04-25 0001333493 ehth:SantaClaraCaliforniaMember 2018-04-25 0001333493 ehth:MountainViewCaliforniaMember 2019-03-31 0001333493 ehth:AustinTexasMember 2018-03-31 0001333493 ehth:SaltLakeCityUtahMember 2019-03-31 0001333493 srt:MinimumMember 2019-01-01 2019-03-31 0001333493 ehth:SaltLakeCityUtahMember 2019-03-26 0001333493 ehth:SaltLakeCityUtahMember 2019-03-25 0001333493 ehth:AustinTexasMember us-gaap:StandbyLettersOfCreditMember 2018-03-31 0001333493 ehth:SantaClaraCaliforniaMember 2019-03-31 0001333493 ehth:MountainViewCaliforniaMember us-gaap:StandbyLettersOfCreditMember 2012-03-31 0001333493 us-gaap:AccountingStandardsUpdate201602Member 2019-03-31 0001333493 srt:MaximumMember 2019-01-01 2019-03-31 0001333493 us-gaap:RevolvingCreditFacilityMember 2018-09-17 0001333493 us-gaap:LetterOfCreditMember 2018-09-17 0001333493 ehth:EligibleCommissionsReceivablesPrecedingThreeMonthsMember us-gaap:RevolvingCreditFacilityMember 2019-01-01 2019-03-31 0001333493 ehth:EligibleCommissionsReceivablesSucceedingThreeMonthsMember us-gaap:RevolvingCreditFacilityMember 2019-01-01 2019-03-31 0001333493 us-gaap:RevolvingCreditFacilityMember 2018-09-17 2018-09-17 0001333493 us-gaap:RevolvingCreditFacilityMember 2019-03-31 0001333493 ehth:EligibleCommissionsReceivablesSucceedingSixMonthsMember us-gaap:RevolvingCreditFacilityMember 2019-01-01 2019-03-31 0001333493 2019-01-22 0001333493 2019-01-01 2019-01-31 0001333493 us-gaap:OverAllotmentOptionMember 2019-01-01 2019-01-31 ehth:employee xbrli:pure ehth:segment iso4217:USD xbrli:shares utreg:sqft ehth:state iso4217:USD xbrli:shares false --12-31 Q1 2019 2019-03-31 10-Q 0001333493 22649067 false Accelerated Filer eHealth, Inc. false EHTH 11013000 3866000 71816000 110230000 2550000 3229000 P15Y 294637 589275 132000 32937000 11103000 15358000 134190000 113834000 211668000 214377000 P3Y 13239000 19944000 0.15 0.20 0.07 0.05 0.05 0.10 0.00 0.15 0.20 0.07 0.05 0.05 0.10 0.00 -1891000 -7147000 22409000 17648000 1053000 0 P11Y P1Y 0.8 0.5 0.8 6000000 0.0175 1937000 2778000 0.20 0.25 0.08 0.10 -7854000 6668000 3488000 3180000 -8296000 16850000 6024000 10826000 8341000 9017000 785615

5688000

4360000

349459000

349500000

331592000

331600000

3601000

3381000

127000

156000

P10Y

P3Y

P1Y1M6D

P1Y9M18D

P8Y8M12D

298024000

445652000

286000

1280000

2801000

3229000

2801000

498000

2303000

165000

343000

1672000

251000

370000

3229000

602000

2627000

273000

549000

1778000

629000

58000

451000

547000

2432000

1006000

1426000

2386000

960000

1426000

18272

26878

32492

28915

41813

439278000

571237000

156168000

259173000

323000

107974000

100000

58000

48295000

5595000

17300000

27700000

13306000

13300000

20000000

20730000

26500000

19270000

71000

100000

11000

4371000

110000

130000

6800000

2000000

4800000

174000

48295000

477000

719000

12766000

27501000

13089000

135475000

40293000

34742000

13089000

135475000

-5551000

122386000

323000

107974000

31000

34000

-4780000

-5130000

0.19

0.10

0.19

0.15

0.19

0.21

0.20

0.17

0.18

0.23

0.20

0.17

7881000

229000

444000

434000

2462000

946000

3366000

152000

-77000

49790000

77956000

1000000

1200000

-1736000

-3543000

47901000

44358000

294000

619000

655000

-0.26

-0.24

50000

62000

0.259

0.402

20763000

11373000

-286000

-1280000

13300000

26800000

40000000

26500000

26000

25000

10065000

8234000

611000

1220000

10612000

8471000

778000

1363000

1960000

1638000

712000

499000

427000

480000

536000

56000

480000

1494000

317000

667000

510000

17200000

9500000

2000000

5700000

17200000

9500000

2000000

5700000

7135000

1266000

1389000

4480000

6588000

1029000

1222000

4337000

10691000

11278000

40233000

26137000

-6536000

-8626000

-1691000

-1700000

-3467000

-3500000

1108000

-567000

-768000

-807000

-221000

-236000

-383000

-289000

2897000

-6912000

-9390000

1793000

-1111000

5114000

12249000

11702000

35137000

4400000

3300000

7200000

17100000

13765000

3972000

4189000

4068000

5502000

3641000

7557000

P90M

P123M

P84M

600000

1500000

439278000

571237000

60619000

55057000

40000000

20730000

19270000

40000000

20730000

19270000

40000000

26500000

5000000

40000000

0.005

5000000

15002000

23941000

-203000

112571000

-16135000

-2996000

10737000

12749000

-4845000

-5159000

15992000

378000

15614000

17039000

342000

16697000

-6720000

-9183000

1300000

27580000

3500000

28100000

24600000

3430000

24150000

900000

25730000

23300000

0.061

P7Y6M

1402000

1450000

11276000

12059000

65000

29000

2425000

5528000

3339000

2022000

-389000

1194000

184000

557000

9542000

9500000

15000000

14929000

217000

1509000

989000

1487000

62000

610000

5288000

6483000

161000

213000

324000

126051000

109000

2367000

7684000

7963000

5000000

110

1856000

1900000

1600000

300000

204965000

199806000

43070000

1219000

2771000

1250000

340000

1441000

2162000

21935000

1159000

5592000

43070000

12307000

30763000

5580000

479000

40707000

3603000

28686000

2359000

2363000

68773000

790000

951000

1316000

462000

2629000

3508000

39843000

2336000

8597000

68773000

13872000

54901000

3519000

1155000

64227000

6137000

50776000

2640000

4546000

Payment is typically received within 60 days of approval.

126100000

2760000

360000

48.50

2801000

3229000

300000

37000

16.78

0.00

1869000

1768000

16.95

17.03

P4Y9M18D

P5Y3M19D

64000

13.56

512000

557000

439000

14.46

11000

33.30

20226000

39521000

1005000

886000

18.34

17.72

37912000

845000

17.50

21.88

0.00

18.99

21006000

P4Y4M24D

8000

P5Y

29880000

-11238000

30235000

-11254000

30863000

-11426000

34090000

-11450000

16000

24000

295000

2760000

60000

108000

172000

5595000

17261000

126054000

126051000

3000

109000

2367000

286664000

201000

281706000

30000

204725000

-199998000

290103000

266000

289925000

30000

199880000

-199998000

303149000

127000

298024000

31000

204965000

-199998000

445650000

156000

445652000

34000

199806000

-199998000

11426292

11449503

10663888

199998000

18873000

21831000

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets acquired and liabilities assumed measured and reported at fair value are classified in one of the following categories based on inputs:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:91%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unadjusted quoted prices in active markets for identical assets or liabilities.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unobservable inputs for the asset or liability.</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental information related to leases was as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,580</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term of operating leases (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average discount rate of operating leases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accounts receivable as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> was comprised of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commissions receivable—current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,834</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,190</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commissions receivable—non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,377</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accounts receivable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331,592</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,459</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-lived assets by geographical area as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):  </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,614</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">China</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,992</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense by operating function for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands): </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended <br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketing and advertising</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer care and enrollment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology and content</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense recorded during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands): </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended <br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,627</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,303</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity under our 2014 Equity Incentive Plan (the “2014 Plan”) for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Available for Grant </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for grant December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units granted </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units cancelled </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options cancelled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for grant March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:101px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Includes grants of restricted stock units with service, performance-based or market-based vesting criteria.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Includes grants of stock options with service, performance-based or market-based vesting criteria.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Includes cancelled restricted stock units with service, performance-based or market-based vesting criteria.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Seasonality—</font><font style="font-family:inherit;font-size:10pt;">A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The majority of our individual and family health insurance plans are sold in the fourth quarter during the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font><font style="font-family:inherit;font-size:10pt;">—The accompanying condensed consolidated balance sheets as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and the condensed consolidated statements of comprehensive loss for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the condensed consolidated statements of stockholders' equity, and the condensed consolidated statements of cash flows for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, are unaudited. The condensed consolidated balance sheet data as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, which was filed with the Securities and Exchange Commission on March 14, 2019. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with such rules and regulations. However, the Company believes the disclosures made are adequate to make the information not misleading. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and include all adjustments necessary for the fair presentation of our financial position as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, our results of operations for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and our cash flows for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. The results for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for any subsequent period or for the fiscal year ending December 31, 2019 and therefore should not be relied upon as an indicator of future results.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The following table presents a summary of our future minimum payments under non-cancellable contractual service and licensing obligations as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> (in thousands): </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">For the Years Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Service and Licensing Obligations</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,462</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">434</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The table below depicts the disaggregation of revenue by product for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and is consistent with how we evaluate our financial performance (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Advantage</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,935</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Supplement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,592</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Part D</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,686</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Individual and Family </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-Qualified Health Plans </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,629</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,441</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Qualified Health Plans</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,508</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,162</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Individual and Family</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,137</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,603</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ancillaries</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dental</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">951</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,771</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Ancillaries</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,519</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,580</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Small Business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission Bonus</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Commission Revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,227</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,707</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,363</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,773</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,070</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:96%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:10px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">We define our Individual and Family Plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both Qualified and Non-Qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase Non-Qualified health plans cannot receive a subsidy in connection with the purchase of Non-Qualified plans.</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the constraints applied to the total estimated lifetime commissions we expect to receive for selling the plan after the carrier approves an application in order to derive the constrained lifetime value of commissions per approved member are as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.98245614035088%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Advantage</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Supplement</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Part D</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Individual and Family</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-Qualified Health Plans </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Qualified Health Plans</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ancillaries</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Small Business</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We classify the inputs used to measure fair value into the following hierarchy:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:81%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unadjusted quoted prices in active markets for identical assets or liabilities.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unobservable inputs for the asset or liability.</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table is a summary of financial assets measured at fair value on a recurring basis and their classification within the fair value hierarchy (in thousands). </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.15204678362574%;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">323</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">323</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">323</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107,974</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107,974</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107,974</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">323</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">323</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">323</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Earnout liability</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">—</font><font style="font-family:inherit;font-size:9pt;">current </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Earnout liability</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">—</font><font style="font-family:inherit;font-size:9pt;">non-current </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,270</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of operating lease liabilities are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,502</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,189</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,765</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Total lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less imputed interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,557</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,580</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition—</font><font style="font-family:inherit;font-size:10pt;">We are compensated by the receipt of commission payments from health insurance carriers whose health insurance policies are purchased through our ecommerce platforms or our customer care centers. We may also receive commission bonuses based on our attaining predetermined target sales levels for Medicare, individual and family, small business and ancillary health insurance products, or other objectives, as determined by the health insurance carrier, which we recognize as commission revenue when we achieve the predetermined target sales levels or other objectives. In addition, we also generate revenue from non-commission revenue sources, which include online sponsorship and advertising, technology licensing and lead referrals. </font><font style="font-family:inherit;font-size:10pt;">Payment is typically received within 60 days of approval.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for revenue under ASC 606</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">—</font><font style="font-family:inherit;font-size:10pt;">Revenue from Contracts with Customers. The core principle of ASC 606 is to recognize revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services. Accordingly, we recognize revenue for our services in accordance with the following five steps outlined in ASC 606:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Identification of the contract, or contracts, with a customer. </font><font style="font-family:inherit;font-size:10pt;"> A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Identification of the performance obligations in the contract. </font><font style="font-family:inherit;font-size:10pt;">Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Determination of the transaction price.</font><font style="font-family:inherit;font-size:10pt;"> The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Allocation of the transaction price to the performance obligations in the contract. </font><font style="font-family:inherit;font-size:10pt;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price ("SSP") basis.    </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recognition of revenue when, or as, we satisfy a performance obligation.</font><font style="font-family:inherit;font-size:10pt;"> We satisfy performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Commission Revenue—</font><font style="font-family:inherit;font-size:10pt;">Our commission revenue is primarily comprised of commissions paid to us by health insurance carriers related to insurance plans that have been purchased by a member through our health insurance exchange service. We define a member as an individual currently covered by an insurance plan, which include Medicare-related, individual and family, small business and ancillary plans. We are compensated by the health insurance carrier, which we define as our customer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We typically enter into contractual agency relationships with health insurance carriers that are non-exclusive and terminable on short notice by either party for any reason. In addition, health insurance carriers often have the ability to terminate or amend our agreements unilaterally on short notice, including provisions in our agreements relating to the commission rates paid to us by the health insurance carriers. The amendment or termination of an agreement we have with a health insurance carrier may adversely impact the commissions we are paid on health insurance plans purchased from the carrier by means of our health insurance exchange services.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For both Medicare Advantage and Medicare Part D prescription drug plans, we receive a fixed, annual commission payment from insurance carriers once the plan is approved by the carrier and either a fixed, monthly or annual commission payment beginning with and subsequent to the second plan year. In the first plan year of a Medicare Advantage and Medicare Part D prescription drug plan, after the health insurance carrier approves the application but during the effective year of the plan, we are paid a fixed commission that is prorated for the number of months remaining in the calendar year. Additionally, if the plan is the first Medicare Advantage or Medicare Part D plan issued to the member, we may receive a higher commission rate that covers a full twelve-month period, regardless of the month the plan was effective. We earn commission revenue for Medicare Advantage and Medicare Part D prescription drug plans for which we are the broker of record, typically until either the policy is cancelled or we otherwise do not remain the agent on the policy. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For individual and family, Medicare Supplement, small business and ancillary plans, our commissions generally represent a flat amount per member per month or a percentage of the premium amount collected by the carrier during the period that a member maintains coverage under a plan. Premium-based commissions are reported to us after the premiums are collected by the carrier, generally on a monthly basis. We generally continue to receive the commission payment from the relevant insurance carrier until the health insurance plan is cancelled or we otherwise do not remain the agent on the policy.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We utilize a practical expedient to estimate commission revenue for each insurance product by applying the use of a portfolio approach to group approved members by the effective month of the relevant policy (referred to as a “cohort”). This allows us to estimate the commissions we expect to collect for each approved member cohort by evaluating various factors, including but not limited to, contracted commission rates, carrier mix and expected member churn.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For Medicare-related, individual and family and ancillary health insurance plans, our services are complete once a submitted application is approved by the relevant health insurance carrier. Accordingly, we recognize commission revenue based upon the total estimated lifetime commissions we expect to receive for selling the plan after the carrier approves an application, net of an estimated constraint. We refer to these estimated and constrained lifetime values as the "constrained LTV" for the plan. We provide annual services in selling and renewing small business health insurance plans; therefore, we recognize small business health insurance plan commission revenue at the time the plan is approved by the carrier, and when it renews each year thereafter, equal to the estimated commissions we expect to collect from the plan over the following 12 months. Our estimate of commission revenue for each product line is based on a number of assumptions, which include, but are not limited to, estimating conversion of an approved member to a paying member, forecasting member churn and forecasting the commission amounts likely to be received per member. These assumptions are based on historical trends and incorporate management’s judgment in interpreting those trends and in applying constraints discussed below. To the extent we make changes to the assumptions, we will recognize any material impact of the changes to commission revenue in the reporting period in which the change is made, including revisions of estimated lifetime commissions either below or in excess of previously estimated constrained LTV recognized as revenue.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For Medicare-related, individual and family and ancillary health insurance plans, we apply constraints to determine the amount of commission revenue to recognize per approved member. The constraints are applied to help ensure that the total estimated lifetime commissions expected to be collected for an approved member’s plan are recognized as revenue only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with future commissions receivable from the plan is subsequently resolved. We evaluate the appropriateness of these constraints on at least an annual basis, including assessing factors affecting our estimate of the estimated lifetime value of commissions per approved member based on current trends impacting our business and assessing whether any adjustment to those constraints should be made. We update the assumptions when we observe a sufficient level of evidence that would suggest that the long term expectation of the assumption has changed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the constraints applied to the total estimated lifetime commissions we expect to receive for selling the plan after the carrier approves an application in order to derive the constrained lifetime value of commissions per approved member are as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.98245614035088%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Advantage</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Supplement</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Part D</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Individual and Family</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-Qualified Health Plans </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Qualified Health Plans</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ancillaries</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Small Business</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Revenue—</font><font style="font-family:inherit;font-size:10pt;">Our sponsorship and advertising program allows carriers to purchase advertising space in specific markets in a sponsorship area on our website. In return, we are typically paid a monthly fee, which is recognized over the period that advertising is displayed, and often a performance fee based on metrics such as submitted health insurance applications, which is recognized based on attainment of metrics. We also offer Medicare advertising services, which include website development, hosting and maintenance. In these instances, we are typically paid a fixed, up-front fee, which we recognize as revenue ratably over the service period.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial technology licensing business allows carriers the use of our ecommerce platform to offer their own health insurance policies on their websites and agents to utilize our technology to power their online quoting, content and application submission processes. Typically, we are paid a one-time implementation fee, which we recognize ratably on a straight-line basis over the estimated term of the customer relationship (generally the initial term of the agreement), commencing once the technology is available for use by the third party, and a performance fee based on metrics such as submitted health insurance applications. The metrics used to calculate performance fees for both sponsorship and advertising and technology licensing are based on performance criteria that are either measured based on data tracked by us, or based on data tracked by the third party. In instances where the performance criteria data is tracked by us, we recognize revenue in the period of performance and when all other revenue recognition criteria have been met. In instances where the performance criteria data is tracked by the third party, we recognize revenue at amounts in which reversal of such amounts is not likely to occur. Typically, this occurs through our receipt of a cash payment from the third party along with a detailed statement containing the data that is tracked by the third party.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Revenue—</font><font style="font-family:inherit;font-size:10pt;">Deferred revenue includes deferred technology licensing implementation fees and amounts billed for or collected from sponsorship or technology licensing customers in advance of our performing our service for such customers. It also includes the amount by which both unbilled and billed services provided under our technology licensing arrangements exceed the straight-line revenue recognized to date.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Incremental Costs to Obtain a Contract</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font><font style="font-family:inherit;font-size:10pt;">We reviewed our sales compensation plans, which are directed at converting leads into approved members, and concluded that they are fulfillment costs and not costs to obtain a contract with a customer. Additionally, we reviewed compensation plans related to personnel responsible for identifying new health insurance carriers and entering into contracts with new health insurance carriers and concluded that no incremental costs are incurred to obtain such contracts.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following are the details of the acquisition consideration allocated to the intangible assets acquired (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names, trademarks and website addresses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangible assets </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,800</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of the following (in thousands): </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended <br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,426</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,426</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,386</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,432</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The major classes of assets and liabilities to which we have preliminarily allocated the acquisition consideration were as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition Consideration</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of equity awards issued to GoMedigap members </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated fair value of earnout liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,295</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Allocation</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission receivable</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">—</font><font style="font-family:inherit;font-size:10pt;">current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission receivable</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">—</font><font style="font-family:inherit;font-size:10pt;">non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(130</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net tangible assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,358</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangible assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,937</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,295</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;">(1) The fair value of equity awards issued was determined based on the January 22, 2018 closing price of our common stock of </font><font style="font-family:inherit;font-size:9pt;">$18.99</font><font style="font-family:inherit;font-size:9pt;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, our cash and cash equivalent balances were invested as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,089</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our benefit from income taxes and our effective tax rates for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands, except effective tax rate):</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before benefit from income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,536</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Benefit from income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,691</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The carrying amounts, accumulated amortization, net carrying value and weighted average remaining life of our definite-lived amortizable intangible assets, as well as our indefinite-lived intangible trademarks, are presented in the tables below for (dollars in thousands, weighted-average remaining life in years):</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Remaining Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Pharmacy and customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,471</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,029</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,234</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Trade names, trademarks and website addresses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,337</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,220</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,480</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total intangible assets subject to amortization</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,612</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,588</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,065</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,135</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indefinite-lived trademarks and domain names</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indefinite</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total intangible assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Carriers representing 10% or more of our total revenue for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> are presented in the table below: </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended <br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Humana</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UnitedHealthcare </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aetna</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">UnitedHealthcare also includes other carriers owned by UnitedHealthcare. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Aetna also includes other carriers owned by Aetna</font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents summary results of our operating segments for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31,</font><font style="font-family:inherit;font-size:10pt;"> 2019 and 2018 (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended <br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenue</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Medicare</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">54,901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,763</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Individual, Family and Small Business</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,872</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,307</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">68,773</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,070</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Segment profit</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Medicare segment profit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Individual, Family and Small Business segment profit</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,024</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total segment profit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,296</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,854</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,229</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(655</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(619</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquisition costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of earnout liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,306</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(547</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(451</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other income, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss before benefit from income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,626</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,536</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes restricted stock unit activity (in thousands, except weighted-average grant date fair value and weighted-average remaining contractual life data): </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Restricted Stock Units</font><font style="font-family:inherit;font-size:9pt;"> </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Grant Date Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Remaining Service Period (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</font><font style="font-family:inherit;font-size:9pt;"> </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested as of December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,869</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.95</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,816</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.56</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.78</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested as of March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.03</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,230</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Includes certain restricted stock units with service, performance-based or market-based vesting criteria. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The aggregate intrinsic value is calculated as the product of our closing stock price as of </font><font style="font-family:inherit;font-size:9pt;">March 31, 2019</font><font style="font-family:inherit;font-size:9pt;"> and </font><font style="font-family:inherit;font-size:9pt;">December 31, 2018</font><font style="font-family:inherit;font-size:9pt;">, and the number of restricted stock units outstanding as of </font><font style="font-family:inherit;font-size:9pt;">March 31, 2019</font><font style="font-family:inherit;font-size:9pt;"> and </font><font style="font-family:inherit;font-size:9pt;">December 31, 2018</font><font style="font-family:inherit;font-size:9pt;">, respectively.   </font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity (in thousands, except weighted-average exercise price and weighted-average remaining contractual life data): </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Stock Options</font><font style="font-family:inherit;font-size:9pt;"> </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</font><font style="font-family:inherit;font-size:9pt;"> </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance outstanding at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">886</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,912</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">439</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Includes certain stock options with service, performance-based or market-based vesting criteria. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The aggregate intrinsic value is calculated as the difference between the closing price of our common stock as of </font><font style="font-family:inherit;font-size:9pt;">March 31, 2019</font><font style="font-family:inherit;font-size:9pt;"> and </font><font style="font-family:inherit;font-size:8pt;">December 31, 2018</font><font style="font-family:inherit;font-size:9pt;"> and the exercise price multiplied by number of in-the-money options. </font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, expected amortization expense in future periods is as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Years Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Pharmacy and Customer Relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trade Names, Trademarks and Website Addresses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">510</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,960</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,960</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,337</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Carriers that represented 10% or more of our total accounts receivable balance of </font><font style="font-family:inherit;font-size:10pt;">$331.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$349.5 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, were as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UnitedHealthcare </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Humana</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aetna</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholder's Equity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2014 Equity Incentive Plan—</font><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity under our 2014 Equity Incentive Plan (the “2014 Plan”) for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Available for Grant </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for grant December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units granted </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units cancelled </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options cancelled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for grant March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:101px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Includes grants of restricted stock units with service, performance-based or market-based vesting criteria.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Includes grants of stock options with service, performance-based or market-based vesting criteria.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Includes cancelled restricted stock units with service, performance-based or market-based vesting criteria.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity (in thousands, except weighted-average exercise price and weighted-average remaining contractual life data): </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Stock Options</font><font style="font-family:inherit;font-size:9pt;"> </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</font><font style="font-family:inherit;font-size:9pt;"> </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance outstanding at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">886</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,912</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">439</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Includes certain stock options with service, performance-based or market-based vesting criteria. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The aggregate intrinsic value is calculated as the difference between the closing price of our common stock as of </font><font style="font-family:inherit;font-size:9pt;">March 31, 2019</font><font style="font-family:inherit;font-size:9pt;"> and </font><font style="font-family:inherit;font-size:8pt;">December 31, 2018</font><font style="font-family:inherit;font-size:9pt;"> and the exercise price multiplied by number of in-the-money options. </font></div></td></tr></table><div style="line-height:120%;text-indent:77px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes restricted stock unit activity (in thousands, except weighted-average grant date fair value and weighted-average remaining contractual life data): </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Restricted Stock Units</font><font style="font-family:inherit;font-size:9pt;"> </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Grant Date Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Remaining Service Period (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</font><font style="font-family:inherit;font-size:9pt;"> </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested as of December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,869</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.95</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,816</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.56</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.78</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested as of March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.03</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,230</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Includes certain restricted stock units with service, performance-based or market-based vesting criteria. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The aggregate intrinsic value is calculated as the product of our closing stock price as of </font><font style="font-family:inherit;font-size:9pt;">March 31, 2019</font><font style="font-family:inherit;font-size:9pt;"> and </font><font style="font-family:inherit;font-size:9pt;">December 31, 2018</font><font style="font-family:inherit;font-size:9pt;">, and the number of restricted stock units outstanding as of </font><font style="font-family:inherit;font-size:9pt;">March 31, 2019</font><font style="font-family:inherit;font-size:9pt;"> and </font><font style="font-family:inherit;font-size:9pt;">December 31, 2018</font><font style="font-family:inherit;font-size:9pt;">, respectively.   </font></div></td></tr></table><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Repurchase Programs—</font><font style="font-family:inherit;font-size:10pt;">We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> stock repurchase activity during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">. In addition to </font><font style="font-family:inherit;font-size:10pt;">10,663,888</font><font style="font-family:inherit;font-size:10pt;"> shares repurchased under our past repurchase programs as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we have in treasury </font><font style="font-family:inherit;font-size:10pt;">785,615</font><font style="font-family:inherit;font-size:10pt;"> shares that were previously surrendered by employees to satisfy tax withholdings due in connection with the vesting of certain restricted stock units. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had a total of </font><font style="font-family:inherit;font-size:10pt;">11,449,503</font><font style="font-family:inherit;font-size:10pt;"> shares and </font><font style="font-family:inherit;font-size:10pt;">11,426,292</font><font style="font-family:inherit;font-size:10pt;"> shares, respectively, held in treasury. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation Expense—</font><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense recorded during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands): </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended <br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,627</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,303</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense by operating function for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands): </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended <br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketing and advertising</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer care and enrollment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology and content</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2018, as part of our workforce reduction, we accelerated the vesting dates of certain stock options and restricted stock units granted to a former employee. We recorded a </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> incremental stock-based compensation expense in connection with this modification.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Business and Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Description of Business—</font><font style="font-family:inherit;font-size:10pt;">eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading private health insurance exchange for individuals, families and small businesses in the United States. Through our website addresses (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">www.eHealth.com</font><font style="font-family:inherit;font-size:10pt;">,  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">www.eHealthInsurance.com</font><font style="font-family:inherit;font-size:10pt;">,  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">www.eHealthMedicare.com, www.Medicare.com, www.PlanPrescriber.com and www.GoMedigap.com)</font><font style="font-family:inherit;font-size:10pt;">, consumers can get quotes from leading health insurance carriers, compare plans side-by-side, and apply for and purchase Medicare-related, individual and family, small business and ancillary health insurance plans. We actively market the availability of Medicare-related insurance plans and offer Medicare plan comparison tools and educational materials for Medicare-related insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans. Our ecommerce technology also enables us to deliver consumers’ health insurance applications electronically to health insurance carriers. We are licensed to market and sell health insurance in all </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;"> states and the District of Columbia. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font><font style="font-family:inherit;font-size:10pt;">—The accompanying condensed consolidated balance sheets as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and the condensed consolidated statements of comprehensive loss for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the condensed consolidated statements of stockholders' equity, and the condensed consolidated statements of cash flows for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, are unaudited. The condensed consolidated balance sheet data as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, which was filed with the Securities and Exchange Commission on March 14, 2019. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with such rules and regulations. However, the Company believes the disclosures made are adequate to make the information not misleading. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and include all adjustments necessary for the fair presentation of our financial position as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, our results of operations for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and our cash flows for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. The results for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for any subsequent period or for the fiscal year ending December 31, 2019 and therefore should not be relied upon as an indicator of future results.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation—</font><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of eHealth, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Segments—</font><font style="font-family:inherit;font-size:10pt;">We report segment information based on how our chief executive officer, who is our chief operating decision maker ("CODM"), regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. The performance measures of our segments include total revenue and profit. Our business structure is comprised of </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> operating segments:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:24px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">•</font><font style="font-family:inherit;font-size:10pt;">Medicare; and</font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:24px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">•</font><font style="font-family:inherit;font-size:10pt;">Individual, Family and Small Business</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Medicare segment consists primarily of commissions earned from our sale of Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans, and to a lesser extent, ancillary products sold to our Medicare-eligible customers, including but not limited to, dental and vision insurance, as well as our advertising program that allows Medicare-related carriers to purchase advertising on a separate website developed, hosted and maintained by us and our delivery and sale to third parties of Medicare-related health insurance leads generated by our ecommerce platforms and our marketing activities.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Individual, Family and Small Business segment consists primarily of commissions earned from our sale of individual and family and small business health insurance plans and ancillary products sold to our non-Medicare-eligible customers, including but not limited to, dental, vision, and short-term insurance. To a lesser extent, the Individual, Family and Small Business segment consists of amounts earned from our online sponsorship program that allows carriers to purchase advertising space in specific markets in a sponsorship area on our website, our licensing to third parties the use of our health insurance ecommerce technology and our delivery and sale to third parties of individual and family health insurance leads generated by our ecommerce platforms and our marketing activities.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect marketing and advertising, customer care and enrollment and technology and content operating expenses are allocated to each segment based on usage. Other indirect general and administrative operating expenses are managed in a corporate shared services environment and, since they are not the responsibility of segment operating management, are not allocated to the </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> operating segments and are presented as a reconciling item to our consolidated financial results.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment profit is calculated as total revenue for the applicable segment less direct and allocated marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses, excluding stock-based compensation, depreciation and amortization expense and amortization of intangible assets.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates—</font><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the useful lives of intangible assets, fair value of investments, recoverability of intangible assets, the commissions we expect to collect for each approved member cohort, valuation allowance for deferred income taxes, provision for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Seasonality—</font><font style="font-family:inherit;font-size:10pt;">A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The majority of our individual and family health insurance plans are sold in the fourth quarter during the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents—</font><font style="font-family:inherit;font-size:10pt;">We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition—</font><font style="font-family:inherit;font-size:10pt;">We are compensated by the receipt of commission payments from health insurance carriers whose health insurance policies are purchased through our ecommerce platforms or our customer care centers. We may also receive commission bonuses based on our attaining predetermined target sales levels for Medicare, individual and family, small business and ancillary health insurance products, or other objectives, as determined by the health insurance carrier, which we recognize as commission revenue when we achieve the predetermined target sales levels or other objectives. In addition, we also generate revenue from non-commission revenue sources, which include online sponsorship and advertising, technology licensing and lead referrals. </font><font style="font-family:inherit;font-size:10pt;">Payment is typically received within 60 days of approval.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for revenue under ASC 606</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">—</font><font style="font-family:inherit;font-size:10pt;">Revenue from Contracts with Customers. The core principle of ASC 606 is to recognize revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services. Accordingly, we recognize revenue for our services in accordance with the following five steps outlined in ASC 606:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Identification of the contract, or contracts, with a customer. </font><font style="font-family:inherit;font-size:10pt;"> A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Identification of the performance obligations in the contract. </font><font style="font-family:inherit;font-size:10pt;">Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Determination of the transaction price.</font><font style="font-family:inherit;font-size:10pt;"> The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Allocation of the transaction price to the performance obligations in the contract. </font><font style="font-family:inherit;font-size:10pt;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price ("SSP") basis.    </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recognition of revenue when, or as, we satisfy a performance obligation.</font><font style="font-family:inherit;font-size:10pt;"> We satisfy performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Commission Revenue—</font><font style="font-family:inherit;font-size:10pt;">Our commission revenue is primarily comprised of commissions paid to us by health insurance carriers related to insurance plans that have been purchased by a member through our health insurance exchange service. We define a member as an individual currently covered by an insurance plan, which include Medicare-related, individual and family, small business and ancillary plans. We are compensated by the health insurance carrier, which we define as our customer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We typically enter into contractual agency relationships with health insurance carriers that are non-exclusive and terminable on short notice by either party for any reason. In addition, health insurance carriers often have the ability to terminate or amend our agreements unilaterally on short notice, including provisions in our agreements relating to the commission rates paid to us by the health insurance carriers. The amendment or termination of an agreement we have with a health insurance carrier may adversely impact the commissions we are paid on health insurance plans purchased from the carrier by means of our health insurance exchange services.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For both Medicare Advantage and Medicare Part D prescription drug plans, we receive a fixed, annual commission payment from insurance carriers once the plan is approved by the carrier and either a fixed, monthly or annual commission payment beginning with and subsequent to the second plan year. In the first plan year of a Medicare Advantage and Medicare Part D prescription drug plan, after the health insurance carrier approves the application but during the effective year of the plan, we are paid a fixed commission that is prorated for the number of months remaining in the calendar year. Additionally, if the plan is the first Medicare Advantage or Medicare Part D plan issued to the member, we may receive a higher commission rate that covers a full twelve-month period, regardless of the month the plan was effective. We earn commission revenue for Medicare Advantage and Medicare Part D prescription drug plans for which we are the broker of record, typically until either the policy is cancelled or we otherwise do not remain the agent on the policy. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For individual and family, Medicare Supplement, small business and ancillary plans, our commissions generally represent a flat amount per member per month or a percentage of the premium amount collected by the carrier during the period that a member maintains coverage under a plan. Premium-based commissions are reported to us after the premiums are collected by the carrier, generally on a monthly basis. We generally continue to receive the commission payment from the relevant insurance carrier until the health insurance plan is cancelled or we otherwise do not remain the agent on the policy.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We utilize a practical expedient to estimate commission revenue for each insurance product by applying the use of a portfolio approach to group approved members by the effective month of the relevant policy (referred to as a “cohort”). This allows us to estimate the commissions we expect to collect for each approved member cohort by evaluating various factors, including but not limited to, contracted commission rates, carrier mix and expected member churn.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For Medicare-related, individual and family and ancillary health insurance plans, our services are complete once a submitted application is approved by the relevant health insurance carrier. Accordingly, we recognize commission revenue based upon the total estimated lifetime commissions we expect to receive for selling the plan after the carrier approves an application, net of an estimated constraint. We refer to these estimated and constrained lifetime values as the "constrained LTV" for the plan. We provide annual services in selling and renewing small business health insurance plans; therefore, we recognize small business health insurance plan commission revenue at the time the plan is approved by the carrier, and when it renews each year thereafter, equal to the estimated commissions we expect to collect from the plan over the following 12 months. Our estimate of commission revenue for each product line is based on a number of assumptions, which include, but are not limited to, estimating conversion of an approved member to a paying member, forecasting member churn and forecasting the commission amounts likely to be received per member. These assumptions are based on historical trends and incorporate management’s judgment in interpreting those trends and in applying constraints discussed below. To the extent we make changes to the assumptions, we will recognize any material impact of the changes to commission revenue in the reporting period in which the change is made, including revisions of estimated lifetime commissions either below or in excess of previously estimated constrained LTV recognized as revenue.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For Medicare-related, individual and family and ancillary health insurance plans, we apply constraints to determine the amount of commission revenue to recognize per approved member. The constraints are applied to help ensure that the total estimated lifetime commissions expected to be collected for an approved member’s plan are recognized as revenue only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with future commissions receivable from the plan is subsequently resolved. We evaluate the appropriateness of these constraints on at least an annual basis, including assessing factors affecting our estimate of the estimated lifetime value of commissions per approved member based on current trends impacting our business and assessing whether any adjustment to those constraints should be made. We update the assumptions when we observe a sufficient level of evidence that would suggest that the long term expectation of the assumption has changed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the constraints applied to the total estimated lifetime commissions we expect to receive for selling the plan after the carrier approves an application in order to derive the constrained lifetime value of commissions per approved member are as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.98245614035088%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Advantage</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Supplement</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Part D</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Individual and Family</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-Qualified Health Plans </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Qualified Health Plans</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ancillaries</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Small Business</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Revenue—</font><font style="font-family:inherit;font-size:10pt;">Our sponsorship and advertising program allows carriers to purchase advertising space in specific markets in a sponsorship area on our website. In return, we are typically paid a monthly fee, which is recognized over the period that advertising is displayed, and often a performance fee based on metrics such as submitted health insurance applications, which is recognized based on attainment of metrics. We also offer Medicare advertising services, which include website development, hosting and maintenance. In these instances, we are typically paid a fixed, up-front fee, which we recognize as revenue ratably over the service period.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial technology licensing business allows carriers the use of our ecommerce platform to offer their own health insurance policies on their websites and agents to utilize our technology to power their online quoting, content and application submission processes. Typically, we are paid a one-time implementation fee, which we recognize ratably on a straight-line basis over the estimated term of the customer relationship (generally the initial term of the agreement), commencing once the technology is available for use by the third party, and a performance fee based on metrics such as submitted health insurance applications. The metrics used to calculate performance fees for both sponsorship and advertising and technology licensing are based on performance criteria that are either measured based on data tracked by us, or based on data tracked by the third party. In instances where the performance criteria data is tracked by us, we recognize revenue in the period of performance and when all other revenue recognition criteria have been met. In instances where the performance criteria data is tracked by the third party, we recognize revenue at amounts in which reversal of such amounts is not likely to occur. Typically, this occurs through our receipt of a cash payment from the third party along with a detailed statement containing the data that is tracked by the third party.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Revenue—</font><font style="font-family:inherit;font-size:10pt;">Deferred revenue includes deferred technology licensing implementation fees and amounts billed for or collected from sponsorship or technology licensing customers in advance of our performing our service for such customers. It also includes the amount by which both unbilled and billed services provided under our technology licensing arrangements exceed the straight-line revenue recognized to date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Disaggregation of Revenue—</font><font style="font-family:inherit;font-size:10pt;">The table below depicts the disaggregation of revenue by product for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and is consistent with how we evaluate our financial performance (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Advantage</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,935</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Supplement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,592</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Part D</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,686</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Individual and Family </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-Qualified Health Plans </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,629</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,441</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Qualified Health Plans</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,508</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,162</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Individual and Family</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,137</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,603</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ancillaries</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dental</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">951</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,771</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Ancillaries</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,519</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,580</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Small Business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission Bonus</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Commission Revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,227</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,707</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,363</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,773</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,070</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:96%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:10px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">We define our Individual and Family Plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both Qualified and Non-Qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase Non-Qualified health plans cannot receive a subsidy in connection with the purchase of Non-Qualified plans.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Incremental Costs to Obtain a Contract</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font><font style="font-family:inherit;font-size:10pt;">We reviewed our sales compensation plans, which are directed at converting leads into approved members, and concluded that they are fulfillment costs and not costs to obtain a contract with a customer. Additionally, we reviewed compensation plans related to personnel responsible for identifying new health insurance carriers and entering into contracts with new health insurance carriers and concluded that no incremental costs are incurred to obtain such contracts.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncement Not Yet Adopted</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments—Credit Losses (Topic 326)—</font><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments—Credit Losses (Topic 326), </font><font style="font-family:inherit;font-size:10pt;">which amends the guidance for accounting for assets which are potentially subject to credit risk. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. ASU 2016-13 is effective for us beginning January 1, 2020 using a modified retrospective transition method. We are still in process of assessing the impact, if any, this ASU will have on our condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncement</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases (Topic 842)—</font><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842).</font><font style="font-family:inherit;font-size:10pt;"> ASU 2016-02 requires lessees to recognize a right-of-use asset and lease liability for all leases with terms of more than 12 months. Recognition, measurement, and presentation of expenses will depend on classification as a finance or operating lease; for lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct finance leases. The guidance also eliminates existing real estate-specific provisions for all entities. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. We adopted the standard using the modified retrospective method on January 1, 2019. As a result of adopting the ASU, as of January 1, 2019, we recorded an increase to our right-of-use asset and lease liability of </font><font style="font-family:inherit;font-size:10pt;">$23.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$24.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which are discussed in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 11—Leases </font><font style="font-family:inherit;font-size:10pt;">in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Notes to Condensed Consolidated Financial Statements</font><font style="font-family:inherit;font-size:10pt;"> of this Quarterly Report on Form 10-Q.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Accounts</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents—</font><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, our cash equivalents consisted of money market accounts that invested in U.S. government-sponsored enterprise bonds and discount notes, U.S. government treasury bills and notes and repurchase agreements collateralized by U.S. government obligations. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, our cash equivalents carried no unrealized gains or losses. We had no restricted cash as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, our cash and cash equivalent balances were invested as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,089</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total Accounts Receivable</font><font style="font-family:inherit;font-size:10pt;">—We do not require collateral or other security for our total accounts receivable. We believe the potential for collection issues with any of our customers was minimal as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">. Accordingly, our estimate for uncollectible amounts at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> was immaterial. Total accounts receivable as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> was comprised of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commissions receivable—current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,834</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,190</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commissions receivable—non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,377</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accounts receivable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331,592</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,459</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font><font style="font-family:inherit;font-size:10pt;">—Our financial instruments that are exposed to concentrations of credit risk principally consist of cash, cash equivalents and total accounts receivable (which includes commissions receivable). We invest our cash and cash equivalents with major banks and financial institutions and, at times, such investments are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not require collateral or other security for our total accounts receivable. Carriers that represented 10% or more of our total accounts receivable balance of </font><font style="font-family:inherit;font-size:10pt;">$331.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$349.5 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, were as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UnitedHealthcare </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Humana</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aetna</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">UnitedHealthcare also includes other carriers owned by UnitedHealthcare. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Aetna also includes other carriers owned by Aetna.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Prepaid Expenses and Other</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Current</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets—</font><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid maintenance contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid insurance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid advertising</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">610</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,402</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,483</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,288</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets—</font><font style="font-family:inherit;font-size:10pt;">The carrying amounts, accumulated amortization, net carrying value and weighted average remaining life of our definite-lived amortizable intangible assets, as well as our indefinite-lived intangible trademarks, are presented in the tables below for (dollars in thousands, weighted-average remaining life in years):</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Remaining Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Pharmacy and customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,471</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,029</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,234</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Trade names, trademarks and website addresses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,337</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,220</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,480</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total intangible assets subject to amortization</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,612</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,588</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,065</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,135</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indefinite-lived trademarks and domain names</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indefinite</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total intangible assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, expected amortization expense in future periods is as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Years Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Pharmacy and Customer Relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trade Names, Trademarks and Website Addresses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">510</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,960</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,960</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,337</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

EX-101.SCH 7 ehth-20190331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2102100 - Disclosure - Acquisition link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Acquisition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Acquisition - Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Balance Sheet Accounts link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Balance Sheet Accounts - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Balance Sheet Accounts - Schedule of Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Balance Sheet Accounts - Schedule of Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Balance Sheet Accounts - Schedule of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2403410 - Disclosure - Balance Sheet Accounts - Schedule of Intangible Asset Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2403409 - Disclosure - Balance Sheet Accounts - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - Balance Sheet Accounts - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Balance Sheet Accounts (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Fair Value Measurements - Earnout Liability Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Fair Value Measurements - Summary of Financial Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Income Taxes (Summary of Income Tax Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Leases - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Leases - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Operating Segments, Geographic Information and Significant Customers link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Operating Segments, Geographic Information and Significant Customers - Schedule Of Long-Lived Assets By Geographical Area (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Operating Segments, Geographic Information and Significant Customers - Schedule of Revenue by Major Customers (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Operating Segments, Geographic Information and Significant Customers - Segment Operating Results (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Operating Segments, Geographic Information and Significant Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Public Offering of Common Stock link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Public Offering of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Stockholder's Equity link:presentationLink link:calculationLink link:definitionLink 2405406 - Disclosure - Stockholder's Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Stockholder's Equity - Schedule of Option Activity Under Stock Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2405405 - Disclosure - Stockholder's Equity - Schedule of Restricted Stock Unit Activity Under Stock Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2405408 - Disclosure - Stockholder's Equity - Schedule of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Stockholder's Equity - Schedule of Stock Plan Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Stockholder's Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of Business and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - Summary of Business and Significant Accounting Policies - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Summary of Business and Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Business and Significant Accounting Policies (Policy) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Summary of Business and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 ehth-20190331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 ehth-20190331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 ehth-20190331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Balance Sheet Related Disclosures [Abstract] Total accounts receivable Accounts Receivable, Net, Current Commissions receivable—current Commissions Receivable, Current Commissions Receivable, Current Commissions receivable—non-current Commissions Receivable, Non-current Commissions Receivable, Non-current Total accounts receivable Accounts Receivable, Net Leases [Abstract] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Operating lease liabilities Operating Lease, Liability Weighted-average remaining lease term of operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Weighted-average discount rate of operating leases Operating Lease, Weighted Average Discount Rate, Percent Operating leases Operating Lease Liabilities, Payments Due [Abstract] Remainder of 2019 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total Lessee, Operating Lease, Liability, Payments, Due Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Restructuring and Related Activities [Abstract] Restructuring Restructuring and Related Activities Disclosure [Text Block] Schedule Of Intangible Assets [Table] Schedule Of Intangible Assets [Table] Schedule Of Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Technology Technology-Based Intangible Assets [Member] Pharmacy and customer relationships Customer Relationships [Member] Trade names, trademarks and website addresses Trademarks and Trade Names [Member] Schedule Of Intangible Assets [Line Items] Schedule Of Intangible Assets [Line Items] Schedule Of Intangible Assets [Line Items] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Total Finite-Lived Intangible Assets, Net Indefinite-lived trademarks and domain names Indefinite-lived Intangible Assets (Excluding Goodwill) Total intangible assets Intangible Assets, Net (Excluding Goodwill) Weighted-Average Remaining Life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Treasury Stock Treasury Stock [Member] Retained Earnings Retained Earnings [Member] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Shares, Outstanding Beginning Balance Stockholders' Equity Attributable to Parent Issuance of common stock in connection with exercise of common stock options and release of vested restricted stock units, net of cash used to net settle equity awards (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock in connection with exercise of common stock options and release of vested restricted stock units, net of cash used to net settle equity awards Stock Issued During Period, Value, Stock Options Exercised Common stock traded for employee tax obligation Adjustments Related to Tax Withholding for Share-based Compensation Common stock traded for employee tax obligation (in shares) Shares Paid for Tax Withholding for Share Based Compensation Stock issued in equity offering (in shares) Stock Issued During Period, Shares, New Issues Stock issued in equity offering Stock Issued During Period, Value, New Issues Stock issued for acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Stock issued for acquisition Stock Issued During Period, Value, Acquisitions Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Foreign currency translation adjustment, net of taxes Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Net loss Net Income (Loss) Attributable to Parent Ending balance (in shares) Ending Balance Stockholders' Equity Note [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted stock units Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Restricted Stock Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Unvested, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unvested, ending balance (in shares) Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Unvested, beginning balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cancelled (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unvested, ending balance (in dollars per share) Weighted-Average Remaining Service Period (years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Aggregate Intrinsic Value Aggregate Intrinsic Value, Balance Outstanding Share-Based Compensation Arrangement By Share-Based Payment Award Restricted Stock Unit Outstanding Aggregate Intrinsic Value Commitments and Contingencies Disclosure [Abstract] Schedule of Future Minimum Rental Payments for Operating Leases Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Commitments and Contingencies Commitments Contingencies and Guarantees [Text Block] Balance Sheet Accounts Supplemental Balance Sheet Disclosures [Text Block] Statement of Cash Flows [Abstract] Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Deferred income taxes Deferred Income Tax Expense (Benefit) Depreciation and amortization Depreciation Amortization of internally developed software Capitalized Computer Software, Amortization Amortization of intangible assets Amortization of Intangible Assets Stock-based compensation expense Share-based Compensation Change in fair value of earnout liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Other non-cash items Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Commissions receivable Increase (Decrease) In Commissions Receivable Increase (Decrease) In Commissions Receivable Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Accrued marketing expenses Increase Decrease In Accrued Marketing Expenses The increase (decrease) during the reporting period in accrued marketing expenses. Accrued restructuring charges Increase (Decrease) in Accrued Restructuring Charges Increase (Decrease) in Accrued Restructuring Charges Deferred revenue Increase (Decrease) in Contract with Customer, Liability Accrued expense and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Capitalized internal-use software and website development costs Payments to Develop Software Purchases of property and equipment and other assets Payments to Acquire Property, Plant, and Equipment Acquisition of business, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock Net proceeds from exercise of common stock options Proceeds from Stock Options Exercised Cash used to net-share settle equity awards Employee Service Share-based Compensation, Cash Flow Effect, Cash Used to Settle Awards Payment of debt Repayments of Long-term Debt Acquisition-related contingent payments Payment for Contingent Consideration Liability, Financing Activities Principal payments in connection with finance leases Finance Lease, Principal Payments Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Earnout liability—current Contingent Consideration, Current [Member] Contingent Consideration, Current [Member] Earnout liability—non-current Contingent Consideration, Non-Current [Member] Contingent Consideration, Non-Current [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Money market funds Money Market Funds [Member] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying Value Reported Value Measurement [Member] Fair Value Estimate of Fair Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total assets measured and recorded at fair value Assets, Fair Value Disclosure Total liabilities measured and recorded at fair value Financial and Nonfinancial Liabilities, Fair Value Disclosure Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Accounts Receivable Accounts Receivable [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] UnitedHealthcare Unitedhealthcare [Member] UnitedHealthcare [Member] Humana Humana [Member] Humana [Member] Aetna Aetna [Member] Aetna [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Major customer revenue, percentage Concentration Risk, Percentage Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] ASU 2016-02 Accounting Standards Update 2016-02 [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] $1.5 Million Standby Letter of Credit 1.5 Million Standby Letter of Credit [Member] 1.5 Million Standby Letter of Credit [Member] $.6 Million Standby Letter of Credit .6 Million Standby Letter of Credit [Member] .6 Million Standby Letter of Credit [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Standby Letters of Credit Standby Letters of Credit [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Salt Lake City, Utah Salt Lake City, Utah [Member] Salt Lake City, Utah [Member] Santa Clara, California Santa Clara, California [Member] Santa Clara, California [Member] Austin, Texas Austin, Texas [Member] Austin, Texas [Member] Mountain View, California Mountain View, California [Member] Mountain View, California [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Lease term Lease, Remaining Lease Term Lease, Remaining Lease Term Operating lease cost Operating Lease, Cost Operating cash outflow from operating leases Operating Lease, Payments Office space, square feet Area of Real Estate Property Operating lease, term Lessee, Operating Lease, Term of Contract Future minimum lease payments Credit facility Letters of Credit Outstanding, Amount Incremental reduction rate Reduction Of Standby Letter Of Credit Amount, Percentage Reduction Of Standby Letter Of Credit Amount, Percentage Reduction of standby letter of credit amount, percentage, sixth year Reduction Of Standby Letter Of Credit Amount,Percentage Sixth Year Reduction Of Standby Letter Of Credit Amount,Percentage Sixth Year Document And Entity Information [Abstract] Document and Entity Information [Abstract] Document Type Document Type EX-101.PRE 11 ehth-20190331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	Apr. 30, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus (Q1,Q2,Q3,FY)	Q1
Trading Symbol	EHTH
Entity Registrant Name	eHealth, Inc.
Entity Central Index Key	0001333493
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding (in shares)		22,649,067

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 135,475	$ 13,089
Accounts receivable	3,381	3,601
Commissions receivable—current	113,834	134,190
Prepaid expenses and other current assets	6,483	5,288
Total current assets	259,173	156,168
Commissions receivable—non-current	214,377	211,668
Property and equipment, net	7,963	7,684
Operating lease right-of-use assets	25,730
Other assets	12,059	11,276
Intangible assets, net	11,702	12,249
Goodwill	40,233	40,233
Total assets	571,237	439,278
Current liabilities:
Accounts payable	4,360	5,688
Accrued compensation and benefits	11,373	20,763
Accrued marketing expenses	3,866	11,013
Earnout liability—current	26,500	20,730
Lease liabilities—current	3,430
Other current liabilities	5,528	2,425
Total current liabilities	55,057	60,619
Debt	0	5,000
Earnout liability—non-current	0	19,270
Deferred income taxes—non-current	44,358	47,901
Lease liabilities—non-current	24,150
Other non-current liabilities	2,022	3,339
Stockholders’ equity:
Common stock	34	31
Additional paid-in capital	445,652	298,024
Treasury stock, at cost	(199,998)	(199,998)
Retained earnings	199,806	204,965
Accumulated other comprehensive income	156	127
Total stockholders’ equity	445,650	303,149
Total liabilities and stockholders’ equity	$ 571,237	$ 439,278

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue
Total revenue	$ 68,773	$ 43,070
Operating costs and expenses:
Cost of revenue	(77)	152
Marketing and advertising	23,941	15,002
Customer care and enrollment	19,944	13,239
Technology and content	9,017	8,341
General and administrative	11,278	10,691
Acquisition costs	0	58
Change in fair value of earnout liability	13,306	0
Restructuring	0	1,856
Amortization of intangible assets	547	451
Total operating costs and expenses	77,956	49,790
Loss from operations	(9,183)	(6,720)
Other income, net	557	184
Loss before benefit from income taxes	(8,626)	(6,536)
Benefit from income taxes	(3,467)	(1,691)
Net loss	$ (5,159)	$ (4,845)
Net loss per share:
Basic and diluted (in usd per share)	$ (0.24)	$ (0.26)
Weighted-average number of shares used in per share amounts:
Basic and diluted (in shares)	21,831	18,873
Foreign currency translation adjustment, net of taxes	$ 29	$ 65
Comprehensive loss	(5,130)	(4,780)
Commission
Revenue
Total revenue	64,227	40,707
Other
Revenue
Total revenue	$ 4,546	$ 2,363

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income
Beginning balance (in shares) at Dec. 31, 2017		29,880		(11,238)
Beginning Balance at Dec. 31, 2017	$ 286,664	$ 30	$ 281,706	$ (199,998)	$ 204,725	$ 201
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of common stock options and release of vested restricted stock units, net of cash used to net settle equity awards (in shares)		60
Issuance of common stock in connection with exercise of common stock options and release of vested restricted stock units, net of cash used to net settle equity awards	109		109
Common stock traded for employee tax obligation	(286)		(286)
Common stock traded for employee tax obligation (in shares)				(16)
Stock issued for acquisition (in shares)		295
Stock issued for acquisition	5,595		5,595
Stock-based compensation expense	2,801		2,801
Foreign currency translation adjustment, net of taxes	65					65
Net loss	(4,845)				(4,845)
Ending balance (in shares) at Mar. 31, 2018		30,235		(11,254)
Ending Balance at Mar. 31, 2018	290,103	$ 30	289,925	$ (199,998)	199,880	266
Beginning balance (in shares) at Dec. 31, 2018		30,863		(11,426)
Beginning Balance at Dec. 31, 2018	303,149	$ 31	298,024	$ (199,998)	204,965	127
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of common stock options and release of vested restricted stock units, net of cash used to net settle equity awards (in shares)		172
Issuance of common stock in connection with exercise of common stock options and release of vested restricted stock units, net of cash used to net settle equity awards	2,367		2,367
Common stock traded for employee tax obligation	(1,280)		(1,280)
Common stock traded for employee tax obligation (in shares)				(24)
Stock issued in equity offering (in shares)		2,760
Stock issued in equity offering	126,054	$ 3	126,051
Stock issued for acquisition (in shares)		295
Stock issued for acquisition	17,261		17,261
Stock-based compensation expense	3,229		3,229
Foreign currency translation adjustment, net of taxes	29					29
Net loss	(5,159)				(5,159)
Ending balance (in shares) at Mar. 31, 2019		34,090		(11,450)
Ending Balance at Mar. 31, 2019	$ 445,650	$ 34	$ 445,652	$ (199,998)	$ 199,806	$ 156

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating activities
Net loss	$ (5,159)	$ (4,845)
Adjustments to reconcile net loss to net cash provided by operating activities:
Deferred income taxes	(3,543)	(1,736)
Depreciation and amortization	655	619
Amortization of internally developed software	719	477
Amortization of intangible assets	547	451
Stock-based compensation expense	3,229	2,801
Change in fair value of earnout liability	13,306	0
Other non-cash items	(1,194)	389
Changes in operating assets and liabilities:
Accounts receivable	221	807
Commissions receivable	17,648	22,409
Prepaid expenses and other assets	1,111	(1,793)
Accounts payable	(768)	(567)
Accrued compensation and benefits	(9,390)	(6,912)
Accrued marketing expenses	(7,147)	(1,891)
Accrued restructuring charges	0	1,053
Deferred revenue	2,897	(289)
Accrued expense and other liabilities	(383)	(236)
Net cash provided by operating activities	12,749	10,737
Investing activities
Capitalized internal-use software and website development costs	(1,487)	(989)
Purchases of property and equipment and other assets	(1,509)	(217)
Acquisition of business, net of cash acquired	0	(14,929)
Net cash used in investing activities	(2,996)	(16,135)
Financing activities
Proceeds from issuance of common stock, net of issuance costs	126,051	0
Net proceeds from exercise of common stock options	2,367	109
Cash used to net-share settle equity awards	(1,280)	(286)
Payment of debt	(5,000)	0
Acquisition-related contingent payments	(9,542)	0
Principal payments in connection with finance leases	(25)	(26)
Net cash provided by (used in) financing activities	112,571	(203)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	62	50
Net increase (decrease) in cash, cash equivalents and restricted cash	122,386	(5,551)
Cash, cash equivalents and restricted cash at beginning of period	13,089	40,293
Cash, cash equivalents and restricted cash at end of period	$ 135,475	$ 34,742

XML 17 R6.htm IDEA: XBRL DOCUMENT

Summary of Business and Significant Accounting Policies

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Summary of Business and Significant Accounting Policies

Operating Segments—We report segment information based on how our chief executive officer, who is our chief operating decision maker ("CODM"), regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. The performance measures of our segments include total revenue and profit. Our business structure is comprised of two operating segments:

•Medicare; and

•Individual, Family and Small Business

Cash Equivalents—We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value.

•


•	Determination of the transaction price. The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.

•


•	Recognition of revenue when, or as, we satisfy a performance obligation. We satisfy performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.



	Three Months Ended
	March 31,
	2019		2018
Medicare
Medicare Advantage	7	%	7	%
Medicare Supplement	5	%	5	%
Medicare Part D	5	%	5	%

Individual and Family
Non-Qualified Health Plans	15	%	15	%
Qualified Health Plans	20	%	20	%

Ancillaries	10	%	10	%

Small Business	—	%	—	%



	Three Months Ended
	March 31, 2019		March 31, 2018
Commission Revenue:
Medicare
Medicare Advantage	$	39,843	$	21,935
Medicare Supplement	8,597		5,592
Medicare Part D	2,336		1,159
Total Medicare	50,776		28,686
Individual and Family ⁽¹⁾
Non-Qualified Health Plans	2,629		1,441
Qualified Health Plans	3,508		2,162
Total Individual and Family	6,137		3,603
Ancillaries
Short-term	1,316		1,250
Dental	790		1,219
Vision	462		340
Other	951		2,771
Total Ancillaries	3,519		5,580
Small Business	2,640		2,359
Commission Bonus	1,155		479
Total Commission Revenue	64,227		40,707
Other Revenue	4,546		2,363
Total Revenue	$	68,773	$	43,070



(1)	We define our Individual and Family Plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both Qualified and Non-Qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase Non-Qualified health plans cannot receive a subsidy in connection with the purchase of Non-Qualified plans.

Incremental Costs to Obtain a Contract

Accounting Pronouncement Not Yet Adopted

Recently Adopted Accounting Pronouncement

XML 18 R7.htm IDEA: XBRL DOCUMENT

Acquisition

3 Months Ended

Mar. 31, 2019

Business Combinations [Abstract]

Acquisition



Acquisition Consideration
Cash paid	$	15,000
Fair value of equity awards issued to GoMedigap members ⁽¹⁾	5,595
Estimated fair value of earnout liability	27,700
	$	48,295
Allocation
Cash and cash equivalents	$	71
Commission receivable—current	4,371
Prepaid expenses and other current assets	11
Commission receivable—non-current	11,103
Property and equipment, net	174
Accounts payable	(110		)
Accrued compensation and benefits	(132		)
Other current liabilities	(130		)
Net tangible assets acquired	15,358
Intangible assets	6,800
Goodwill	26,137
Total intangible assets acquired	32,937
Total net assets acquired	$	48,295

(1) The fair value of equity awards issued was determined based on the January 22, 2018 closing price of our common stock of $18.99.

Assets acquired and liabilities assumed measured and reported at fair value are classified in one of the following categories based on inputs:



Level 1	Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2	Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability.
Level 3	Unobservable inputs for the asset or liability.

Following are the details of the acquisition consideration allocated to the intangible assets acquired (in thousands):



Technology	$	2,000
Trade names, trademarks and website addresses	4,800
Total intangible assets	$	6,800

We incurred $0.1 million acquisition-related costs during the first quarter of 2018, which were expensed as incurred.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Balance Sheet Accounts

3 Months Ended

Mar. 31, 2019

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Accounts

As of March 31, 2019 and December 31, 2018, our cash and cash equivalent balances were invested as follows (in thousands):



	March 31, 2019		December 31, 2018
Cash	$	27,501	$	12,766
Money market funds	107,974		323
Total cash and cash equivalents	$	135,475	$	13,089



	March 31, 2019		December 31, 2018
Accounts receivable	$	3,381	$	3,601
Commissions receivable—current	113,834		134,190
Commissions receivable—non-current	214,377		211,668
Total accounts receivable	$	331,592	$	349,459



	March 31, 2019		December 31, 2018
UnitedHealthcare ⁽¹⁾	20	%	19	%
Humana	18	%	19	%
Aetna⁽²⁾	20	%	19	%


(1)	UnitedHealthcare also includes other carriers owned by UnitedHealthcare.


(2)	Aetna also includes other carriers owned by Aetna.

Prepaid Expenses and Other Current Assets—Prepaid expenses and other current assets consisted of the following (in thousands):



	March 31, 2019		December 31, 2018
Prepaid maintenance contracts	$	2,778	$	1,937
Equity issuance costs	—		294
Prepaid insurance	213		161
Prepaid rent	324		324
Income tax receivable	1,108		1,108
Prepaid advertising	610		62
Other current assets	1,450		1,402
Total prepaid expenses and other current assets	$	6,483	$	5,288



	March 31, 2019								December 31, 2018
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Weighted-Average Remaining Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Technology	$	2,000	$	(778	)	$	1,222	1.8	$	2,000	$	(611	)	$	1,389
Pharmacy and customer relationships	9,500		(8,471		)	1,029		1.1	9,500		(8,234		)	1,266
Trade names, trademarks and website addresses	5,700		(1,363		)	4,337		8.7	5,700		(1,220		)	4,480
Total intangible assets subject to amortization	$	17,200	$	(10,612	)	6,588			$	17,200	$	(10,065	)	7,135
Indefinite-lived trademarks and domain names						5,114		Indefinite						5,114
Total intangible assets						$	11,702							$	12,249

As of March 31, 2019, expected amortization expense in future periods is as follows (in thousands):



Years Ending December 31,	Technology		Pharmacy and Customer Relationships		Trade Names, Trademarks and Website Addresses		Total
Remainder of 2019	$	499	$	712	$	427	$	1,638
2020	667		317		510		1,494
2021	56		—		480		536
2022	—		—		480		480
2023	—		—		480		480
Thereafter	—		—		1,960		1,960
Total	$	1,222	$	1,029	$	4,337	$	6,588

XML 20 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements



Level 1		Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2		Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability.
Level 3		Unobservable inputs for the asset or liability.

The following table is a summary of financial assets measured at fair value on a recurring basis and their classification within the fair value hierarchy (in thousands).



	March 31, 2019								December 31, 2018
	Carrying Value		Level 1		Level 3		Total		Carrying Value		Level 1		Level 3		Total
Assets
Money market funds	$	107,974	$	107,974	$	—	$	107,974	$	323	$	323	$	—	$	323
Total assets measured and recorded at fair value	$	107,974	$	107,974	$	—	$	107,974	$	323	$	323	$	—	$	323

Liabilities
Earnout liability—current	$	26,500	$	—	$	26,500	$	26,500	$	20,730	$	—	$	20,730	$	20,730
Earnout liability—non-current	—		—		—		—		19,270		—		19,270		19,270
Total liabilities measured and recorded at fair value	$	26,500	$	—	$	26,500	$	26,500	$	40,000	$	—	$	40,000	$	40,000

Earnout liability activity during the three months ended March 31, 2019 was as follows (in thousands):



Balance at December 31, 2018	$	40,000
Settlement of first earnout liability	(26,800		)
Change in fair value	13,300
Balance at March 31, 2019	$	26,500

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Stockholder's Equity

3 Months Ended

Mar. 31, 2019

Stockholders' Equity Note [Abstract]

Stockholder's Equity

2014 Equity Incentive Plan—The following table summarizes activity under our 2014 Equity Incentive Plan (the “2014 Plan”) for the three months ended March 31, 2019 (in thousands):



	Shares Available for Grant
Shares available for grant December 31, 2018	512
Restricted stock units granted ⁽¹⁾	—
Options granted ⁽²⁾	—
Restricted stock units cancelled ⁽³⁾	37
Options cancelled	8
Shares available for grant March 31, 2019	557


(1)	Includes grants of restricted stock units with service, performance-based or market-based vesting criteria.


(2)	Includes grants of stock options with service, performance-based or market-based vesting criteria.


(3)	Includes cancelled restricted stock units with service, performance-based or market-based vesting criteria.

The following table summarizes stock option activity (in thousands, except weighted-average exercise price and weighted-average remaining contractual life data):



	Number of Stock Options ⁽¹⁾		Weighted Average Exercise Price		Weighted-Average Remaining Contractual Life (years)	Aggregate Intrinsic Value ⁽²⁾
Balance outstanding at December 31, 2018	1,005		$	18.34	5.0	$	20,226
Granted	—		$	—
Exercised	(108	)	$	21.88
Cancelled	(11	)	$	33.30
Balance outstanding at March 31, 2019	886		$	17.72	5.0	$	39,521
Vested and expected to vest at March 31, 2019	845		$	17.50	5.0	$	37,912
Exercisable at March 31, 2019	439		$	14.46	4.4	$	21,006


(1)	Includes certain stock options with service, performance-based or market-based vesting criteria.


(2)	The aggregate intrinsic value is calculated as the difference between the closing price of our common stock as of March 31, 2019 and December 31, 2018 and the exercise price multiplied by number of in-the-money options.

The following table summarizes restricted stock unit activity (in thousands, except weighted-average grant date fair value and weighted-average remaining contractual life data):



	Number of Restricted Stock Units ⁽¹⁾		Weighted-Average Grant Date Fair Value		Weighted-Average Remaining Service Period (years)	Aggregate Intrinsic Value ⁽²⁾
Unvested as of December 31, 2018	1,869		$	16.95	4.8	$	71,816
Granted	—		$	—
Vested	(64	)	$	13.56
Cancelled	(37	)	$	16.78
Unvested as of March 31, 2019	1,768		$	17.03	5.3	$	110,230


(1)	Includes certain restricted stock units with service, performance-based or market-based vesting criteria.


(2)	The aggregate intrinsic value is calculated as the product of our closing stock price as of March 31, 2019 and December 31, 2018, and the number of restricted stock units outstanding as of March 31, 2019 and December 31, 2018, respectively.

Stock-Based Compensation Expense—The following table summarizes stock-based compensation expense recorded during the three months ended March 31, 2019 and 2018 (in thousands):



	Three Months Ended March 31,
	2019		2018
Common stock options	$	602	$	498
Restricted stock units	2,627		2,303
Total stock-based compensation expense	$	3,229	$	2,801

The following table summarizes stock-based compensation expense by operating function for the three months ended March 31, 2019 and 2018 (in thousands):



	Three Months Ended March 31,
	2019		2018
Marketing and advertising	$	629	$	370
Customer care and enrollment	273		165
Technology and content	549		343
General and administrative	1,778		1,672
Restructuring	—		251
Total stock-based compensation expense	$	3,229	$	2,801

XML 22 R11.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Mar. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

The following table summarizes our benefit from income taxes and our effective tax rates for the three months ended March 31, 2019 and 2018 (in thousands, except effective tax rate):



	Three Months Ended March 31,
	2019			2018
Loss before benefit from income taxes	$	(8,626	)	$	(6,536	)
Benefit from income taxes	(3,467		)	(1,691		)
Effective tax rate	40.2		%	25.9		%

XML 23 R12.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Net Loss Per Share



	Three Months Ended March 31,
	2019	2018
Common stock options	960	1,006
Restricted stock units	1,426	1,426
Total	2,386	2,432

XML 24 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Operating Leases

Refer to Note 11—Leases for commitments related to our operating leases.

Contingencies

Legal Proceedings

Service and Licensing Obligations

The following table presents a summary of our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2019 (in thousands):



For the Years Ending December 31,	Service and Licensing Obligations
Remainder of 2019	$	3,366
2020	2,462
2021	946
2022	434
2023	444
Thereafter	229
Total	$	7,881

XML 25 R14.htm IDEA: XBRL DOCUMENT

Operating Segments, Geographic Information and Significant Customers

3 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

Operating Segments, Geographic Information and Significant Customers

Operating Segments

•Medicare

•Individual, Family and Small Business

The Individual, Family and Small Business segment consists primarily of commissions earned from our sale of individual and family and small business health insurance plans and ancillary products sold to our non-Medicare-eligible customers, including but not limited to, dental, vision, and short-term health insurance. To a lesser extent, the Individual, Family and Small Business segment consists of amounts earned from our online sponsorship program that allows carriers to purchase advertising space in specific markets in a sponsorship area on our website, our licensing to third parties the use of our health insurance ecommerce technology and our delivery and sale to third parties of individual and family health insurance leads generated by our ecommerce platforms and our marketing activities.

The following table presents summary results of our operating segments for the three months ended March 31, 2019 and 2018 (in thousands):



	Three Months Ended March 31,
	2019			2018
Revenue
Medicare	$	54,901		$	30,763
Individual, Family and Small Business	13,872			12,307
Total revenue	$	68,773		$	43,070

Segment profit
Medicare segment profit	$	10,826		$	3,180
Individual, Family and Small Business segment profit	6,024			3,488
Total segment profit	16,850			6,668
Corporate	(8,296		)	(7,854		)
Stock-based compensation expense	(3,229		)	(2,550		)
Depreciation and amortization	(655		)	(619		)
Acquisition costs	—			(58		)
Change in fair value of earnout liability	(13,306		)	—
Restructuring	—			(1,856		)
Amortization of intangible assets	(547		)	(451		)
Other income, net	557			184
Loss before benefit from income taxes	$	(8,626	)	$	(6,536	)

There are no internal revenue transactions between our operating segments. Our CODM does not separately evaluate assets by segment, and therefore assets by segment are not presented.

Geographic Information



	March 31, 2019		December 31, 2018
United States	$	16,697	$	15,614
China	342		378
Total	$	17,039	$	15,992

Significant Customers



	Three Months Ended March 31,
	2019		2018
Humana	23	%	15	%
UnitedHealthcare ⁽¹⁾	17	%	21	%
Aetna⁽²⁾	17	%	10	%


(1)	UnitedHealthcare also includes other carriers owned by UnitedHealthcare.


(2)	Aetna also includes other carriers owned by Aetna.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Restructuring	3 Months Ended
Restructuring	Mar. 31, 2019
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In February 2018, our Board of Directors approved a plan to close our sales call center in Massachusetts and to terminate the employment of other employees in certain other locations. As part of this plan, we eliminated approximately 110 full-time positions, representing approximately 10% of our workforce, primarily within customer care and enrollment, and to a lesser extent, in our marketing and advertising and general and administrative groups. Total pre-tax restructuring charges for the year ended December 31, 2018 were $1.9 million, which included approximately $1.6 million for employee termination benefits and $0.3 million in non-cash accelerated stock based compensation. Substantially all of the restructuring charges resulted in cash expenditures. The restructuring activities comprising the plan were completed by December 31, 2018, and there were no restructuring charges during the three months ended March 31, 2019.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Mar. 31, 2019

Leases [Abstract]

Leases

Adoption of ASC 842

Supplemental information related to leases was as follows (in thousands):



	March 31, 2019
Operating lease right-of-use assets	$	25,730
Operating lease liabilities	$	27,580

Weighted-average remaining lease term of operating leases (in years)	7.5
Weighted-average discount rate of operating leases	6.1		%

Maturities of operating lease liabilities are as follows (in thousands):



Year ending December 31,
Remainder of 2019	$	3,641
2020	5,502
2021	4,068
2022	4,189
2023	3,972
Thereafter	13,765
Total lease payments	35,137
Less imputed interest	(7,557		)
Total	$	27,580

Operating Lease Obligations

XML 28 R17.htm IDEA: XBRL DOCUMENT

Debt	3 Months Ended
Debt	Mar. 31, 2019
Debt Disclosure [Abstract]
Debt	Debt On September 17, 2018, we entered into a Credit Agreement with Royal Bank of Canada (“RBC”), as administrative agent and collateral agent (the “Credit Agreement”). The Credit Agreement provides for a $40 million secured asset-backed revolving credit facility with a $5 million letter of credit sub-facility. The commitments under the Credit Agreement expire on September 17, 2021, at which time any amounts drawn under facility are contractually due. The borrowing base under the Credit Agreement is comprised of an amount equal to (a) the lesser of (i) eighty percent (80%) of Eligible Commissions Receivables (as defined in the Credit Agreement) we actually collected by during the immediately preceding period of three months or (ii) eighty percent (80%) of our Eligible Commission Receivables for the immediately succeeding period of three months, plus (b) fifty percent (50%) of our Eligible Commission Receivables for the immediately succeeding period of six months (excluding the immediately succeeding period of three months), in each case subject to reserves established by RBC (the “Borrowing Base”). The proceeds of the loans under the Credit Agreement may be used for working capital and general corporate purposes. The Borrowers have the right to prepay the loans under the Credit Agreement in whole or in part at any time without penalty. Subject to availability under the Borrowing Base, amounts repaid may be reborrowed. Amounts not borrowed under the Credit Agreement will be subject to a commitment fee of 0.5% per annum on the daily unused portion of the credit facility, to be paid in arrears on the first business day of each calendar quarter. At closing, the Company paid a one-time facility fee of 1.75% of the total commitments under the Credit Agreement. The Company is also obligated to pay other customary administration fees for a credit facility of this size and type. Availability under the credit facility is up to the lesser of $40 million or the Borrowing Base, which may be reduced from time to time pursuant to the Credit Agreement. In addition, the Credit Agreement contains a financial covenant requiring that we maintain Excess Availability (as defined in the Credit Agreement) at or above $6 million at any time. As of March 31, 2019, we were in compliance with all debt covenants. We incurred $1.2 million of issuance costs in connection with the Credit Agreement, which were capitalized as part of other assets on the balance sheet. As of March 31, 2019, the balance of these issuance costs was $1.0 million. As of March 31, 2019, we had no outstanding principal amount under our revolving credit facility.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Public Offering of Common Stock	3 Months Ended
Public Offering of Common Stock	Mar. 31, 2019
Equity [Abstract]
Public Offering of Common Stock	Public Offering of Common Stock Pursuant to the effective registration statement which was filed on December 17, 2018, and amended on January 22, 2019, we entered into an underwriting agreement to issue a total of 2,760,000 shares of common stock, which included the exercise in full of the underwriters’ option to purchase 360,000 additional shares of common stock, at a price to the public of $48.50 per share in January 2019. Net proceeds from the offering were approximately $126.1 million after deducting underwriting discounts, commissions and expenses of the offering. We intend to use the net proceeds of the offering for general corporate purposes, including working capital.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Summary of Business and Significant Accounting Policies (Policy)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Description of Business

Basis of Presentation

Principles of Consideration

Operating Segments

•Medicare; and

•Individual, Family and Small Business

Use of Estimates

Seasonality

Cash Equivalents

Cash Equivalents—We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value.

Revenue Recognition

•


•	Determination of the transaction price. The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.

•


•	Recognition of revenue when, or as, we satisfy a performance obligation. We satisfy performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.



	Three Months Ended
	March 31,
	2019		2018
Medicare
Medicare Advantage	7	%	7	%
Medicare Supplement	5	%	5	%
Medicare Part D	5	%	5	%

Individual and Family
Non-Qualified Health Plans	15	%	15	%
Qualified Health Plans	20	%	20	%

Ancillaries	10	%	10	%

Small Business	—	%	—	%

Incremental Costs to Obtain a Contract

Accounting Pronouncement Not Yet Adopted; Recently Adopted Accounting Pronouncement

Accounting Pronouncement Not Yet Adopted

Recently Adopted Accounting Pronouncement

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Business and Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Disaggregation of Revenue

The table below depicts the disaggregation of revenue by product for the three months ended March 31, 2019 and 2018 and is consistent with how we evaluate our financial performance (in thousands):



	Three Months Ended
	March 31, 2019		March 31, 2018
Commission Revenue:
Medicare
Medicare Advantage	$	39,843	$	21,935
Medicare Supplement	8,597		5,592
Medicare Part D	2,336		1,159
Total Medicare	50,776		28,686
Individual and Family ⁽¹⁾
Non-Qualified Health Plans	2,629		1,441
Qualified Health Plans	3,508		2,162
Total Individual and Family	6,137		3,603
Ancillaries
Short-term	1,316		1,250
Dental	790		1,219
Vision	462		340
Other	951		2,771
Total Ancillaries	3,519		5,580
Small Business	2,640		2,359
Commission Bonus	1,155		479
Total Commission Revenue	64,227		40,707
Other Revenue	4,546		2,363
Total Revenue	$	68,773	$	43,070



(1)	We define our Individual and Family Plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both Qualified and Non-Qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase Non-Qualified health plans cannot receive a subsidy in connection with the purchase of Non-Qualified plans.



	Three Months Ended
	March 31,
	2019		2018
Medicare
Medicare Advantage	7	%	7	%
Medicare Supplement	5	%	5	%
Medicare Part D	5	%	5	%

Individual and Family
Non-Qualified Health Plans	15	%	15	%
Qualified Health Plans	20	%	20	%

Ancillaries	10	%	10	%

Small Business	—	%	—	%

XML 32 R21.htm IDEA: XBRL DOCUMENT

Acquisition (Tables)

3 Months Ended

Mar. 31, 2019

Business Combinations [Abstract]

Schedule of Business Acquisitions

The major classes of assets and liabilities to which we have preliminarily allocated the acquisition consideration were as follows (in thousands):



Acquisition Consideration
Cash paid	$	15,000
Fair value of equity awards issued to GoMedigap members ⁽¹⁾	5,595
Estimated fair value of earnout liability	27,700
	$	48,295
Allocation
Cash and cash equivalents	$	71
Commission receivable—current	4,371
Prepaid expenses and other current assets	11
Commission receivable—non-current	11,103
Property and equipment, net	174
Accounts payable	(110		)
Accrued compensation and benefits	(132		)
Other current liabilities	(130		)
Net tangible assets acquired	15,358
Intangible assets	6,800
Goodwill	26,137
Total intangible assets acquired	32,937
Total net assets acquired	$	48,295

(1) The fair value of equity awards issued was determined based on the January 22, 2018 closing price of our common stock of $18.99.

Acquisition Fair Value Measurements

Assets acquired and liabilities assumed measured and reported at fair value are classified in one of the following categories based on inputs:



Level 1	Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2	Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability.
Level 3	Unobservable inputs for the asset or liability.

Schedule of Acquired Indefinite-lived Intangible Assets by Major Class

Following are the details of the acquisition consideration allocated to the intangible assets acquired (in thousands):



Technology	$	2,000
Trade names, trademarks and website addresses	4,800
Total intangible assets	$	6,800

XML 33 R22.htm IDEA: XBRL DOCUMENT

Balance Sheet Accounts (Tables)

3 Months Ended

Mar. 31, 2019

Balance Sheet Related Disclosures [Abstract]

Schedule Of Cash And Cash Equivalents

As of March 31, 2019 and December 31, 2018, our cash and cash equivalent balances were invested as follows (in thousands):



	March 31, 2019		December 31, 2018
Cash	$	27,501	$	12,766
Money market funds	107,974		323
Total cash and cash equivalents	$	135,475	$	13,089

Schedule of Accounts Receivable

Total accounts receivable as of March 31, 2019 and December 31, 2018 was comprised of the following (in thousands):



	March 31, 2019		December 31, 2018
Accounts receivable	$	3,381	$	3,601
Commissions receivable—current	113,834		134,190
Commissions receivable—non-current	214,377		211,668
Total accounts receivable	$	331,592	$	349,459

Schedule of Credit Risk

Carriers that represented 10% or more of our total accounts receivable balance of $331.6 million and $349.5 million as of March 31, 2019 and December 31, 2018, respectively, were as follows (in thousands):



	March 31, 2019		December 31, 2018
UnitedHealthcare ⁽¹⁾	20	%	19	%
Humana	18	%	19	%
Aetna⁽²⁾	20	%	19	%

Schedule Of Prepaid Expenses And Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):



	March 31, 2019		December 31, 2018
Prepaid maintenance contracts	$	2,778	$	1,937
Equity issuance costs	—		294
Prepaid insurance	213		161
Prepaid rent	324		324
Income tax receivable	1,108		1,108
Prepaid advertising	610		62
Other current assets	1,450		1,402
Total prepaid expenses and other current assets	$	6,483	$	5,288

Schedule Of Intangible Assets

The carrying amounts, accumulated amortization, net carrying value and weighted average remaining life of our definite-lived amortizable intangible assets, as well as our indefinite-lived intangible trademarks, are presented in the tables below for (dollars in thousands, weighted-average remaining life in years):



	March 31, 2019								December 31, 2018
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Weighted-Average Remaining Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Technology	$	2,000	$	(778	)	$	1,222	1.8	$	2,000	$	(611	)	$	1,389
Pharmacy and customer relationships	9,500		(8,471		)	1,029		1.1	9,500		(8,234		)	1,266
Trade names, trademarks and website addresses	5,700		(1,363		)	4,337		8.7	5,700		(1,220		)	4,480
Total intangible assets subject to amortization	$	17,200	$	(10,612	)	6,588			$	17,200	$	(10,065	)	7,135
Indefinite-lived trademarks and domain names						5,114		Indefinite						5,114
Total intangible assets						$	11,702							$	12,249

Schedule Of Intangible Assets Future Amortization Expense

As of March 31, 2019, expected amortization expense in future periods is as follows (in thousands):



Years Ending December 31,	Technology		Pharmacy and Customer Relationships		Trade Names, Trademarks and Website Addresses		Total
Remainder of 2019	$	499	$	712	$	427	$	1,638
2020	667		317		510		1,494
2021	56		—		480		536
2022	—		—		480		480
2023	—		—		480		480
Thereafter	—		—		1,960		1,960
Total	$	1,222	$	1,029	$	4,337	$	6,588

XML 34 R23.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

We classify the inputs used to measure fair value into the following hierarchy:



Level 1		Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2		Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability.
Level 3		Unobservable inputs for the asset or liability.

Summary of Financial Assets Measured at Fair Value on a Recurring Basis

The following table is a summary of financial assets measured at fair value on a recurring basis and their classification within the fair value hierarchy (in thousands).



	March 31, 2019								December 31, 2018
	Carrying Value		Level 1		Level 3		Total		Carrying Value		Level 1		Level 3		Total
Assets
Money market funds	$	107,974	$	107,974	$	—	$	107,974	$	323	$	323	$	—	$	323
Total assets measured and recorded at fair value	$	107,974	$	107,974	$	—	$	107,974	$	323	$	323	$	—	$	323

Liabilities
Earnout liability—current	$	26,500	$	—	$	26,500	$	26,500	$	20,730	$	—	$	20,730	$	20,730
Earnout liability—non-current	—		—		—		—		19,270		—		19,270		19,270
Total liabilities measured and recorded at fair value	$	26,500	$	—	$	26,500	$	26,500	$	40,000	$	—	$	40,000	$	40,000

Summary of Earnout Liability Activity

Earnout liability activity during the three months ended March 31, 2019 was as follows (in thousands):



Balance at December 31, 2018	$	40,000
Settlement of first earnout liability	(26,800		)
Change in fair value	13,300
Balance at March 31, 2019	$	26,500

XML 35 R24.htm IDEA: XBRL DOCUMENT

Stockholder's Equity (Tables)

3 Months Ended

Mar. 31, 2019

Stockholders' Equity Note [Abstract]

Schedule Of Stock Option Share Activity Under Stock Plans

The following table summarizes activity under our 2014 Equity Incentive Plan (the “2014 Plan”) for the three months ended March 31, 2019 (in thousands):



	Shares Available for Grant
Shares available for grant December 31, 2018	512
Restricted stock units granted ⁽¹⁾	—
Options granted ⁽²⁾	—
Restricted stock units cancelled ⁽³⁾	37
Options cancelled	8
Shares available for grant March 31, 2019	557


(1)	Includes grants of restricted stock units with service, performance-based or market-based vesting criteria.


(2)	Includes grants of stock options with service, performance-based or market-based vesting criteria.


(3)	Includes cancelled restricted stock units with service, performance-based or market-based vesting criteria.

Schedule Of Activity Under Stock Plans

The following table summarizes stock option activity (in thousands, except weighted-average exercise price and weighted-average remaining contractual life data):



	Number of Stock Options ⁽¹⁾		Weighted Average Exercise Price		Weighted-Average Remaining Contractual Life (years)	Aggregate Intrinsic Value ⁽²⁾
Balance outstanding at December 31, 2018	1,005		$	18.34	5.0	$	20,226
Granted	—		$	—
Exercised	(108	)	$	21.88
Cancelled	(11	)	$	33.30
Balance outstanding at March 31, 2019	886		$	17.72	5.0	$	39,521
Vested and expected to vest at March 31, 2019	845		$	17.50	5.0	$	37,912
Exercisable at March 31, 2019	439		$	14.46	4.4	$	21,006


(1)	Includes certain stock options with service, performance-based or market-based vesting criteria.


(2)	The aggregate intrinsic value is calculated as the difference between the closing price of our common stock as of March 31, 2019 and December 31, 2018 and the exercise price multiplied by number of in-the-money options.

Schedule Of Restricted Stock Unit Activity Under Stock Plans

The following table summarizes restricted stock unit activity (in thousands, except weighted-average grant date fair value and weighted-average remaining contractual life data):



	Number of Restricted Stock Units ⁽¹⁾		Weighted-Average Grant Date Fair Value		Weighted-Average Remaining Service Period (years)	Aggregate Intrinsic Value ⁽²⁾
Unvested as of December 31, 2018	1,869		$	16.95	4.8	$	71,816
Granted	—		$	—
Vested	(64	)	$	13.56
Cancelled	(37	)	$	16.78
Unvested as of March 31, 2019	1,768		$	17.03	5.3	$	110,230


(1)	Includes certain restricted stock units with service, performance-based or market-based vesting criteria.


(2)	The aggregate intrinsic value is calculated as the product of our closing stock price as of March 31, 2019 and December 31, 2018, and the number of restricted stock units outstanding as of March 31, 2019 and December 31, 2018, respectively.

Schedule Of Stock-Based Compensation Expense By Award Type

The following table summarizes stock-based compensation expense recorded during the three months ended March 31, 2019 and 2018 (in thousands):



	Three Months Ended March 31,
	2019		2018
Common stock options	$	602	$	498
Restricted stock units	2,627		2,303
Total stock-based compensation expense	$	3,229	$	2,801

Schedule Of Stock-Based Compensation Expense By Operating Function

The following table summarizes stock-based compensation expense by operating function for the three months ended March 31, 2019 and 2018 (in thousands):



	Three Months Ended March 31,
	2019		2018
Marketing and advertising	$	629	$	370
Customer care and enrollment	273		165
Technology and content	549		343
General and administrative	1,778		1,672
Restructuring	—		251
Total stock-based compensation expense	$	3,229	$	2,801

XML 36 R25.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

3 Months Ended

Mar. 31, 2019

Income Tax Disclosure [Abstract]

Schedule Of Components Of Income Tax Expense

The following table summarizes our benefit from income taxes and our effective tax rates for the three months ended March 31, 2019 and 2018 (in thousands, except effective tax rate):



	Three Months Ended March 31,
	2019			2018
Loss before benefit from income taxes	$	(8,626	)	$	(6,536	)
Benefit from income taxes	(3,467		)	(1,691		)
Effective tax rate	40.2		%	25.9		%

XML 37 R26.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Schedule Of Anti-dilutive Shares Excluded From Computation Of Net Income Per Share

The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of the following (in thousands):



	Three Months Ended March 31,
	2019	2018
Common stock options	960	1,006
Restricted stock units	1,426	1,426
Total	2,386	2,432

XML 38 R27.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

The following table presents a summary of our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2019 (in thousands):



For the Years Ending December 31,	Service and Licensing Obligations
Remainder of 2019	$	3,366
2020	2,462
2021	946
2022	434
2023	444
Thereafter	229
Total	$	7,881

XML 39 R28.htm IDEA: XBRL DOCUMENT

Operating Segments, Geographic Information and Significant Customers (Tables)

3 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table presents summary results of our operating segments for the three months ended March 31, 2019 and 2018 (in thousands):



	Three Months Ended March 31,
	2019			2018
Revenue
Medicare	$	54,901		$	30,763
Individual, Family and Small Business	13,872			12,307
Total revenue	$	68,773		$	43,070

Segment profit
Medicare segment profit	$	10,826		$	3,180
Individual, Family and Small Business segment profit	6,024			3,488
Total segment profit	16,850			6,668
Corporate	(8,296		)	(7,854		)
Stock-based compensation expense	(3,229		)	(2,550		)
Depreciation and amortization	(655		)	(619		)
Acquisition costs	—			(58		)
Change in fair value of earnout liability	(13,306		)	—
Restructuring	—			(1,856		)
Amortization of intangible assets	(547		)	(451		)
Other income, net	557			184
Loss before benefit from income taxes	$	(8,626	)	$	(6,536	)

Schedule Of Long Lived Assets By Geographical Areas

Long-lived assets by geographical area as of March 31, 2019 and December 31, 2018 were as follows (in thousands):



	March 31, 2019		December 31, 2018
United States	$	16,697	$	15,614
China	342		378
Total	$	17,039	$	15,992

Schedule Of Revenue By Major Customers

Carriers representing 10% or more of our total revenue for the three months ended March 31, 2019 and 2018 are presented in the table below:



	Three Months Ended March 31,
	2019		2018
Humana	23	%	15	%
UnitedHealthcare ⁽¹⁾	17	%	21	%
Aetna⁽²⁾	17	%	10	%


(1)	UnitedHealthcare also includes other carriers owned by UnitedHealthcare.


(2)	Aetna also includes other carriers owned by Aetna

XML 40 R29.htm IDEA: XBRL DOCUMENT

Leases (Tables)

3 Months Ended

Mar. 31, 2019

Leases [Abstract]

Schedule of Supplemental Balance Sheet Information

Supplemental information related to leases was as follows (in thousands):



	March 31, 2019
Operating lease right-of-use assets	$	25,730
Operating lease liabilities	$	27,580

Weighted-average remaining lease term of operating leases (in years)	7.5
Weighted-average discount rate of operating leases	6.1		%

Schedule of Operating Lease Maturities

Maturities of operating lease liabilities are as follows (in thousands):



Year ending December 31,
Remainder of 2019	$	3,641
2020	5,502
2021	4,068
2022	4,189
2023	3,972
Thereafter	13,765
Total lease payments	35,137
Less imputed interest	(7,557		)
Total	$	27,580

XML 41 R30.htm IDEA: XBRL DOCUMENT

Summary of Business and Significant Accounting Policies - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019 USD ($) segment state	Jan. 01, 2019 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of states in which the Company is licensed to market and sell health insurance \| state	50
Number of operating segments \| segment	2
Payment terms	Payment is typically received within 60 days of approval.
Operating lease right-of-use assets	$ 25,730
Operating lease liabilities	27,580
ASU 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets		$ 23,300
Operating lease liabilities	$ 28,100	$ 24,600

XML 42 R31.htm IDEA: XBRL DOCUMENT

Summary of Business and Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Total revenue	$ 68,773	$ 43,070
Medicare
Disaggregation of Revenue [Line Items]
Total revenue	$ 50,776	$ 28,686
Medicare \| Medicare Advantage
Disaggregation of Revenue [Line Items]
LTV Commissions	7.00%	7.00%
Total revenue	$ 39,843	$ 21,935
Medicare \| Medicare Supplement
Disaggregation of Revenue [Line Items]
LTV Commissions	5.00%	5.00%
Total revenue	$ 8,597	$ 5,592
Medicare \| Medicare Part D
Disaggregation of Revenue [Line Items]
LTV Commissions	5.00%	5.00%
Total revenue	$ 2,336	$ 1,159
Individual and Family
Disaggregation of Revenue [Line Items]
Total revenue	$ 6,137	$ 3,603
Individual and Family \| Non-Qualified Health Plans
Disaggregation of Revenue [Line Items]
LTV Commissions	15.00%	15.00%
Total revenue	$ 2,629	$ 1,441
Individual and Family \| Qualified Health Plans
Disaggregation of Revenue [Line Items]
LTV Commissions	20.00%	20.00%
Total revenue	$ 3,508	$ 2,162
Ancillaries
Disaggregation of Revenue [Line Items]
LTV Commissions	10.00%	10.00%
Total revenue	$ 3,519	$ 5,580
Ancillaries \| Short-term
Disaggregation of Revenue [Line Items]
Total revenue	1,316	1,250
Ancillaries \| Dental
Disaggregation of Revenue [Line Items]
Total revenue	790	1,219
Ancillaries \| Vision
Disaggregation of Revenue [Line Items]
Total revenue	462	340
Ancillaries \| Other
Disaggregation of Revenue [Line Items]
Total revenue	$ 951	$ 2,771
Small Business
Disaggregation of Revenue [Line Items]
LTV Commissions	0.00%	0.00%
Total revenue	$ 2,640	$ 2,359
Commission Bonus
Disaggregation of Revenue [Line Items]
Total revenue	1,155	479
Commission
Disaggregation of Revenue [Line Items]
Total revenue	64,227	40,707
Other
Disaggregation of Revenue [Line Items]
Total revenue	$ 4,546	$ 2,363

XML 43 R32.htm IDEA: XBRL DOCUMENT

Acquisition - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended
Acquisition - Narrative (Details) - USD ($) $ in Thousands	Jan. 22, 2018	Mar. 31, 2019	Mar. 31, 2018
Business Acquisition [Line Items]
Acquisition-related contingent payments		$ (9,542)	$ 0
Change in fair value of earnout liability		13,306	0
Acquisition costs		0	$ 58
GoMedigap
Business Acquisition [Line Items]
Cash paid	$ 15,000
Cash and cash equivalents	$ 71
Shares acquired (in shares)	294,637
Earnout consideration	$ 20,000
Earnout consideration (in shares)	589,275
Goodwill deductible period	15 years
Acquisition-related contingent payments		(9,500)
Stock issued for acquisition	$ 5,595	17,300
Change in fair value of earnout liability		$ 13,300
Trade names, trademarks and website addresses
Business Acquisition [Line Items]
Weighted-Average Remaining Life		8 years 8 months 12 days
Minimum \| Trade names, trademarks and website addresses \| GoMedigap
Business Acquisition [Line Items]
Weighted-Average Remaining Life		3 years
Maximum \| Trade names, trademarks and website addresses \| GoMedigap
Business Acquisition [Line Items]
Weighted-Average Remaining Life		10 years

XML 44 R33.htm IDEA: XBRL DOCUMENT

Acquisition - Purchase Price Allocation (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	Jan. 22, 2018	Mar. 31, 2019	Dec. 31, 2018
Allocation
Goodwill		$ 40,233	$ 40,233
Share price (usd per share)	$ 18.99
GoMedigap
Acquisition Consideration
Cash paid	$ 15,000
Fair value of equity awards issued to GoMedigap members	5,595	$ 17,300
Estimated fair value of earnout liability	27,700
Purchase price	48,295
Allocation
Cash and cash equivalents	71
Commission receivable—current	4,371
Prepaid expenses and other current assets	11
Commission receivable—non-current	11,103
Property and equipment, net	174
Accounts payable	(110)
Accrued compensation and benefits	(132)
Other current liabilities	(130)
Net tangible assets acquired	15,358
Intangible assets	6,800
Goodwill	26,137
Total intangible assets acquired	32,937
Total net assets acquired	48,295
Technology \| GoMedigap
Allocation
Intangible assets	2,000
Trade names, trademarks and website addresses \| GoMedigap
Allocation
Intangible assets	$ 4,800

XML 45 R34.htm IDEA: XBRL DOCUMENT

Balance Sheet Accounts - Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Cash	$ 27,501	$ 12,766
Money market funds	107,974	323
Total cash and cash equivalents	$ 135,475	$ 13,089

XML 46 R35.htm IDEA: XBRL DOCUMENT

Balance Sheet Accounts - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Total accounts receivable	$ 3,381	$ 3,601
Commissions receivable—current	113,834	134,190
Commissions receivable—non-current	214,377	211,668
Total accounts receivable	$ 331,592	$ 349,459

XML 47 R36.htm IDEA: XBRL DOCUMENT

Balance Sheet Accounts - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Accounts receivable	$ 331,592	$ 349,459

XML 48 R37.htm IDEA: XBRL DOCUMENT

Balance Sheet Accounts - Schedule of Credit Risk (Details) - Customer Concentration Risk - Accounts Receivable	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
UnitedHealthcare
Concentration Risk [Line Items]
Major customer revenue, percentage	20.00%	19.00%
Humana
Concentration Risk [Line Items]
Major customer revenue, percentage	18.00%	19.00%
Aetna
Concentration Risk [Line Items]
Major customer revenue, percentage	20.00%	19.00%

XML 49 R38.htm IDEA: XBRL DOCUMENT

Balance Sheet Accounts - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Prepaid maintenance contracts	$ 2,778	$ 1,937
Equity issuance costs	0	294
Prepaid insurance	213	161
Prepaid rent	324	324
Income tax receivable	1,108	1,108
Prepaid advertising	610	62
Other current assets	1,450	1,402
Total prepaid expenses and other current assets	$ 6,483	$ 5,288

XML 50 R39.htm IDEA: XBRL DOCUMENT

Balance Sheet Accounts - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Schedule Of Intangible Assets [Line Items]
Gross Carrying Amount	$ 17,200	$ 17,200
Accumulated Amortization	(10,612)	(10,065)
Total	6,588	7,135
Indefinite-lived trademarks and domain names	5,114	5,114
Total intangible assets	11,702	12,249
Technology
Schedule Of Intangible Assets [Line Items]
Gross Carrying Amount	2,000	2,000
Accumulated Amortization	(778)	(611)
Total	$ 1,222	1,389
Weighted-Average Remaining Life	1 year 9 months 18 days
Pharmacy and customer relationships
Schedule Of Intangible Assets [Line Items]
Gross Carrying Amount	$ 9,500	9,500
Accumulated Amortization	(8,471)	(8,234)
Total	$ 1,029	1,266
Weighted-Average Remaining Life	1 year 1 month 6 days
Trade names, trademarks and website addresses
Schedule Of Intangible Assets [Line Items]
Gross Carrying Amount	$ 5,700	5,700
Accumulated Amortization	(1,363)	(1,220)
Total	$ 4,337	$ 4,480
Weighted-Average Remaining Life	8 years 8 months 12 days

XML 51 R40.htm IDEA: XBRL DOCUMENT

Balance Sheet Accounts - Schedule of Intangible Asset Future Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Fiscal Year Maturity [Abstract]
Remainder of 2019	$ 1,638
2020	1,494
2021	536
2022	480
2023	480
Thereafter	1,960
Total	6,588	$ 7,135
Technology
Fiscal Year Maturity [Abstract]
Remainder of 2019	499
2020	667
2021	56
2022	0
2023	0
Thereafter	0
Total	1,222	1,389
Pharmacy and customer relationships
Fiscal Year Maturity [Abstract]
Remainder of 2019	712
2020	317
2021	0
2022	0
2023	0
Thereafter	0
Total	1,029	1,266
Trade names, trademarks and website addresses
Fiscal Year Maturity [Abstract]
Remainder of 2019	427
2020	510
2021	480
2022	480
2023	480
Thereafter	1,960
Total	$ 4,337	$ 4,480

XML 52 R41.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Summary of Financial Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	$ 107,974	$ 323
Total liabilities measured and recorded at fair value	26,500	40,000
Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	107,974	323
Total liabilities measured and recorded at fair value	26,500	40,000
Fair Value \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	107,974	323
Total liabilities measured and recorded at fair value	0	0
Fair Value \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	0	0
Total liabilities measured and recorded at fair value	26,500	40,000
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	107,974	323
Money market funds \| Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	107,974	323
Money market funds \| Fair Value \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	107,974	323
Money market funds \| Fair Value \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	0	0
Earnout liability—current
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	26,500	20,730
Earnout liability—current \| Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	26,500	20,730
Earnout liability—current \| Fair Value \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	0	0
Earnout liability—current \| Fair Value \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	26,500	20,730
Earnout liability—non-current
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	0	19,270
Earnout liability—non-current \| Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	0	19,270
Earnout liability—non-current \| Fair Value \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	0	0
Earnout liability—non-current \| Fair Value \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	$ 0	$ 19,270

XML 53 R42.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Earnout Liability Activity (Details) - Contingent Consideration - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2018	$ 26,500	$ 40,000
Settlement of first earnout liability	(26,800)
Change in fair value	13,300
Balance at March 31, 2019	$ 26,500

XML 54 R43.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended
	Jan. 22, 2018	Mar. 31, 2019	Mar. 31, 2018
Business Acquisition [Line Items]
Acquisition-related contingent payments		$ (9,542)	$ 0
GoMedigap
Business Acquisition [Line Items]
Acquisition-related contingent payments		(9,500)
Stock issued for acquisition	$ 5,595	$ 17,300

XML 55 R44.htm IDEA: XBRL DOCUMENT

Stockholder's Equity - Schedule of Stock Plan Activity (Details) - 2014 Equity Incentive Plan shares in Thousands	3 Months Ended
	Mar. 31, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award, Movement in Shares Available for Grant [Roll Forward]
Shares available for grant (in shares)	512
Restricted stock units granted (in shares)	0
Options granted (in shares)	0
Restricted stock units cancelled (in shares)	37
Options cancelled (in shares)	8
Shares available for grant (in shares)	557

XML 56 R45.htm IDEA: XBRL DOCUMENT

Stockholder's Equity - Schedule of Option Activity Under Stock Plans (Details) - Common stock options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Number of Stock Options
Balance outstanding (in shares)	1,005
Granted (in shares)	0
Exercised (in shares)	(108)
Cancelled (in shares)	(11)
Balance outstanding (in shares)	886	1,005
Options vested and expected to vest (in shares)	845
Options exercisable (in shares)	439
Weighted Average Exercise Price
Weighted-average exercise price, balance outstanding (in dollars per share)	$ 18.34
Granted (in dollars per share)	0.00
Exercised (in dollars per share)	21.88
Cancelled (in dollars per share)	33.30
Weighted-average exercise price, balance outstanding (in dollars per share)	17.72	$ 18.34
Weighted-average exercise price, vested and expected to vest (in dollars per share)	17.50
Weighted-average exercise price, exercisable (in dollars per share)	$ 14.46
Weighted-average remaining contractual life (years), balance outstanding	5 years	5 years
Weighted-average remaining contractual life (years), vested and expected to Vest	5 years
Weighted-average remaining contractual life (years), exercisable	4 years 4 months 24 days
Aggregate intrinsic value, balance outstanding	$ 39,521	$ 20,226
Aggregate intrinsic value, vested and expected to vest	37,912
Aggregate intrinsic value, exercisable	$ 21,006

XML 57 R46.htm IDEA: XBRL DOCUMENT

Stockholder's Equity - Schedule of Restricted Stock Unit Activity Under Stock Plans (Details) - Restricted stock units - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Number of Restricted Stock Units
Unvested, beginning balance (in shares)	1,869
Granted (in shares)	0
Vested (in shares)	(64)
Cancelled (in shares)	(37)
Unvested, ending balance (in shares)	1,768	1,869
Weighted-Average Grant Date Fair Value
Unvested, beginning balance (in dollars per share)	$ 16.95
Granted (in dollars per share)	0.00
Vested (in dollars per share)	13.56
Cancelled (in dollars per share)	16.78
Unvested, ending balance (in dollars per share)	$ 17.03	$ 16.95
Weighted-Average Remaining Service Period (years)	5 years 3 months 19 days	4 years 9 months 18 days
Aggregate Intrinsic Value	$ 110,230	$ 71,816

XML 58 R47.htm IDEA: XBRL DOCUMENT

Stockholder's Equity - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		60 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Number of shares repurchased under share repurchase plan (in shares)	0		10,663,888
Treasury shares that were previously surrendered by employees to satisfy tax withholdings (in shares)	785,615
Treasury stock (in shares)	11,449,503		11,449,503	11,426,292
Incremental stock-based compensation expense		$ 0.3

XML 59 R48.htm IDEA: XBRL DOCUMENT

Stockholder's Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 3,229	$ 2,801
Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	602	498
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	2,627	2,303
Marketing and advertising
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	629	370
Customer care and enrollment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	273	165
Technology and content
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	549	343
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,778	1,672
Restructuring
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 0	$ 251

XML 60 R49.htm IDEA: XBRL DOCUMENT

Income Taxes (Summary of Income Tax Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Loss before benefit from income taxes	$ (8,626)	$ (6,536)
Benefit from income taxes	$ (3,467)	$ (1,691)
Effective tax rate	40.20%	25.90%

XML 61 R50.htm IDEA: XBRL DOCUMENT

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Benefit from income taxes	$ 3,467	$ 1,691
Effective tax rate	40.20%	25.90%

XML 62 R51.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,386	2,432
Common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	960	1,006
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,426	1,426

XML 63 R52.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) $ in Thousands	3 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Mar. 31, 2019 USD ($)
Commitments And Contingencies Disclosure [Line Items]
Remainder of 2019	$ 3,366
2020	2,462
2021	946
2022	434
2023	444
Thereafter	229
Total	$ 7,881
Service and Licensing Obligations
Commitments And Contingencies Disclosure [Line Items]
Contractual obligation, term of contract	3 years

XML 64 R53.htm IDEA: XBRL DOCUMENT

Operating Segments, Geographic Information and Significant Customers - Segment Operating Results (Details) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019 USD ($) segment	Mar. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments \| segment	2
Total revenue	$ 68,773	$ 43,070
Stock-based compensation expense	(3,229)	(2,550)
Depreciation and amortization	(655)	(619)
Acquisition costs	0	(58)
Change in fair value of earnout liability	(13,306)	0
Restructuring benefit	0	(1,856)	$ (1,900)
Amortization of intangible assets	(547)	(451)
Other income, net	557	184
Loss before benefit from income taxes	(8,626)	(6,536)
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	68,773	43,070
Segment profit (loss)	16,850	6,668
Operating Segments \| Medicare
Segment Reporting Information [Line Items]
Total revenue	54,901	30,763
Segment profit (loss)	10,826	3,180
Operating Segments \| Individual, Family and Small Business
Segment Reporting Information [Line Items]
Total revenue	13,872	12,307
Segment profit (loss)	6,024	3,488
Corporate
Segment Reporting Information [Line Items]
Segment profit (loss)	$ (8,296)	$ (7,854)

XML 65 R54.htm IDEA: XBRL DOCUMENT

Operating Segments, Geographic Information and Significant Customers - Schedule Of Long-Lived Assets By Geographical Area (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Total	$ 17,039	$ 15,992
United States
Segment Reporting Information [Line Items]
Total	16,697	15,614
China
Segment Reporting Information [Line Items]
Total	$ 342	$ 378

XML 66 R55.htm IDEA: XBRL DOCUMENT

Operating Segments, Geographic Information and Significant Customers - Schedule of Revenue by Major Customers (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Revenue, Major Customer [Line Items]
Accounts receivable	$ 331,592		$ 349,459
Customer Concentration Risk \| Revenue \| Humana
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	23.00%	15.00%
Customer Concentration Risk \| Revenue \| UnitedHealthcare
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	17.00%	21.00%
Customer Concentration Risk \| Revenue \| Aetna
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	17.00%	10.00%

XML 67 R56.htm IDEA: XBRL DOCUMENT

Restructuring (Details) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
Restructuring (Details) $ in Thousands	Feb. 28, 2018 employee	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)
Restructuring Cost and Reserve [Line Items]
Positions eliminated \| employee	110
Percentage of total workforce	10.00%
Charges		$ 0	$ 1,856	$ 1,900
Employee termination costs
Restructuring Cost and Reserve [Line Items]
Charges				1,600
Non-cash employee termination costs - stock-based compensation
Restructuring Cost and Reserve [Line Items]
Charges				$ 300

XML 68 R57.htm IDEA: XBRL DOCUMENT

Leases - Narrative (Details) $ in Thousands		3 Months Ended
Leases - Narrative (Details) $ in Thousands	Apr. 25, 2018 USD ($) ft²	Mar. 31, 2019 USD ($)	Mar. 31, 2012 USD ($) ft²	Mar. 26, 2019 ft²	Mar. 25, 2019 ft²	Jan. 01, 2019 USD ($)	Mar. 31, 2018 USD ($) ft²
Lessee, Lease, Description [Line Items]
Operating lease cost		$ 1,300
Operating cash outflow from operating leases		900
Operating lease right-of-use assets		25,730
Operating lease liabilities		27,580
Future minimum lease payments		$ 35,137
Minimum
Lessee, Lease, Description [Line Items]
Lease term		1 year
Maximum
Lessee, Lease, Description [Line Items]
Lease term		11 years
Salt Lake City, Utah
Lessee, Lease, Description [Line Items]
Operating lease liabilities		$ 3,500
Office space, square feet \| ft²				41,813	28,915
Operating lease, term				84 months
Future minimum lease payments		7,200
Santa Clara, California
Lessee, Lease, Description [Line Items]
Office space, square feet \| ft²	32,492
Operating lease, term	123 months
Future minimum lease payments		17,100
Austin, Texas
Lessee, Lease, Description [Line Items]
Office space, square feet \| ft²							26,878
Operating lease, term							90 months
Future minimum lease payments		4,400
Mountain View, California
Lessee, Lease, Description [Line Items]
Office space, square feet \| ft²			18,272
Future minimum lease payments		3,300
Standby Letters of Credit \| Santa Clara, California
Lessee, Lease, Description [Line Items]
Credit facility	$ 1,500
Standby Letters of Credit \| Austin, Texas
Lessee, Lease, Description [Line Items]
Credit facility							$ 600
Standby Letters of Credit \| Mountain View, California
Lessee, Lease, Description [Line Items]
Credit facility			$ 600
$1.5 Million Standby Letter of Credit \| Standby Letters of Credit \| Santa Clara, California
Lessee, Lease, Description [Line Items]
Incremental reduction rate	20.00%
Reduction of standby letter of credit amount, percentage, sixth year	8.00%
$.6 Million Standby Letter of Credit \| Standby Letters of Credit \| Mountain View, California
Lessee, Lease, Description [Line Items]
Incremental reduction rate			25.00%
ASU 2016-02
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets						$ 23,300
Operating lease liabilities		$ 28,100				$ 24,600

XML 69 R58.htm IDEA: XBRL DOCUMENT

Leases - Supplemental Balance Sheet Information (Details) $ in Thousands	Mar. 31, 2019 USD ($)
Leases [Abstract]
Operating lease right-of-use assets	$ 25,730
Operating lease liabilities	$ 27,580
Weighted-average remaining lease term of operating leases (in years)	7 years 6 months
Weighted-average discount rate of operating leases	6.10%

XML 70 R59.htm IDEA: XBRL DOCUMENT

Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Mar. 31, 2019 USD ($)
Operating leases
Remainder of 2019	$ 3,641
2020	5,502
2021	4,068
2022	4,189
2023	3,972
Thereafter	13,765
Total	35,137
Less imputed interest	(7,557)
Operating lease liabilities	$ 27,580

XML 71 R60.htm IDEA: XBRL DOCUMENT

Debt (Details) - USD ($)		3 Months Ended
Debt (Details) - USD ($)	Sep. 17, 2018	Mar. 31, 2019
Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing capacity	$ 40,000,000
Commitment fee percentage	0.50%
Facility fee percentage	1.75%
Maximum borrowing capacity	$ 40,000,000
Covenant, minimum cash and cash equivalents	6,000,000
Debt issuance costs	1,200,000	$ 1,000,000
Borrowings under line of credit		$ 0
Letter of Credit
Debt Instrument [Line Items]
Borrowing capacity	$ 5,000,000
Eligible Commissions Receivables, Preceding Three Months \| Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing base percentage		80.00%
Eligible Commissions Receivables, Succeeding Three Months \| Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing base percentage		80.00%
Eligible Commissions Receivables, Succeeding Six Months \| Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing base percentage		50.00%

XML 72 R61.htm IDEA: XBRL DOCUMENT

Public Offering of Common Stock (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Jan. 31, 2019	Mar. 31, 2019	Jan. 22, 2019
Subsidiary, Sale of Stock [Line Items]
Sale of stock, shares issued (in shares)	2,760,000
Sale of stock, price per share (in dollars per share)			$ 48.50
Net proceeds from sale of stock		$ 126.1
Over-Allotment Option
Subsidiary, Sale of Stock [Line Items]
Sale of stock, shares issued (in shares)	360,000

EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 218 283 1 false 74 0 false 8 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.ehealthinsurance.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 4 false false R5.htm 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 2101100 - Disclosure - Summary of Business and Significant Accounting Policies Sheet http://www.ehealthinsurance.com/role/SummaryOfBusinessAndSignificantAccountingPolicies Summary of Business and Significant Accounting Policies Notes 6 false false R7.htm 2102100 - Disclosure - Acquisition Sheet http://www.ehealthinsurance.com/role/Acquisition Acquisition Notes 7 false false R8.htm 2103100 - Disclosure - Balance Sheet Accounts Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccounts Balance Sheet Accounts Notes 8 false false R9.htm 2104100 - Disclosure - Fair Value Measurements Sheet http://www.ehealthinsurance.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 2105100 - Disclosure - Stockholder's Equity Sheet http://www.ehealthinsurance.com/role/StockholdersEquity Stockholder's Equity Notes 10 false false R11.htm 2106100 - Disclosure - Income Taxes Sheet http://www.ehealthinsurance.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 2107100 - Disclosure - Net Loss Per Share Sheet http://www.ehealthinsurance.com/role/NetLossPerShare Net Loss Per Share Notes 12 false false R13.htm 2108100 - Disclosure - Commitments and Contingencies Sheet http://www.ehealthinsurance.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 2109100 - Disclosure - Operating Segments, Geographic Information and Significant Customers Sheet http://www.ehealthinsurance.com/role/OperatingSegmentsGeographicInformationAndSignificantCustomers Operating Segments, Geographic Information and Significant Customers Notes 14 false false R15.htm 2110100 - Disclosure - Restructuring Sheet http://www.ehealthinsurance.com/role/Restructuring Restructuring Notes 15 false false R16.htm 2111100 - Disclosure - Leases Sheet http://www.ehealthinsurance.com/role/Leases Leases Notes 16 false false R17.htm 2112100 - Disclosure - Debt Sheet http://www.ehealthinsurance.com/role/Debt Debt Notes 17 false false R18.htm 2113100 - Disclosure - Public Offering of Common Stock Sheet http://www.ehealthinsurance.com/role/PublicOfferingOfCommonStock Public Offering of Common Stock Notes 18 false false R19.htm 2201201 - Disclosure - Summary of Business and Significant Accounting Policies (Policy) Sheet http://www.ehealthinsurance.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicy Summary of Business and Significant Accounting Policies (Policy) Policies http://www.ehealthinsurance.com/role/SummaryOfBusinessAndSignificantAccountingPolicies 19 false false R20.htm 2301302 - Disclosure - Summary of Business and Significant Accounting Policies (Tables) Sheet http://www.ehealthinsurance.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesTables Summary of Business and Significant Accounting Policies (Tables) Tables http://www.ehealthinsurance.com/role/SummaryOfBusinessAndSignificantAccountingPolicies 20 false false R21.htm 2302301 - Disclosure - Acquisition (Tables) Sheet http://www.ehealthinsurance.com/role/AcquisitionTables Acquisition (Tables) Tables http://www.ehealthinsurance.com/role/Acquisition 21 false false R22.htm 2303301 - Disclosure - Balance Sheet Accounts (Tables) Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccountsTables Balance Sheet Accounts (Tables) Tables http://www.ehealthinsurance.com/role/BalanceSheetAccounts 22 false false R23.htm 2304301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.ehealthinsurance.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.ehealthinsurance.com/role/FairValueMeasurements 23 false false R24.htm 2305301 - Disclosure - Stockholder's Equity (Tables) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityTables Stockholder's Equity (Tables) Tables http://www.ehealthinsurance.com/role/StockholdersEquity 24 false false R25.htm 2306301 - Disclosure - Income Taxes (Tables) Sheet http://www.ehealthinsurance.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.ehealthinsurance.com/role/IncomeTaxes 25 false false R26.htm 2307301 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.ehealthinsurance.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.ehealthinsurance.com/role/NetLossPerShare 26 false false R27.htm 2308301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.ehealthinsurance.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.ehealthinsurance.com/role/CommitmentsAndContingencies 27 false false R28.htm 2309301 - Disclosure - Operating Segments, Geographic Information and Significant Customers (Tables) Sheet http://www.ehealthinsurance.com/role/OperatingSegmentsGeographicInformationAndSignificantCustomersTables Operating Segments, Geographic Information and Significant Customers (Tables) Tables http://www.ehealthinsurance.com/role/OperatingSegmentsGeographicInformationAndSignificantCustomers 28 false false R29.htm 2311301 - Disclosure - Leases (Tables) Sheet http://www.ehealthinsurance.com/role/LeasesTables Leases (Tables) Tables http://www.ehealthinsurance.com/role/Leases 29 false false R30.htm 2401403 - Disclosure - Summary of Business and Significant Accounting Policies - Narrative (Details) Sheet http://www.ehealthinsurance.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails Summary of Business and Significant Accounting Policies - Narrative (Details) Details http://www.ehealthinsurance.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesTables 30 false false R31.htm 2401405 - Disclosure - Summary of Business and Significant Accounting Policies - Disaggregation of Revenue (Details) Sheet http://www.ehealthinsurance.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesDisaggregationOfRevenueDetails Summary of Business and Significant Accounting Policies - Disaggregation of Revenue (Details) Details 31 false false R32.htm 2402402 - Disclosure - Acquisition - Narrative (Details) Sheet http://www.ehealthinsurance.com/role/AcquisitionNarrativeDetails Acquisition - Narrative (Details) Details 32 false false R33.htm 2402403 - Disclosure - Acquisition - Purchase Price Allocation (Details) Sheet http://www.ehealthinsurance.com/role/AcquisitionPurchasePriceAllocationDetails Acquisition - Purchase Price Allocation (Details) Details 33 false false R34.htm 2403402 - Disclosure - Balance Sheet Accounts - Schedule of Cash and Cash Equivalents (Details) Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccountsScheduleOfCashAndCashEquivalentsDetails Balance Sheet Accounts - Schedule of Cash and Cash Equivalents (Details) Details 34 false false R35.htm 2403403 - Disclosure - Balance Sheet Accounts - Schedule of Accounts Receivable (Details) Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccountsScheduleOfAccountsReceivableDetails Balance Sheet Accounts - Schedule of Accounts Receivable (Details) Details 35 false false R36.htm 2403404 - Disclosure - Balance Sheet Accounts - Narrative (Details) Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccountsNarrativeDetails Balance Sheet Accounts - Narrative (Details) Details 36 false false R37.htm 2403405 - Disclosure - Balance Sheet Accounts - Schedule of Credit Risk (Details) Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccountsScheduleOfCreditRiskDetails Balance Sheet Accounts - Schedule of Credit Risk (Details) Details 37 false false R38.htm 2403406 - Disclosure - Balance Sheet Accounts - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccountsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails Balance Sheet Accounts - Schedule of Prepaid Expenses and Other Current Assets (Details) Details 38 false false R39.htm 2403409 - Disclosure - Balance Sheet Accounts - Schedule of Intangible Assets (Details) Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccountsScheduleOfIntangibleAssetsDetails Balance Sheet Accounts - Schedule of Intangible Assets (Details) Details 39 false false R40.htm 2403410 - Disclosure - Balance Sheet Accounts - Schedule of Intangible Asset Future Amortization Expense (Details) Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccountsScheduleOfIntangibleAssetFutureAmortizationExpenseDetails Balance Sheet Accounts - Schedule of Intangible Asset Future Amortization Expense (Details) Details 40 false false R41.htm 2404402 - Disclosure - Fair Value Measurements - Summary of Financial Assets (Details) Sheet http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryOfFinancialAssetsDetails Fair Value Measurements - Summary of Financial Assets (Details) Details 41 false false R42.htm 2404403 - Disclosure - Fair Value Measurements - Earnout Liability Activity (Details) Sheet http://www.ehealthinsurance.com/role/FairValueMeasurementsEarnoutLiabilityActivityDetails Fair Value Measurements - Earnout Liability Activity (Details) Details 42 false false R43.htm 2404404 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.ehealthinsurance.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 43 false false R44.htm 2405403 - Disclosure - Stockholder's Equity - Schedule of Stock Plan Activity (Details) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityScheduleOfStockPlanActivityDetails Stockholder's Equity - Schedule of Stock Plan Activity (Details) Details 44 false false R45.htm 2405404 - Disclosure - Stockholder's Equity - Schedule of Option Activity Under Stock Plans (Details) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityScheduleOfOptionActivityUnderStockPlansDetails Stockholder's Equity - Schedule of Option Activity Under Stock Plans (Details) Details 45 false false R46.htm 2405405 - Disclosure - Stockholder's Equity - Schedule of Restricted Stock Unit Activity Under Stock Plans (Details) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityScheduleOfRestrictedStockUnitActivityUnderStockPlansDetails Stockholder's Equity - Schedule of Restricted Stock Unit Activity Under Stock Plans (Details) Details 46 false false R47.htm 2405406 - Disclosure - Stockholder's Equity - Narrative (Details) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityNarrativeDetails Stockholder's Equity - Narrative (Details) Details 47 false false R48.htm 2405408 - Disclosure - Stockholder's Equity - Schedule of Stock-Based Compensation Expense (Details) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityScheduleOfStockBasedCompensationExpenseDetails Stockholder's Equity - Schedule of Stock-Based Compensation Expense (Details) Details 48 false false R49.htm 2406402 - Disclosure - Income Taxes (Summary of Income Tax Benefit) (Details) Sheet http://www.ehealthinsurance.com/role/IncomeTaxesSummaryOfIncomeTaxBenefitDetails Income Taxes (Summary of Income Tax Benefit) (Details) Details http://www.ehealthinsurance.com/role/IncomeTaxesTables 49 false false R50.htm 2406403 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.ehealthinsurance.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.ehealthinsurance.com/role/IncomeTaxesTables 50 false false R51.htm 2407403 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) Sheet http://www.ehealthinsurance.com/role/NetLossPerShareScheduleOfAntiDilutiveSharesExcludedFromComputationOfNetIncomePerShareDetails Net Loss Per Share - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) Details 51 false false R52.htm 2408402 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.ehealthinsurance.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.ehealthinsurance.com/role/CommitmentsAndContingenciesTables 52 false false R53.htm 2409402 - Disclosure - Operating Segments, Geographic Information and Significant Customers - Segment Operating Results (Details) Sheet http://www.ehealthinsurance.com/role/OperatingSegmentsGeographicInformationAndSignificantCustomersSegmentOperatingResultsDetails Operating Segments, Geographic Information and Significant Customers - Segment Operating Results (Details) Details 53 false false R54.htm 2409403 - Disclosure - Operating Segments, Geographic Information and Significant Customers - Schedule Of Long-Lived Assets By Geographical Area (Details) Sheet http://www.ehealthinsurance.com/role/OperatingSegmentsGeographicInformationAndSignificantCustomersScheduleOfLongLivedAssetsByGeographicalAreaDetails Operating Segments, Geographic Information and Significant Customers - Schedule Of Long-Lived Assets By Geographical Area (Details) Details 54 false false R55.htm 2409404 - Disclosure - Operating Segments, Geographic Information and Significant Customers - Schedule of Revenue by Major Customers (Details) Sheet http://www.ehealthinsurance.com/role/OperatingSegmentsGeographicInformationAndSignificantCustomersScheduleOfRevenueByMajorCustomersDetails Operating Segments, Geographic Information and Significant Customers - Schedule of Revenue by Major Customers (Details) Details 55 false false R56.htm 2410401 - Disclosure - Restructuring (Details) Sheet http://www.ehealthinsurance.com/role/RestructuringDetails Restructuring (Details) Details http://www.ehealthinsurance.com/role/Restructuring 56 false false R57.htm 2411402 - Disclosure - Leases - Narrative (Details) Sheet http://www.ehealthinsurance.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 57 false false R58.htm 2411403 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) Sheet http://www.ehealthinsurance.com/role/LeasesSupplementalBalanceSheetInformationDetails Leases - Supplemental Balance Sheet Information (Details) Details 58 false false R59.htm 2411404 - Disclosure - Leases - Maturities of Lease Liabilities (Details) Sheet http://www.ehealthinsurance.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails Leases - Maturities of Lease Liabilities (Details) Details 59 false false R60.htm 2412401 - Disclosure - Debt (Details) Sheet http://www.ehealthinsurance.com/role/DebtDetails Debt (Details) Details http://www.ehealthinsurance.com/role/Debt 60 false false R61.htm 2413401 - Disclosure - Public Offering of Common Stock (Details) Sheet http://www.ehealthinsurance.com/role/PublicOfferingOfCommonStockDetails Public Offering of Common Stock (Details) Details http://www.ehealthinsurance.com/role/PublicOfferingOfCommonStock 61 false false All Reports Book All Reports ehth-20190331.xml ehth-20190331.xsd ehth-20190331_cal.xml ehth-20190331_def.xml ehth-20190331_lab.xml ehth-20190331_pre.xml http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 78 0001628280-19-005953-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-19-005953-xbrl.zip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�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end